MicroRNAs 155 and 125b Physiologically and Pathologically Regulate Hematopoiesis and Immunity by Chaudhuri, Aadel Ahmed
  
 
MICRORNAS 155 AND 125B PHYSIOLOGICALLY AND PATHOLOGICALLY 
REGULATE HEMATOPOIESIS AND IMMUNITY 
 
 
Thesis by 
Aadel A. Chaudhuri 
 
 
In Partial Fulfillment of the Requirements 
for the Degree of 
Doctor of Philosophy 
 
 
 
 
 
California Institute of Technology 
Pasadena, California 
2012 
(Defended August 8, 2011) 
 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2012 
Aadel A. Chaudhuri 
All Rights Reserved 
 
iii 
Acknowledgements 
I have so many people to thank and so much to be thankful for that it’s hard to 
know where to begin! I want to begin by thanking my parents for supporting and loving 
me unconditionally. Both my parents came to this country from the Indian Subcontinent 
in search of higher education. My mother went to Brown University where she got her 
PhD in Chemistry. Indeed, she defended her doctoral thesis when she was seven 
months pregnant with me. Perhaps this pre-birth experience somehow inspired me to 
also go into science. My father received his Masters at Caltech and his PhD at the 
University of Southern California (USC) in Civil Engineering. He spoke fondly to me of 
his experiences at Caltech, telling me stories about this small but powerful research 
institute where students are treated as colleagues and professors would call him at 
home to ask the status of a research project. I enjoyed the stories, but growing up I 
could not have imagined embarking on a similar path and having the opportunity to 
experience these things for myself. 
I want to thank my brother, Munir Chaudhuri, who was an undergraduate at USC 
during much of my time here at Caltech. Thank you for being my closest friend and for 
spending so much time with me when I first arrived at Caltech and knew nobody. I also 
want to thank all my cousins, aunts and uncles, especially my Shaukat Khala and my 
Mamu, for supporting me constantly and unconditionally.  
It’s been a long journey since I first stepped foot on Beckman Lawn five years 
ago as an HHMI Medical Research Fellow determined to do just one year of research, 
no more. Little did I know back then that Caltech would change my entire worldview and 
my very definition of myself. Like a child in a sandbox, I became captivated by my 
environment and I spent the next half-decade pursuing questions of utmost interest to 
me. What started as a whim of “Let me try my hand at research” has turned into the 
 
iv 
body of work I present here. Thank you Caltech for making my experience utterly 
fulfilling. 
As I begin to acknowledge the folks at Caltech who have been integral to my 
success, it’s only fitting that I begin with Dr. Ryan O’Connell. Ryan showed me how 
exciting and productive scientific research can be. My friendship with him and his 
surefooted mentorship convinced me to stay longer at Caltech than my originally 
intended year and to pursue my doctorate degree. “Meetings” with Ryan were always at 
the basketball court or the weight room. In-between games where he would beat me 
handily, or sets of bench press where he would literally lift twice what I was lifting, we 
would discuss our ideas and plan the next set of exciting experiments. Indeed, Dr. Kai 
Zinn, the chair of my committee (and also a gym enthusiast) scolded us on more than 
one occasion for talking too much science in the gym! 
I would also like to thank Dr. Alex So, a bold young post-doc in our lab, for 
teaching me to be bold. I had ideas on what miR-125b was doing in macrophages and in 
hematopoiesis, and I had a robust experimental system up and running. I guess I was 
just afraid of asking the biggest questions: Does miR-125b regulate hematopoietic stem 
cell numbers? Does miR-125b physiologically regulate hematopoiesis? Does heightened 
miR-125b affect immune function? Alex taught me to boldly ask and answer the biggest 
questions in the field regarding our work. He also taught me how to organize and 
communicate my ideas effectively. 
I would like to thank Dinesh Rao, one of my closest friends in the Baltimore lab. 
Dinesh is a role model and someone I look up to (both figuratively and literally). At 6’4”, 
Dinesh towered above the rest of us in lab. As a “gentle giant” and a talented medical 
researcher, Dinesh taught me how to ask questions that were relevant to human health 
and disease. I remember him telling me “When you’re collaborating with others and 
they’re also interested in what you’re doing, that means what you’re doing is interesting. 
 
v 
It’s better than sitting alone in a room by yourself.” Indeed, I’ve taken to heart the 
importance of collaboration in science, and this thesis would not have been possible 
without the input of many others. 
I’d like to thank Jimmy Zhao, a brilliant graduate student in our lab for challenging 
me constantly and for pushing me to ask interesting questions. Jimmy’s also a handful 
on the basketball court. I’d like to thank Arnav Mehta, a bright young graduate student in 
our lab, for being a good friend and collaborator on our recent projects. You’ll do well 
Arnav and I look forward to staying in touch with you. 
Alex Balazs, where would I be without you? I’ve asked “Alex B” for advice on 
everything from computers, vector cloning, PCR, transfection, flow cytometry, travel 
deals, and “Why isn’t the Coulter Counter working?” Alex, thank you for being an 
amazing bay-mate and a good friend. I couldn’t have done it without you. 
And Alex Sigal, who taught me to challenge my body as hard as I challenge my 
mind. From biking to the peak of Mount Wilson to running to the summit of Echo 
Mountain in the 2pm summer heat, we were doing it all as long as we were dead 
exhausted by the end. Of course we also rewarded ourselves generously by going to 21 
Choices or Souplantation afterwards. Thank you Alex for loving the outdoors with me 
and for helping me stay balanced in graduate school. 
 Caltech undergraduate students are simply amazing, They’re gifted, bright, and 
relentlessly hardworking. And they have a mischievous spark that keeps things 
interesting in lab. Jonathan Tsai, you were great, thanks for putting up with me while I 
was a young first-year grad student still trying to figure things out for myself. Will Gibson, 
thank you for being amazing in lab and for immersing yourself in everything you did. 
Your passion for life inspires me. And to Nikita Sinha, who is working with me currently 
and doing a remarkable job, your dedication is unparalleled and I appreciate the hard 
work and long hours you spend on our projects. I also want to thank Rebecca Scholz, 
 
vi 
Theresa Geiger and Aarathi Minisandaram. I hope that all the undergraduates I’ve 
worked with have learned from me that science, the pursuit of discovery, is exciting and 
driven ultimately by human curiosity. 
 I’d like to thank Dr. Jean-Lou Chameau, the Caltech President, and his wife, Dr. 
Carol Carmichael, for supporting me and helping me achieve my goals here at Caltech. 
I’d like to thank Barbara Green, Thomas Mannion, Geoff Blake, Karen Blake, Sue 
Chiarchiaro and Fleming House for integrating me into the greater Caltech community 
through the Resident Associate Program, thus enriching my life with the myriad 
experiences available to Caltech students. And I’d like to thank the members of SBD, the 
GSC basketball team I’m a part of. We won back-to-back championships! And we had a 
blast doing it. 
 Dr. Ellen Rothenberg, thank you for getting me so excited about hematopoiesis. 
Every class of Hematopoiesis was absolutely amazing. You’ve taught me to think deeply 
about science, to think out-of-the-box, and to approach my work with a high level of 
passion and intensity. You’ve also been encouraging and had the utmost faith in my 
abilities. Indeed the reason to enroll in a small institution like Caltech is to form close 
bonds with world-class faculty such as yourself. 
 Finally I would like to thank my thesis committee members, Dr. Paul Patterson, 
Dr. Kai Zinn, Dr. Shuou Shan and Dr. Sarkis Mazmanian. Dr. Patterson, your relaxed 
demeanor puts everyone at ease and you’re quick to provide me with thoughtful advice. 
Dr. Kai Zinn, your feats of strength in the gym continue to amaze me, as do your 
adventurous stories of climbing, cliff jumping and white water rafting. I hope to someday 
become as interesting a person as you are. Dr. Shuou Shan, I’d like to begin by 
congratulating you on your tenure. You’re a remarkable scientist with refreshing ideas 
and I feel lucky to have you on my committee. Finally I’d like to thank Sarkis Mazmanian, 
one of my closest mentors here at Caltech. Sarkis, you’ve been an inspiration to me and 
 
vii 
it’s hard for me to put into words how much I appreciate all that you’ve done on my 
behalf. You helped me mature from a naïve young graduate student into what I am now. 
And you made mentoring a priority. I will miss you Sarkis. 
 Last but not least, I’d like to thank my advisor Dr. David Baltimore. David, thank 
you for being the ultimate source of inspiration for me. Your love for science is so 
genuine and pure. David, what you taught me most was to love science and to love it 
passionately. I still remember during the first class of your course “Virology,” you told the 
students with a smile on your face, “I study virology because to me viruses are a joy.” I 
remember you showing us the two pages from your lab notebook where you asked 
whether an enzyme existed to convert RNA back to DNA. At the bottom of the page you 
wrote simply, “Yes, there is DNA.” It’s your child-like love for science that inspires me 
most. Your willingness to sit with me as I ramble on about the million ideas I have; I 
appreciate that. And you’ve let me be free, David. You let me work on whatever I wanted 
and you didn’t hold me back from anything. Any other advisor would have balked by my 
seemingly unfocused approach, but you let me be myself and explore science the way I 
wanted to. I genuinely thank you for that. My experience as your graduate student has 
been unparalleled by anything else in the world.  
 
 
 
 
 
 
 
 
 
 
viii 
Abstract 
MicroRNAs are a class of ~ 22 nucleotide RNA molecules with roles in diverse biological 
processes. Here I focus on two microRNAs, miR-155 and miR-125b, and reveal 
pathways by which their dysregulation leads to myeloproliferative disorder (MPD) and 
leukemia, respectively. I begin by searching for miR-155 target genes relevant to MPD. 
By writing an algorithm to search microarray data for predicted microRNA target genes, I 
identified 89 candidate target genes for miR-155 in myeloid cells. Literature search 
whittled this list down to 11, and one gene among them, SHIP1, turned out to be largely 
responsible for miR-155’s ability to cause MPD.  My focus shifted to miR-125b when I 
noticed that miR-125b was enriched in macrophages and thus might play important roles 
in that cell type. Indeed, gain- and loss-of-function experiments indicated that miR-125b 
is a potent activator of macrophage activation, and I identified IRF4 as the primary target 
gene in this process. Finally I asked whether miR-125b plays pathophysiological roles in 
the development of the hematopoietic system. Thus I overexpressed miR-125b in the 
hematopoietic system and, to my surprise, observed a very aggressive myeloid leukemia 
capable of infiltrating peripheral organs including the lungs, liver, kidneys and brain. To 
determine whether miR-125b is physiologically necessary for normal hematopoietic 
development, I designed a loss-of-function sponge vector that acts as a decoy, attracting 
the microRNA away from its normal targets. Use of the sponge in the mouse 
hematopoietic system led to significantly decreased overall hematopoietic ouput, 
indicating that miR-125b is physiologically required for normal hematopoiesis. Next, I 
assayed in vitro a panel of miR-125b target genes and saw that one, Lin28, was superior 
to the rest. Indeed, Lin28 gain- and loss-of-function in vivo recapitulated major aspects 
of miR-125b loss- and gain-of-function, respectively. Thus I identified Lin28 as a primary 
target of miR-125b in the hematopoietic system. In summary, my work shows that two 
 
ix 
microRNAs, miR-155 and miR-125b, physiologically and pathologically control 
hematopoietic development. I also identify important target genes for each of these 
microRNAs in their respective disease processes. Indeed, therapeutic targeting of these 
pathways may prove useful in the treatment of cancer. 
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Overview of MicroRNAs 
MicroRNAs (miRNAs) are a class of ~ 22 nucleotide RNA species that are 
generated from Drosha and Dicer-mediated cleavage of endogenous PolII-generated 
transcripts1. The first microRNA, lin-4, was discovered in 1993 by Victor Ambros and 
Gary Ruvkun and was shown to regulate early C. elegans larval development by 
mediating gene suppression2-4. Since that seminal finding, hundreds of other microRNAs 
have been discovered and sequenced in eukaryotic organisms, indicating that 
microRNAs are ubiquitous regulators of gene expression5,6. Indeed, it is thought that 
over half of all mammalian genes are regulated by microRNAs7,8.  
The mammalian immune system is a complex developmental system in which 
cells of hematopoietic origin differentiate and proliferate in response to environmental 
cues. The immune system is also in a constant state of renewal as hematopoietic stem 
cells give rise to new lineage-specific cells while memory lymphocytes wait in 
quiescence until they receive the proper signals to rapidly proliferate into effector cells9. 
In many ways, the development and function of the immune system is as dynamic as 
early embryonic development; thus, it is not surprising that microRNAs, such as in the 
case of lin-4 in C. elegans development, help orchestrate the development and function 
of the immune system.  
 
MicroRNA Biogenesis and Function 
MicroRNAs are transcribed from the genome by RNA polymerase II, initially as long 
transcripts called pri-miRNAs. Pri-miRNAs are cleaved by the enzyme Drosha into ~ 70 
nucleotide pre-miRNAs, which are exported out of the nucleus by the exportin 5 
transporter. Dicer cleaves each pre-miRNA into a 21-25 nucleotide, double-stranded 
RNA. The two RNA strands are separated and the strand with the thermodynamically 
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less stable 5’ end becomes the mature miRNA, which is finally loaded onto a RISC 
complex. The miRNA-RISC complex mediates translational repression by partially 
complementing with sites in the 3’ UTR of its target mRNA transcript1,10-12. 
 The mechanism by which a microRNA selects and suppresses a particular mRNA 
transcript is not exactly known13. As result we can only predict which genes a particular 
miRNA targets. Prediction algorithms rely on conservation of target sites among multiple 
species, and the observation that a microRNA represses its target when at least 6-8 
consecutive nucleotides in its 5’ end (known as the seed region) perfectly complement a 
site in the target gene’s 3’ UTR14,15. Via this site, miRNAs downregulate expression of 
their targets by translational repression and in some cases by mRNA degradation1,16. 
 
Regulation of innate immunity by MicroRNAs 
Cells of the innate immune system, such as granulocytes, monocytes (which 
differentiate into myeloid-derived dendritic cells (DCs) or macrophages), and natural 
killer (NK) cells provide an important first line of defense against infection. Emerging 
data have identified an important contribution of miRNAs to the development and 
function of innate immune cells (Figure 1). Furthermore, studies investigating myeloid 
development and function have identified a recurring theme of a dynamic interplay 
between lineage specific transcription factors (TFs) and miRNAs.  
 
Granulocytes 
Granulocytes arise from granulocyte/monocyte progenitors under the influence of the 
transcription factor growth factor independent 1 (GFI1). GFI1 was recently shown to bind 
to the promoter regions of pri-miR-21 and pri-miR-196b and repress their expression17. 
Furthermore, overexpression of miR-21 and miR-196 in lineage (LIN) depleted bone 
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marrow cells blocked granulopoiesis in vitro, leading to a decrease in neutrophil 
development, as is also observed in Gfi1-/- mice18. On a related note, we found that 
sustained expression of miR-155 can increase immature granulocyte numbers in vivo, 
and that several targets including Src homology-2 domain-containing inositol 5-
phosphatase 1 (SHIP1) are likely involved in this process19,20.   
In addition to regulating granulocyte development, miRNAs also regulate their 
function. In particular, myeloid-specific miR-223 is important for modulating neutrophil 
proliferation and activation21. miR-223, which is induced by the myeloid-relevant 
transcription factors PU.1 and CEBPβ22, negatively regulates proliferation and activity of 
neutrophils. Cultured miR-223-/- neutrophils had increased oxidative bursts and more 
effectively killed Candida albicans than wild-type cells21. Indicative of hyperactivity, miR-
223-/- neutrophils had increased nuclear lobularity and hypersegmentation. MEF2C was 
shown to be an important target of miR-223 because mice lacking both miR-223 and 
MEF2C had normal neutrophil proliferation21. Still, these neutrophils displayed 
histological signs of hyperactivion, suggesting that other uncharacterized miR-223 
targets regulate activation. In short, miR-223, miR-155, miR-21, miR-196b, and likely a 
plethora of other microRNAs, form vital components of the molecular network regulating 
granulocyte biology (Figure 1). 
 
Monocytes, macrophages and DCs  
Both macrophages and myeloid-derived DCs have key roles in the innate immune 
response to infection. Macrophages and DCs are derived from monocytes, which 
themselves arise from granulocyte/monocyte progenitors. Like granulocytes, several 
studies have shown that transcription factors involved in monocytopoiesis23 are 
regulated by and/or regulate specific miRNAs, again demonstrating a connection 
between these molecular species during development.  
 
5 
The expression levels of miRNAs 17-5p, 20a and 106a, members of the miR-17-
92 and related miR-106a-92 polycistrons, have been shown to decrease during the 
differentiation of human haematopoietic progenitor cells into monocytes, leading to a 
lack of repression of their target gene runt-related transcription factor 1 (RUNX1; also 
known as AML1)24. The resulting increase in RUNX1 expression promoted monocyte 
differentiation, presumably by increasing CSF1R expression. RUNX1 was also found to 
bind the miR-17-92 and miR-106a-92 promoter regions and repress their expression, 
suggesting that miR-17-92 and RUNX1 are involved in a mutual negative feedback loop. 
PU.1 is a transcription factor that is crucial for monocyte and macrophage differentiation 
and has been shown to upregulate miR-424 levels during TPA (12 O-tetradecanoyl 
phorbol 13-acetate)-mediated monocyte differentiation of NB4 cells25. Enforced 
expression of miR-424 in NB4 cells promoted monocytic differentiation, increasing 
numbers of CD11b+CD14+ cells and inducing morphological changes consistent with 
monocytic maturation. MiR-424 promoted monocytic differentiation by inhibiting the 
expression of nuclear factor I/A (NFI-A), which is important for myeloid cell differentiation 
and had been shown previously to be targeted by miR-223 during granulocyte 
differentiation in vitro26.  
The macrophage inflammatory response to infection involves the upregulation of 
several microRNAs, such as miR-155, miR-146 and miR-927-29. Indeed, miR-155 
expression is induced in mouse bone marrow-derived macrophages in response to a 
variety of different Toll-like receptor (TLR) ligands, and by the proinflammatory cytokines 
tumor necrosis factor (TNF) and interferon-β28. Interferons do not directly induce miR-
155 expression by macrophages, but rather do so indirectly through TNF autocrine or 
paracrine signaling. The primary transcript encoding miR-155, known as the B-cell 
integration cluster (BIC), was shown to be transcriptionally activated by the transcription 
factors activator protein 1 (AP1) and nuclear factor-kB (NF-κB)28,30,31. Certain TLR 
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ligands and ligands for the cytoplasmic sensor retinoic acid-inducible gene I (RIG-I) also 
induce miR-146 expression in a NF-kB-dependent manner29,32. In peripheral human 
monocytes and neutrophils, miR-9 is similarly upregulated by pro-inflammatory signals in 
a Myeloid differentiation primary-response protein 88 (MyD88)- and NF-κB-dependent 
manner27. Therefore, certain inflammatory miRNAs are regulated transcriptionally like 
other inflammatory genes that encode protein.    
The inflammatory response to infection must be robust enough to eradicate 
microbial pathogens, yet resolved in a timely manner to avoid excess damage to the 
host or the promotion of neoplasia. MicroRNAs have been shown to impact both of these 
aspects of inflammation. Both miR-146 and miR-155 are induced by TLR ligands and 
there is evidence that they can negatively regulate the activation of inflammatory 
pathways in myeloid cells10,29,32-35. MiR-146 directly represses several signaling 
molecules that are downstream from TLRs, including IL-1R-associated kinase 1 
(IRAK1), IRAK2 and TNFR-associated factor 6 (TRAF6), all of which promote 
inflammation29,32,34,35. In human myeloid-derived DCs, knockdown of miR-155 expression 
significantly increased expression of the pro-inflammatory cytokine interleukin-1b (IL-
1b)36. Furthermore, addition of a miR-155 mimic decreased the expression of a NF-κB 
reporter plasmid in cell lines36,37. MiR-155 has also been shown to repress the 
expression of the pro-inflammatory signaling molecule TAK1-binding protein 2 (TAB2), 
suggesting a mechanistic basis for its anti-inflammatory impact in certain settings36. By 
contrast, it has been shown that in certain settings miR-155 can positively regulate 
inflammatory pathways, enhancing rather than diminishing them. Indeed as we show 
here, enforced expression of miR-155 in the bone marrow compartment of adult mice 
leads to a myeloproliferative phenotype that is reminiscent of what occurs transiently 
after LPS injection20. We also show here that miR-155 negatively regulates SHIP1, an 
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important negative regulator of phosphoinositide 3-kinase (PI3K) and the downstream 
AKT pathway19,38. SHIP1 is a negative regulator of TLR4 signaling39, and therefore 
repression of SHIP1 by miR-155 may counter this negative regulation and increase 
downstream AKT signaling.  
Interestingly, AKT signaling has recently been shown to repress miR-155 
expression in macrophages40, suggesting the existence of a negative feedback loop. 
LPS-stimulated Akt-/- macrophages expressed higher levels of miR-155 and miR-125b, 
and also lower levels of let-7e and miR-181c compared with wild-type controls. AKT-/- 
macrophages were more responsive to LPS, an effect mediated in part by the increased 
miR-155 and decreased let-7e levels. Notably, miR-155 directly repressed suppressor of 
cytokine signaling 1 (SOCS1), which, similar to SHIP1, is a negative regulator of the TLR 
pathway. Let-7e directly downregulated expression of the LPS receptor, TLR4. The in 
vivo relevance of this pathway is supported by the finding that Akt-/- mice have a reduced 
tolerance to systemically delivered LPS compared with wild-type mice. Taken together, it 
is clear that specific microRNAs are involved in regulating inflammation, presumably to 
help create a properly balanced response to pathogens and noxious stimuli. However, 
the role of miR-155 seems to be complex possibly owing to its wide range of relevant 
target genes and the cellular contexts in which it is expressed.  
There are also reports indicating that miRNAs regulate distinct aspects of DC 
biology, and thus are involved in the crucial connection between innate and adaptive 
immune responses. MiR-34 and miR-21 were shown to be important for human myeloid-
derived DC differentiation by targeting Jagged1 and WNT141. Myeloid-derived DCs from 
BIC-/- (miR-155-deficient) mice displayed defects in antigen presentation to T cells, 
despite expressing normal levels of MHC class II and co-stimulatory molecules; thus, the 
mechanism behind the defect remains elusive42. In addition, another study found that 
miR-155 downregulates expression of DC-specific ICAM3-grabbing non-integrin (DC-
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SIGN) by human monocyte-derived DCs (MDDCs) through suppression of PU.143. DC-
SIGN is a cell surface C-type lectin that binds pathogens, implicating miRNAs in the 
regulation of pathogen uptake by DCs.  
 
 
Figure 1: MicroRNAs in the network of myeloid development and function. 
(© O’Connell et al., Nature Reviews Immunology, 2010.) 
 
 
NK and NKT cells 
 NK cells are important components of immune surveillance against cancer and viral 
infection and microRNAs have been implicated in their development and function. NK 
cells express the receptor natural killer group 2, member D (NKG2D), which recognizes 
MHC class I polypeptide-related sequence A (MICA) and MICB, ligands that are 
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expressed by cells undergoing stress triggered by events such as viral infection or 
transformation. Engagement of NKG2D by NK cells leads to direct killing of the target 
cell. A recent study showed that a set of miRNAs, many of which are overexpressed in 
various cancers, could downregulate MICA and MICB expression in human cell lines44. 
Treatment of cells with antagomirs (antisense oligodeoxynucleotides) that inhibit the 
function of specific miRNAs led to increased cell surface expression of MICA and MICB 
and increased NK cell-dependent killing. Overexpression of these miRNAs had the 
opposite effect. Interestingly, although heat shock-induced cell stress increased MICA 
and MICB expression in the HCT-116 cell line, expression of the relevant miRNAs did 
not concomitantly decrease. Rather, these miRNAs seem to set a threshold for MICA 
and MICB expression that prevents their expression during non-stress conditions. It is 
interesting to note that certain herpesvirus family members, namely cytomegalovirus, 
Epstein–Barr virus and Kaposi's sarcoma-associated virus, produce miRNAs that target 
the MICB mRNA, and this has been proposed as a mechanism of immune evasion by 
these viruses45,46.  
Invariant NKT (iNKT) cells are a class of innate-like T cells that express an 
invariant T cell receptor (TCR) that recognizes lipids presented by the MHC class I-like 
CD1d molecule. Two recent studies identified a requirement for Dicer in the 
development of iNKT cells47,48. Both studies observed a near complete loss of iNKT cells 
in the thymus and periphery in the absence of Dicer. Developing NK cells from 
conditional Dicer knockout animals exhibited increased apoptosis and decreased 
differentiation, whereas mature NK cells had major activation defects. 
The studies described above clearly implicate miRNAs in the regulation of 
various aspects of innate immunity. This appears to include direct microbial killing, the 
production of cytokines and the presentation of antigens in the context of MHC. Here we 
will focus on just two microRNAs—miR-155 and miR-125b—and attempt to obtain a 
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mechanistic understanding of their roles in myeloid development and disease. We begin 
by showing that miR-155 overexpression in the hematopoietic system causes a 
myeloproliferative disorder49, and show that miR-155 exerts its pathology via repression 
of the SHIP1 phosphatase50. Following this we focus on the microRNA, miR-125b, which 
we observed was enriched in hematopoietic stem cells51. When we overexpressed miR-
125b in the hematopoietic compartment, we saw a very aggressive myeloid leukemia 4-
5 months post-reconstitution51 that was capable of infiltrating peripheral organs including 
the brain. We set out to identify the mechanism underlying miR-125b’s function in the 
hematopoietic system and identified the stem cell gene, Lin28, as a primary target. Gain- 
and loss-of-function of lin28 mirrored important aspects of loss- and gain-of-function of 
miR-125b, respectively. Thus we integrate miR-125b and miR-155 and their target 
genes into the broader network of myeloid development, and importantly, we present a 
new set of pathways that could be therapeutically manipulated in the treatment of 
hematopoietic diseases and immune disorders. 
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Abstract 
Mammalian microRNAs (miRNAs) are emerging as key regulators of the development 
and function of the immune system. Here, we report a strong but transient induction of 
miR-155 in mouse bone marrow after injection of bacterial LPS correlated with 
granulocyte/monocyte (GM) expansion. Demonstrating the sufficiency of miR-155 to 
drive GM expansion, enforced expression in mouse bone marrow cells caused GM 
proliferation in a manner reminiscent of LPS treatment. However, the mir-155-induced 
GM populations displayed pathological features characteristic of myeloid neoplasia. 
Extending possible relevance to human disease, miR-155 was found to be 
overexpressed in the bone marrow of patients with certain subsets of acute myeloid 
leukemia (AML). Furthermore, miR-155 repressed a subset of genes implicated in 
hematopoietic development and disease. These data implicate miR-155 as a contributor 
to physiological GM expansion during inflammation and to certain pathological features 
associated with AML, emphasizing the importance of proper miR-155 regulation in 
developing myeloid cells during times of inflammatory stress. 
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Introduction 
Mammalian hematopoiesis involves the generation of blood cells from a common 
hematopoietic stem cell (HSC) through many intermediate stages, each of which can 
give rise to various types of malignancies upon their dysregulation. However, the 
molecular mechanisms that govern this process are incompletely understood. In 
particular, the quantitative decisions regarding how many cells take which pathway of 
maturation remain obscure. Most studies of this process have focused on cytokines and 
transcription factors, which can control cellular proliferation and differentiation decisions 
(Rosenbauer and Tenen 2007). MicroRNAs (miRNAs) are a novel class of small, 
regulatory RNA molecules that play evolutionarily conserved roles in cellular 
development and function, and mediate target gene repression through 3’ untranslated 
region (UTR) interactions (Ambros 2004; Bartel and Chen 2004; He and Hannon 2004). 
Recently, a growing body of evidence has implicated specific miRNAs in the modulation 
of mammalian hematopoiesis during both physiological and pathological conditions 
(Kluiver, Kroesen et al. 2006; Georgantas, Hildreth et al. 2007).  
Among miRNAs expressed by hematopoietic cells, miR-155 has emerged as 
having significant impact on the biology of lymphocytes (Costinean, Zanesi et al. 2006; 
Rodriguez, Vigorito et al. 2007; Thai, Calado et al. 2007). MiR-155 is upregulated to high 
levels in response to B or T cell receptor engagement (Haasch, Chen et al. 2002; van 
den Berg, Kroesen et al. 2003), and plays a B-cell intrinsic role in germinal center 
formation and subsequent antibody production in vivo following antigen challenge 
(Rodriguez, Vigorito et al. 2007; Thai, Calado et al. 2007). Furthermore, miR-155 
deficient T cells exhibit a Th2 bias, likely through repression of c-Maf. Beyond its 
apparent contribution to the humoral immune response, the need to properly regulate 
miR-155 levels is suggested by its dramatically elevated expression in several types of 
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human B-cell lymphomas (van den Berg, Kroesen et al. 2003; Eis, Tam et al. 2005; 
Kluiver, Poppema et al. 2005), and its reported sufficiency in triggering B-cell lymphoma 
when overexpressed in a B-cell-restricted manner in mice (Costinean, Zanesi et al. 
2006).  
In contrast to the emerging picture of miR-155 functions in lymphocytes, the role 
or consequences of miR-155 expression in hematopoietic cells of myeloid origin have 
been largely uncharacterized. Our group recently reported high levels of miR-155 
expression in cells of the innate immune system, such as monocytes and macrophages, 
following exposure to inflammatory stimuli (Taganov, Boldin et al. 2006; O'Connell, 
Taganov et al. 2007). As in lymphocytes, miR-155 expression is tightly regulated in 
myeloid cells, suggesting a specialized function during times of inflammatory stress. 
Interestingly, the inflammatory process is known to have a significant impact on 
hematopoiesis by enhancing production of granulocyte/monocyte (GM) populations in 
order to replenish those that become depleted while combating infection (Ueda, Kondo 
et al. 2005; Shortman and Naik 2007). This developmental reprogramming is driven in 
part by cytokines and growth factors produced during inflammation, and by direct 
recognition of pathogen associated molecular patterns such as LPS by mammalian Toll-
like receptors (TLRs) expressed on hematopoietic stem and progenitor cell populations 
(Nagai, Garrett et al. 2006). Because miR-155 is part of the TLR-induced gene program, 
we have examined its potential role in regulating GM expansion in the bone marrow 
during inflammation.  
In the present study, we demonstrate that miR-155 expression is greatly 
increased in mouse bone marrow cells after LPS injection and is sufficient to drive 
granulocyte/monocyte (GM) expansion when constitutively expressed in mouse HSCs in 
vivo. However, sustained expression of miR-155 also leads to several features 
characteristic of pathological myeloid proliferations, correlating with its overexpression in 
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a portion of samples from human AML patients. Finally, miR-155 directly repressed a 
broad range of target mRNAs implicated in myeloid hyperplasia and/or hematopoiesis. 
These data suggest an important physiological role for miR-155 in GM expansion during 
times of inflammation, yet underscore the importance of its proper regulation for 
maintaining the balance between an efficient immune response and the potentiality for 
inducing malignant disease.  
 
Results 
LPS induces bone marrow expression of miR-155 prior to myeloid expansion in 
vivo 
Although miR-155 is expressed at low levels in mice under steady-state 
conditions, we examined whether its expression is elevated in the bone marrow 
compartment following the onset of inflammation in vivo, as seen in cultured 
macrophages (O'Connell, Taganov et al. 2007). Mice were injected i.p. with a sub-lethal 
dose of LPS (50 ug), or PBS control, and their bone marrow cells were analyzed for 
miR-155 expression. Strong induction of miR-155 levels were observed following 24 
hours of LPS treatment, which returned to control levels by 72 hours (Fig. 1A). 
Upregulated miR-155 expression was also detected upon direct LPS or GM-CSF 
stimulation of isolated bone marrow cells from Wt or Rag1-/- mice, demonstrating that 
cells other than mature B and T lymphocytes contribute to this response (Fig. 1B).  
In addition to miR-155 expression, we also monitored bone marrow cell dynamics 
in response to LPS. While there was little change in bone marrow GM (Mac1+Gr1+), B-
cell (B220+) and erythroid precursor (Ter119+) populations by 24 hours post-LPS 
treatment (Supplemental Fig. 1), substantial expansion of GM cells and reductions in B-
cells and erythroid precursors was evident by 72 hours (Fig. 1C), consistent with a 
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previous study(Ueda, Kondo et al. 2005). Histological analyses also showed myeloid 
preponderance and hyperplasia, with relative erythroid hypoplasia, after 72 hours of LPS 
treatment (Fig. 1D). Together, these data indicate that LPS-induced miR-155 expression 
in the bone marrow precedes GM cell expansion. 
 
Enforced expression of miR-155 in hematopoietic stem cells causes a 
myeloproliferative disorder in the bone marrow 
We next investigated whether miR-155 is sufficient to mediate GM expansion in 
the mouse bone marrow in vivo. Retroviral-mediated gene transfer was used to force 
expression of GFP and miR-155 in HSCs (Fig. 2A), followed by engraftment of these 
cells into lethally irradiated C57BL6 mouse recipients. By two months post-
reconstitution, mice were sacrificed and coexpression of miR-155 and GFP was 
detected in various hematopoietic tissues, including the bone marrow (Fig. 2B), thymus, 
spleen, and lymph nodes (Supplemental Fig. 2). Control mice only expressed GFP but 
not miR-155. 
 Gross analyses of femurs and tibias from mice expressing miR-155 revealed a 
white-tan bone marrow coloration unlike the vibrant red seen in controls (Fig. 2C). Upon 
microscopic inspection of H&E-stained bone marrow sections and Wright-stained bone 
marrow smears (Fig. 2D), miR-155-expressing bone marrow was dominated by GM 
cells at a variety of either normal or abnormal developmental stages based upon their 
morphology (Fig. 2E). Indeed, many of the cells that appeared to be granulocytic 
precursors showed irregular segmentation of their nuclei and lacked condensation of 
nuclear chromatin. Conversely, miR-155 expression also lead to a reduction in 
erythrocytes, megakaryocytes and lymphocytes in the bone marrow (Figs. 2D and 2E).  
Flow cytometry identified approximately twice as many CD11b+GR1+ GM cells, 
very few Ter119+ erythroid precursors and a reduction in B220+ B-cells in the bone 
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marrow of mice expressing miR-155 versus the control vector (Fig. 2F). When gated on 
GFP+ cells (expressing miR-155), there was a dramatic increase in large, granular cells, 
as defined by having high Forward Scatter (FSC) and Side Scatter (SSC), respectively 
(Fig. 2G). Back-gating confirmed that these cells were Mac1+, with a majority also 
positive for Gr1. Furthermore, the cells responsible for the overall GM, B and erythroid 
precursor differences were largely GFP+ (Fig. 2H). These observations reveal profound 
myeloid proliferation with dysplastic changes in the bone marrow of mice expressing 
miR-155 compared to controls.  
  
MiR-155 expression in hematopoietic stem cells causes splenomegaly and 
extramedullary hematopoiesis 
Splenomegaly was observed in miR-155-expressing compared to control mice 
(Fig. 3A). H&E staining of splenic sections from miR-155-expressing mice revealed 
expanded interfollicular regions containing various hematopoietic elements, as well as 
constricted and disrupted B-cell follicles compared to control spleens (Fig. 3B). Upon 
analyses of Wright-stained splenic touch preparations we observed a large number of 
erythroid precursors, megakaryocytes and some developing GM cells in the spleens of 
miR-155-expressing mice, while very few of these cell types in control spleens (Fig. 3B).  
FACS analyses corroborated these observations: we saw elevated numbers of 
Mac1+Gr1+ myeloid cells and Ter119+ erythroid cells, with little change in CD4+ T cells 
and B220+ B-cells in miR-155-expressing compared to control spleens (Fig. 3C). When 
gated on GFP+ cells (expressing miR-155), there were elevated numbers of large, 
granular cells, as defined by having high FSC and SSC, respectively, with a majority 
coexpressing Mac1 and Gr1 (Fig. 3D). Furthermore, miR-155-expressing splenocytes 
contained overall higher numbers of Mac1+ cells that expressed GFP compared to 
controls (Fig. 3E). Conversely, the Ter-119+ cell population from miR-155-expressing 
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spleens was largely negative for GFP, possibly arising from non-transduced HSCs. 
These results clearly demonstrate the presence of splenic extramedullary hematopoiesis 
in miR-155-expressing mice, likely compensating for the bone marrow defects.  
 
Expression of miR-155 in hematopoietic stem cells perturbs peripheral blood cell 
populations 
Consistent with the disrupted hematopoiesis observed in miR-155-expressing 
mice, their peripheral blood demonstrated several distinct abnormalities compared to 
controls. By two months post-reconstitution, FACS detected significantly elevated 
numbers of Mac1+ cells (Fig. 4A), and Wright stained blood smears revealed the 
presence of morphologically abnormal GM cells in miR-155 expressing mice (Fig. 4B). 
Complete blood cell counts showed a significant reduction in red blood cell, hemoglobin, 
and platelet levels (Fig. 4C), FACS found decreased B220+ B-cells and CD4+ T 
lymphocytes (Fig. 4c), and Wright staining identified several immature erythrocytes 
demonstrating polychromatophilia in miR-155-expressing animals (Fig. 4D).  
 
A subset of human AML patients overexpress miR-155 
Several of the pathological features observed in miR-155-expressing mice are 
associated with human myeloid malignancies, including acute myeloid leukemia (AML). 
Therefore, bone marrow samples from 24 AML patients and 6 normal people were 
assayed for miR-155 and 5S expression levels by quantitative PCR. On average, the 
AML samples significantly overexpressed miR-155 compared to healthy donors, with a 
level approximately 4.5 times higher (Fig. 5A). A few AML samples had miR-155 levels 
that were lower than the normal samples, while the overall AML sample distribution had 
a wide variance. In contrast, no significant difference in the average expression levels of 
5S RNA was observed between the groups (Fig. 5A). MiR-155 levels in different 
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subtypes of AML were next ascertained using the WHO classification system. Patients 
with acute myelomonocytic leukemia and acute monocytic leukemia, corresponding to 
FAB-AML-M4 and FAB-AML-M5, respectively, exhibited significant overexpression of 
miR-155 compared to normal samples (Fig. 5B). These observations demonstrate that 
miR-155 expression in the bone marrow is significantly elevated in a subset of patients 
suffering from AML.  
 
MiR-155 can directly repress genes implicated in hematopoietic development and 
disease 
MiRNAs exert their biological functions through the degradation and/or 
translational repression of target mRNAs. To identify miR-155 target genes that may be 
involved in the observed myeloproliferative phenotype, we first transduced RAW 264.7 
myeloid cells with a miR-155-expressing retrovirus that increased miR-155 cellular levels 
within 2 fold of those observed following LPS stimulation (Supplemental Fig. 3). A mRNA 
microarray analysis was next performed on RNA samples collected from miR-155 
expressing and control cells to identify genes regulated by miR-155 (Supplemental Fig. 
4). 1080 transcripts were downregulated more than 1.2 fold with a p value of < 0.08 and 
89 of the repressed mRNAs contained conserved (human and mouse) miR-155 binding 
sites with 7- or 8-mer seeds in their 3’ UTRs according to published lists of 
computationally predicted target genes found on the Targetscan 4.0 website (Lewis, 
Shih et al. 2003; Grimson, Farh et al. 2007). Finally, genes with reported roles in myeloid 
hyperplasias and/or hematopoiesis were identified through literature searching. Using 
these criteria, our attention was drawn to 10 candidate targets: Bach1, Sla, Cutl1, Csf1r, 
Jarid2, Cebpb, PU.1, Arntl, Hif1a and Picalm (Fig. 6A). To confirm the microarray 
results, qPCR was performed using gene specific primers: it showed that the mRNAs 
encoding these proteins were downregulated approximately 20% to 70% in RAW 264.7 
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cells expressing miR-155 versus empty vector control (Fig. 6A). We also observed 
strong repression of Cebpb, PU.1, Cutl1 and Picalm protein levels in RAW 264.7 cells 
expressing miR-155 (Fig. 6B).  
 Next, we tested whether miR-155 could directly repress the identified mRNA 
targets through 3’ UTR interactions. Each full length 3’ UTR, or in 2 cases (Bach1 and 
Cebpb) the region of the UTR containing the miR-155 binding site/s, was cloned into a 
reporter vector downstream from luciferase. These vectors were then used to assess 
whether miR-155 could repress luciferase gene expression in 293T cells. From 22% to 
73% repression of luciferase expression was observed depending upon the 3’ UTR 
tested (Fig. 7). There was even a rough correlation between the qPCR results in RAW 
264.7 cells and the luciferase repression in 293T cells. To demonstrate a direct 
interaction between miR-155 and the 3’ UTRs tested, we systematically mutated each 
conserved miR-155 7- or 8-mer seed region and found that a majority of the miR-155-
mediated repression was abolished (Figure 7). As a control, miR-155 repressed a 
reporter construct containing tandem miR-155 sites approximately 80%. However, 
luciferase levels were relatively unaffected when the Traf6 or Irak1 3’ UTRs were tested, 
consistent with their lack of miR-155 binding sites (Fig. 7). These results provide strong 
evidence that miR-155 can directly regulate several genes with relevance to 
hematopoiesis and the myeloproliferative phenotype.  
 
Discussion 
 As cells of the innate immune system combat infectious pathogens, their 
numbers are often depleted and must be replenished. This process is characterized by 
an increased production of GM populations, a response shown to involve GM-CSF- and 
LPS-mediated signaling events (Zhan, Lieschke et al. 1998; Ueda, Kondo et al. 2005; 
 
24 
Nagai, Garrett et al. 2006). Our present findings demonstrate that miR-155 is induced by 
GM-CSF and LPS in the bone marrow compartment, and sufficient to increase the 
relative and absolute numbers of GM cells when expressed in HSCs and throughout 
hematopoietic development. This expansion appears to be at the expense of B 
lymphocytes and erythroid precursors in the bone marrow, as also observed following 
LPS treatment. Thus, miR-155 may play a regulatory role in hematopoietic cell fates 
during times of inflammatory stress when factors like LPS or GM-CSF are present. 
Because stimulation of most Toll-like receptors induces miR-155 in macrophages 
(O'Connell, Taganov et al. 2007), our results with LPS can probably be generalized to 
many conditions of microbial invasion.    
It remains unclear whether miR-155 participates in hematopoiesis under steady-
state conditions. A recent study detected miR-155 expression in human CD34+ cells, a 
population containing HSCs and early progenitors of lymphoid and myeloid lineages 
(Georgantas, Hildreth et al. 2007). However, defective myeloid populations in miR-155 
deficient mice were not observed when analyzed under steady-state (non-inflammatory) 
conditions (Rodriguez, Vigorito et al. 2007).     
Whether miR-155 is only sufficient or in fact required for increased myelopoiesis 
during inflammation, our findings demonstrate that its unregulated expression triggers a 
myeloproliferative disorder, exhibiting many pre-leukemic aspects. Because frank 
myeloid leukemia was not observed in any of our mice analyzed within 2 months of 
reconstitution with miR-155-expressing HSCs, such a transition may require additional 
mutations. However, the relevance of our observed phenotype in mice is substantiated 
by the elevated expression levels of miR-155 seen in human patients with AML. 
Interestingly, the two AML subgroups found to be overexpressing miR-155 are 
characterized as myelomonocytic (M4) and monocytic (M5), both thought to be derived 
from cells demonstrating aspects of GM cell differentiation, similar to the expanded GM 
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cells in our miR-155-expressing mice. It is of note that miR-155 may also be elevated in 
other subtypes of AML where we did not have enough samples to make such a 
conclusion. If miR-155 does prove to be dysregulated in specific subtypes of AML, it 
might complement the recent finding that miR181 expression positively correlates with 
M1 and M2 subtypes of AML, but not M4 or M5. Furthermore, as the full spectrum of 
miRNAs that become dysregulated during AML is defined, these small RNAs may prove 
to have utility as diagnostic indicators of AML subtypes (Debernardi, Skoulakis et al. 
2007). 
Despite the similarities mentioned above, certain aspects of the miR-155-induced 
myeloproliferative phenotype were not observed following LPS-mediated acute 
inflammation, including extramedullary hematopoiesis, GM dysplasia, peripheral blood 
leukopenia and polychromatophilic RBCs, and reduced megakaryocyte and platelet 
levels (data not shown). These observations may reflect a differential effect of sustained 
miR-155 expression in cell types that require strictly regulated levels of this miRNA. 
However, chronic inflammation (which may also sustain high miR-155 expression levels) 
might trigger some of these pathological events given enough time. For instance, 
following months of polymicrobial sepsis in mice, there is reported extramedullary 
hematopoiesis in the spleen and significantly increased numbers of morphologically 
heterogeneous GM cells in both the spleen and bone marrow compartments (Delano, 
Scumpia et al. 2007). The inflammatory response in the bone marrow involves profound 
myeloid proliferation, and through factors such as miR-155, may prove to create a 
microenvironment suitable for cancer formation and development if not resolved in a 
timely manner.  
Unlike a previous report, which found that B-cell restricted, transgenic expression 
of miR-155 triggers B-cell lymphoma in mice (Costinean, Zanesi et al. 2006), we did not 
observe a B-cell malignancy in our model. This may be explained by differences in the 
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systems used, because our model allows for miR-155 expression beginning in adult 
hematopoietic stem cells, which precedes formation of pro-B-cells during hematopoietic 
development (Rosenbauer and Tenen 2007). These observations suggest that miR-155 
may trigger unique phenotypes when expressed at different stages or in distinct cell 
type/s during hematopoiesis. There is also evidence that developing B-cells and GMs 
may occupy an overlapping bone marrow niche. Based upon our current findings, miR-
155 expression may allow for GM progenitors to dominate this compartment and inhibit 
B-cell development, which has been proposed to occur during inflammation (Ueda, 
Kondo et al. 2005). This mechanism might also block events required for miR-155-
dependent B-cell transformation.   
In an effort to explore the mechanistic basis for the myeloproliferative phenotype 
caused by HSC expression of miR-155, we identified several mRNA targets that were 
directly repressed by miR-155 according to 3’ UTR reporter assays. Of note, the reduced 
expression or altered function of some of these targets has been linked to AML, as in the 
case of PU.1 and Picalm (Metcalf, Dakic et al. 2006; Okada, Jiang et al. 2006), or 
myeloproliferative conditions, as is true for Cutl1 and Csf1r (Sinclair, Lee et al. 2001; 
Fontana, Pelosi et al. 2007). Other identified targets have been implicated in control of 
various aspects of hematopoiesis involving many of the cell types that are perturbed in 
mice expressing miR-155 in HSCs. These include Cebpb (Hirai, Zhang et al. 2006), 
Bach1 (Toki, Katsuoka et al. 2005), Arntl (Scortegagna, Morris et al. 2003), Sla 
(Dragone, Myers et al. 2006), Jarid2 (Kitajima, Kojima et al. 1999), and Hif1a (Yoon, 
Pastore et al. 2006). Thus, miR-155 could mediate its overall biological affects, both 
physiological and pathological, through the combinatorial repression of a broad range of 
targets in a variety of cell types. Such a multi-target regulation has recently been 
described for T-cell receptor signaling (Li, Chau et al. 2007). Therefore, it is possible that 
complete rescue of this phenotype will not be achieved through replacing any one of the 
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specific miR-155 target genes. However, the specific spatial and temporal contributions 
of individual targets to the myeloproliferative phenotype and AML in the context of miR-
155 repression remains an area of future investigation.  
There is emerging evidence that individual miRNAs are part of a more complex 
regulatory network involving other miRNAs and transcriptional regulators that cooperate 
to govern myelopoiesis. For example, Csf1r is important for monocyte development and 
has recently been reported to be regulated indirectly by miRNAs 17-5p-20a-106a 
(Fontana, Pelosi et al. 2007).  miRNAs 17-5p-20a-106a repress the transcriptional 
regulator AML1 required for Csfr1 transcription. Therefore, both miRNAs 17-5p-20a-
106a and miR-155 can influence Csfr1 expression through different mechanisms. In the 
case of miR-155 targets PU.1 and Cebpb, they have been shown to transcriptionally 
regulate expression of miR-223, a myeloid-specific microRNA (Fukao, Fukuda et al. 
2007). miR-223 is subsequently involved in unleashing CEBPa function, a central 
transcription factor in myelopoiesis, through the direct repression of its inhibitor NFI-A 
(Fazi, Rosa et al. 2005). Such dynamic systems require appropriate miRNA expression 
levels and kinetics to carefully orchestrate hematopoietic development, as has been 
recently described during T cell development in the thymus (Neilson, Zheng et al. 2007). 
However, it is easy to see how this delicate process would be vulnerable to dysregulated 
miRNA expression leading to pathological outcomes. This concept is exemplified by the 
dysplastic features observed in many GM cells from our miR-155-expressing mice. It is 
possible that while initial miR-155 expression expands GM numbers, its timely 
downregulation is necessary for these cells to complete their developmental programs. 
Such a model would be consistent with the transient expression of miR-155 that 
precedes expansion of morphologically normal GM populations in the bone marrow after 
LPS treatment. 
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Based upon our current study, miR-155 appears to play a role in promoting GM 
cell expansion during inflammatory responses, while initiating pathological processes 
under forced expression. Due to the enhanced expression of miR-155 in a subset of 
AML patients, and its ability to repress several genes relevant to myeloid malignancies, 
therapeutic targeting of miR-155 with such agents as antagomirs may provide a 
beneficial option (Krutzfeldt, Rajewsky et al. 2005). Because miR-155 knockout mice 
display few detrimental phenotypes in the absence of infection (Rodriguez, Vigorito et al. 
2007), decreasing miR-155 function in human patients suffering from myeloid, lymphoid 
or other malignancies correlated with enhanced miR-155 expression may provide more 
benefits than harm.  
 
Materials and Methods 
Cell culture and reagents. RAW 264.7 and 293T cells were both cultured in complete 
DMEM containing 10% FBS, 100 units/ml penicillin, and 100 units/ml streptomycin with 
5% C02. LPS from E.coli strain 055:B5 was purchased from Sigma Aldrich, and 
recombinant mouse GM-CSF from eBioscience.  
DNA constructs. A miR-155 expression cassette containing the human miR-155 hairpin 
sequence and flanking regions was cloned from a B-cell cDNA library into pcDNA3 as 
described (Eis, Tam et al. 2005). This cassette was subcloned into pMSCVpuro, FUW, 
or pMG. pMG155 is a modified MSCV vector whereby GFP was placed downstream 
from the 5’ LTR, and the miR-155 expression cassette was cloned downstream from the 
GFP stop codon (detailed cloning strategy available upon request). For reporter assays, 
the 3’UTRs of the respective mRNAs were cloned into pmiReport (Ambion) after 
amplification from a mouse macrophage cDNA library. Primer sequences are described 
in Supplemental Table 1. The Bach1 3’ UTR region was amplified from a human B cell 
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library. Site directed mutagenesis was used to change specific nucleotides found within 
the miR-155 seed regions (Supplemental Table 2). The 2-mer Control insert consists of 
a tandem repeat of the complimentary sequence to the mature mouse miR-155 
sequence. Cloning of the TRAF6 and IRAK1 3’ UTR into pmiReport was previously 
described (Taganov, Boldin et al. 2006). 
Mice. Wt C57BL6 mice were purchased from the Jackson Laboratories and Rag1-/- 
mice were bred in house. All experiments involved female mice and were carried out 
according to IACUC approved protocols. 
Retroviral infections, stable lines and bone marrow reconstitution. To generate 
VsVg pseudotyped retroviruses containing the miR-155 expression cassette, 2x106 293T 
cells were transfected with pMSCVpuro-miR-155, pGag-Pol, and pVsVg using a 
standard calcium phosphate protocol. After 48 hours, viral supernatant was harvested 
and used to infect 5x105 RAW 264.7 cells for 8 hours in the presence of polybrene at 10 
ug/ml. Following 48 hours, stably transfected cells were selected using puromycin at 7 
ug/ml, and miR-155 expression was assessed at the same time as experiments were 
performed by Northern blotting or QPCR for all batches made.  
To obtain HSC-enriched bone marrow cells, mice were injected intraperitoneally 
with 5 ug of 5-Fluorouracil for 5 days prior to bone marrow harvest (Yang and Baltimore 
2005). Cells were collected from the bone marrow and RBCs were removed using an 
RBC lysis solution (Invitrogen). Cells were cultured for 24 hours in IL-3 (20 ng/ml), IL-6 
(50 ng/ml) and SCF (50 ng/ml), all from eBioscience, containing complete RPMI (10% 
FBS, 100 units/ml penicillin, 100 units/ml streptomycin, and 50 uM beta-
marcaptoethanol) before initial retroviral infection. To generate retroviruses for infecting 
HSC-enriched bone marrow cells, 293Ts were transfected with pMG155 and pCL-Eco. 
After 48 hours, polybrene (8 ug/ml) was added to culture supernatant containing 
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retroviruses and this was used to spin infect 106 HSC-enriched cells per donor for 1.5 hrs 
at 2500 RPM and 30 degrees Celsius. This procedure was repeated 3 times once daily, 
followed by injection of 106 retrovirally infected, HSC-enriched cells per lethally irradiated 
(1100 Rads from Cesium 137 source at 50 Rads/minute) recipient. Recipients were 
maintained on Septra throughout the reconstitution period.   
RNA quantification. Northern blotting and qPCR were used to assay miR-155 and 
other mRNAs as described (O'Connell, Taganov et al. 2007). Gene-specific primer 
sequences used for qPCR are located in Supplemental Table 3. For the microarray 
study, total RNA was collected from 5 RAW 264.7 stably infected clones expressing 
miR-155 or empty vector using the RNeasy Mini Kit per manufacturer’s instructions 
(Qiagen). The microarray analysis was then carried out using pooled RNA from each 
group by the Millard and Muriel Jacobs Genetics and Genomics Laboratory at Caltech 
according to their detailed protocols (http://mmjggl.caltech.edu). Data was analyzed 
using Rosetta Resolver Software.  
Western blotting. Western blotting was performed using standard protocols and the 
following antibody clones from Santa Cruz Biotechnology: Cebpb (C-19), PU.1 (T-21), 
Cutl1 (M-222), Picalm (C-18) and aTubulin (AA12). Protein expression differences were 
determined using Scion Image software. 
Flow cytometry. Fluorophor-conjugated monoclonal antibodies specific for either Mac1, 
Gr1, Ter-119, B220, and CD4 (all from eBiosciences) were used in various combinations 
to stain RBC-depleted splenocytes, bone marrow or peripheral blood mononuclear cells, 
and fixed after washing using paraformaldehyde (1% final). Stained cells were assayed 
using a BD FACSCaliber flow cytometer and further analyzed with FloJo software. 
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Luciferase reporter assays. 8 x 104 293T cells were plated in DMEM media containing 
5% FBS for 12 hours, followed by transfection of relevant plasmids using Lipofectamine 
(Invitrogen) per manufacturer’s instructions. Luciferase assays were performed 48 hours 
later using a dual luciferase kit (Promega). A β-gal expression plasmid was 
cotransfected and β-gal levels were assayed and used to normalize the luciferase 
values. 
Human AML sample collection and analysis. Bone marrow biopsy samples collected 
from patients with acute myeloid leukemia were flash frozen and stored at -80C after the 
completion of diagnostic work in a tissue bank at UCLA. For this study, 24 samples were 
rapidly thawed and subjected to TRIzol purification of RNA. In addition, 6 RNA samples 
were isolated from normal volunteers. AML cases were categorized according to the 
World Health Organization “Classification of Tumors” using anonymous clinical reports. 
All work performed on these tissues was approved by the Institutional Review Board 
(IRB) at UCLA, and required written consent by the participating patients. 
Morphologic assessment of hematolymphoid tissues. For histologic sectioning, 
organs were placed into 10% neutral buffered formalin immediately after necropsy, fixed 
for 12-18 hours, washed and transferred to 70% ethanol prior to standard paraffin 
embedding, sectioning and staining with H&E. Bones were also decalcified. For cytologic 
assessment, touch preparations were made of the cut surface of the spleen. Peripheral 
blood smears were obtained from tail vein bleeds or from the heart at necropsy. Bone 
marrow smears were prepared from extracted bone marrow of reconstituted mice. All 
cytologic preparations were air dried, and stained with Wright’s stain. Both histologic and 
cytologic preparations were examined on an Olympus BX-51 microscope, and 
photographed using a Spot® Digital Camera and software. Complete blood cell counts 
were performed at UCLA’s Department of Laboratory Animal Medicine. 
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Statistical tests. All statistical analyses were performed using Microsoft Excel ® 
statistical software module. For patient samples, an F-test determined that the 
distributions of miR-155 expression in normal samples versus AML samples were 
heteroscedastic (p=4.5x10-6 for F-test). Similarly, the distributions of miR-155 
expression in normal versus AML-M4 was determined to be heteroscedastic 
(p=0.000018 for F-test). Following this, a two-tailed T-test was performed assuming 
heteroscedastic distributions for both comparisons. For all other data, a student’s two-
tailed T-test was used.     
Online supplemental material. Supplemental Figure 1 provides FACS data showing 
the percentage of Mac1+, Gr1+, B220+, Ter119+ or CD4+ cells in the bone marrow 
following 24 hours of LPS versus PBS treatment. Supplemental Figure 2 presents the 
coexpression of miR-155 and GFP in several different immune organs from reconstituted 
mice. Supplemental Figure 3 compares miR-155 expression in Raw 264.7 cells and 
primary macrophages mediated by retroviral overexpression versus LPS stimulation. 
Supplemental Figure 4 outlines the scheme used to identify miR-155 targets with 
relevance to hematopoiesis. Supplemental Table 1 provides the primer sequences used 
for cloning different 3’ UTRs into pmiReport. Supplemental Table 2 provides sequence 
information regarding mutations introduced into the 3’ UTRs used for reporter assays. 
Supplemental Table 3 provides the primer sequences used to assay miR-155 target 
mRNAs by qPCR.   
 
Figure Legends 
Figure 1. LPS treatment induces bone marrow expression of miR-155 prior to GM 
expansion. (A) Wt mice (n=3 per group) were injected i.p. with 50 ug of LPS (dissolved 
in PBS), or PBS alone. RNA was collected from total bone marrow cells and miR-155 
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expression assayed by qPCR (mean +/-SD). (B) Bone marrow was flushed out of femurs 
and tibias of Wt and Rag1-/- mice, stimulated with LPS (100 ng/ml), GM-CSF (GM)(100 
ng/ml) or medium (M) for 24 hours, and RNA was then assayed for miR-155 expression 
levels (mean +/-SD). NC-no template control. (C) BM cells collected from mice in A at 
the 72 hour timepoint were stained with antibodies against Mac1, Gr1, B220, Ter-119 or 
CD4 and analyzed by FACS. (D) Wright-stained bone marrow smears (top, scale bar=60 
mM) or H&E-stained bone marrow sections (bottom, scale bar=25 mM) from Wt mice 
injected with LPS or PBS for 72 hours. 
 
Figure 2. Expression of miR-155 in HSCs causes a myeloproliferative disorder in 
the bone marrow. (A) Depiction of the retroviral construct used to enable both miR-155 
and GFP expression in HSCs. (B) Bone marrow cells of mice reconstituted with MG155- 
or control vector-infected HSCs were analyzed for their expression of GFP by FACS, 
where the % of GFP positive cells is indicated: black line-C57BL6 control; grey line-
MG155 or control vector. Cells from the same compartments were analyzed for miR-155 
expression using qPCR (mean +/- SD). (C) Tibias were removed from mice reconstituted 
with MG155 or control vector HSCs for 2 months, or untreated C57BL6 (B6) mice, and 
photographs were taken. (D) H&E-stained bone marrow sections from miR-155-
expressing or control mice (scale bar=60 mM) (E) Wright-stained bone marrow smears 
from mice reconstituted with MG155 or control vector HSCs (scale bar=25 mm). 
Examples of dysplastic myeloid cells observed in miR-155-expressing bone marrow are 
enlarged on the left. (F) Number of specified cell types found in the bone marrow (1 
femur+1 tibia) of mice reconstituted with MG155 or control vector HSCs (mean +/- SD). 
(G) GFP-gated bone marrow cells from mice reconstituted with MG155 or control vector 
HSCs were analyzed for Forward (FSC) and Side (SSC) Scatter Counts and expression 
of Mac1 and Gr1. (H) Bone marrow cells from mice reconstituted with MG155 or control 
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vector HSCs were analyzed for expression of Mac1, Ter-119 or B220 on both GFP 
positive and negative cells by FACS. Data represent at least 6 independent animals in 
each group and *p values of < 0.05 were considered significant following a student’s 2 
tailed t-test. 
  
Figure 3. Expression of miR-155 in HSCs triggers extramedullary hematopoiesis in 
the spleen. (A) Spleens were removed from mice reconstituted with MG155 or control 
vector HSCs for 2 months and photographs were taken (top). Spleen weight was also 
determined in the two groups (bottom, mean +/- SD). (B) H&E stained sections (top, 
scale bar=200 mm) or Wright stained touch preps (bottom, scale bar=25 mm) from mice 
reconstituted with MG155 or control vector HSCs. (C) Number of specified cell types 
found in the spleens of mice reconstituted with MG155 or control vector HSCs (mean +/- 
SD). (D) GFP-gated spleen cells from mice reconstituted with MG155 or control vector 
HSCs were analyzed for Forward (FSC) and Side (SSC) Scatter Counts and expression 
of Mac1 and Gr1. (E) Splenocytes from mice reconstituted with MG155 or control vector 
HSCs were analyzed for expression of Mac1, Ter-119, CD4 or B220 on GFP positive 
and negative cells by FACS. Data represent at least 6 independent animals in each 
group and *p values of < 0.05 were considered significant using a student’s 2 tailed t-
test. 
 
Figure 4. Expression of miR-155 in HSCs perturbs peripheral blood cell 
populations. (A) Peripheral blood was collected from mice reconstituted with MG155 or 
control vector HSCs for 2 months and analyzed by FACS to determine Forward (FSC) 
and Side (SSC) Scatter Counts and expression of Mac1. Total Mac1 cells were also 
determined. (B) Photomicrographs of a normal Wright stained monocyte (Mo) and 
neutrophil (Ne) from the blood of mice reconstituted with control vector HSCs, and 2 
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examples of the Wright stained irregular myeloid cells found in MG155 HSC 
reconstituted animals. (C) RBC, Hemoglobin (Hb), platelet, WBC, B220 B-cell and CD4 
T cell levels in the blood of mice reconstituted with MG155 or control vector HSCs. (D) 
Microscopic photographs of Wright stained peripheral blood RBCs from mice 
reconstituted with MG155 or control vector HSCs. Data represent at least 9 independent 
animals in each group and *p values of < 0.05 were considered significant following a 
student’s 2 tailed t-test. 
 
Figure 5. Overexpression of miR-155 in a subset of human AML patients. (A) RNA 
was collected from the bone marrow of 6 normal patients and 24 patients diagnosed with 
AML. MiR-155 (left) and 5S RNA (right) expression levels were assessed using qPCR. 
(B) MiR-155 and 5S RNA expression data were compared between normal subjects and 
AML patients of the FAB subtypes M4 and M5. *Group differences were considered 
statistically significant when the p value was < 0.05. 
 
Figure 6. Repression of specific target genes involved in myeloid hyperplasia 
and/or hematopoiesis by miR-155. (A) Messenger RNA from Raw 264.7 cells infected 
with MSCVpuro-155 or empty vector control was subjected to a microarray analysis and 
results indicate expression changes mediated by miR-155. The intensities of red and 
green correlate with increased or decreased mRNA levels, respectively, and numerical 
repression values for each mRNA are listed. RNA from the same cell types were 
converted to cDNA and used to assay expression of these genes by qPCR (mean +/- 
SD). All values have been normalized to L32 mRNA levels, are displayed as % 
expression of control, and are the average of 3 independent experiments. (B) Western 
blotting was performed to assay Cebpb, PU.1, Cutl1, Picalm or aTubulin using extract 
from Raw 264.7 cells stably expressing miR-155 or empty vector, and data are 
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representative of at least 3 independent experiments (left). Expression of miR-155 in 
Raw 264.7 cells infected with MSCVpuro-155 or empty vector control was assayed by 
Northern blotting to ensure proper expression of mature miR-155. 
 
Figure 7. MiR-155 repression of specific target genes occurs through direct 3’ UTR 
interactions. (A) The 3’ UTR regions from identified miR-155 target mRNAs containing 
the miR-155 binding site/s with conserved 7- or 8-mer seeds (grey boxes), non-
conserved 7-mer seed (Arntl, white box) or conserved 6-mer seed (Cutl1, white box), 
were cloned downstream from luciferase (pmiReport vector). Mutations to these specific 
seed regions are marked with an X. The region of the 3’ UTR cloned is designated with a 
red line, and the cartoon schematics of the UTRs are not drawn to scale. These 
constructs were used for reporter assays in 293T cells by co-transfection with a control 
b-galactosidase expression plasmid, and a miR-155 expression vector (FUW-155) or 
empty vector control (FUW). Control vectors containing tandem miR-155 binding sites or 
the 3’ UTR from Irak1 Traf6 which lack miR-155 sites, were also included. Wt 3’ UTRs 
are in black, while mutant UTRs are in grey. All luciferase values have been normalized 
to β-galactosidase, and are represented as % luciferase expression of control (mean +/- 
SD). All data are a triplicate set representing at least two independent experiments.  
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Figures 
 
 
Figure 1.  LPS treatment induces bone marrow expression of miR-155 prior to GM 
expansion 
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Figure 2.  Expression of miR-155 causes a myeloproliferative disorder in the bone 
marrow 
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Figure 3.  Expression of miR-155 in HSCs triggers extramedullary hematopoiesis 
in the spleen 
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Figure 4.  Expression of miR-155 in HSCs perturbs peripheral blood cell 
populations 
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Figure 5.  Overexpression of miR-155 in a subset of human AML patients 
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Figure 6.  Repression of specific target genes involved in myeloid hyperplasia 
and/or hematopoiesis by miR-155 
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Figure 7.  MiR-155 repression of specific target genes occurs through direct 3’ 
UTR interactions 
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Supplemental Figures 
 
 
Figure S1.  Mature cell–depleted bone marrow populations upregulate miR-155 to 
higher levels in response to LPS than mature cell–enriched populations. Mature 
cell–enriched populations were positively selected from mouse bone marrow using 
biotinylated antibodies against Mac-1, B220, and Ter119, and streptavidin-conjugated 
magnetic beads and a MACS column. Mature cell–depleted populations were negatively 
selected using the same column. FACS was used to verify the presence or absence of 
lineage marker expression. Cells were stimulated with medium or LPS (100 ng/ml) for 6 
or 24 h, followed by miR-155 expression quantification by quantitative PCR. 
 
45 
 
 
 
 
 
 
Figure S2.  Bone marrow cell dynamics after 24 h of LPS treatment. C57BL6 mice 
were injected i.p. with 50 µg LPS or PBS for 24 h. B220, Gr1, or Mac1 surface 
expression was assayed on RBC-depleted bone marrow cells using FACS. 
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Figure S3.  Coexpression of GFP and miR-155 in several lymphoid organs.  
RBC-depleted cells from the spleen (sp), lymph nodes (ln), and thymus (th) of mice 
reconstituted with MG155- or control vector–infected HSCs were analyzed for their 
expression of GFP by FACS, where the percentage of GFP+ cells is indicated. Black 
line, C57BL6 control; gray line, MG155 or control vector. Cells from the same 
compartments were analyzed for miR-155 expression using quantitative PCR. 
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Figure S4.  Comparative expression of miR-155 induced by LPS or produced from 
MSCV-155 in myeloid cells. MiR-155 expression was assayed in (left) Raw264.7 cells 
stably transfected with MSCV and treated with media or 50 ng/ml LPS, stably infected 
with MSCV-155 or (right) bone marrow–derived macrophages (BMMs) generated from 
MG-infected bone marrow treated with media or LPS (5 ng/ml), or generated from 
MG155-infected bone marrow. 
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Figure S5.  MiR-155 target identification and analysis scheme 
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Supplemental Tables 
 
Table S1.  Primer sequences used for cloning 
Primer Name Sequence 
Bach1 F CCAGAGCTTAAATATAATTTGTAAAGC 
Bach1 R ACATTGAGAAGGCCAGTTCATAA  
Sla F GTAACTAGTTGACCTGGCTTGTACACACAC  
Sla R GTTAAGCTTTAAATACATGATTTGGCAAAGTGTAA  
Cutl1 F TCAAGAGCTCGGCAAAATCGCCATAGGC  
Cutl1 R AGCTACGCGTCCCTTCCTAACAATCAGATTAATAAAAT  
Csf1r F GTAACTAGTTCCTGCCGCTCTCTACGT  
Csf1r R GTTAGCTTCTGGCTGTGTTAATGCTGTTAGTT  
Jarid2 F GTAACTAGTAGATGCCGAACCCATGGT  
Jarid2 R GTTAAGCTTATGAAGAGAAAAAATAGACAAGAGGA  
Cebpb F GTAACTAGTTGCAATCCGGATCAAACG  
Cebpb R GTTAAGCTTGGCTTTTAAACATTCTCCAAAAAA  
PU.1 F GTAACTAGTCCGGCCATAGCATTAACC  
PU.1 R GTTAAGCTTGGGAGAATAGCTGTCAATAATTTTACT  
Arntl F GTAACTAGTACACTACATTTGCTTTGGCAAC  
Arntl R AGCTACGCGTAGAACAAGGGAAACATTTATTAAAAAT  
Hif1a F TCAAGAGCTCCTGAGCGTTTCCTAATCTCATTC  
Hif1a R AGCTACGCGTCCTGGTCCACAGAAGATGTTT  
Picalm F TCAAGAGCTCATGGAAGAGAATGGAATTACTCCA  
Picalm R GTTAAGCTTTGTTTTGTGGAAGCTGCATT  
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Table S2.  MiR-155 3’ UTR seed sequences and introduced mutations  
(Mutated nucleotides are in red) 
miR-155 seed Wt  Mutant 
Bach1 1 AGCATTAA  AGGTAAAA 
Bach1 2 AGCATTA  AGGTAAA 
PU.1 AGCATTAA AGGTAAAA 
Cutl1 1 AGCATTAA AGGTAAAA 
Cutl1 2 GCATTA GCTAAA 
Picalm 1 GCATTAA GGAGTGA 
Picalm 2 AGCATTA AGCTAAA 
Arntl 1 GCATTAA GCAAATA 
Arntl 2 GCATTAA GCTAAAA 
Csf1r AGCATTAA AGCAAATA 
Sla AGCATTA AGCAAAT 
Arntl 1 GCATTAA GCAAATA 
Jarid2 1 AGCATTAA ACGTAATA 
Jarid2 2 AGCATTAA AGCAAATA 
Hif1a AGCATTA AGCAAAT 
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Table S3.  Primer sequences used for qPCR 
Primer Name Sequence 
Bach1 F TGAGTGAGAGTGCGGTATTTGC 
Bach1 R GTCAGTCTGGCCTACGATTCT 
Sla F ATGGGGAATAGCATGAAATCCAC 
Sla R GGAGATGGGTAGTCAGTCAGC 
Cutl1 F CGCAGAGAACTGTTCATTGAGG 
Cutl1 R GAGCTGAAGGTGAGTCGCT 
Csf1r F TGTCATCGAGCCTAGTGGC  
Csf1r R CGGGAGATTCAGGGTCCAAG  
Jarid2 F GAAGGCGGTAAATGGGCTTCT 
Jarid2 R TCGTTGCTAGTAGAGGACACTT 
Cebpb F GACAAGCACAGCGACGAGTA 
Cebpb R AGCTGCTCCACCTTCTTCTG  
PU.1 F ATGTTACAGGCGTGCAAAATGG 
PU.1 R TGATCGCTATGGCTTTCTCCA 
Arntl F ACCACAGGAACTTCTAGGTACAT 
Arntl R GGACATTGGCTAAAACAACAGTG  
Hif1a F ACCTTCATCGGAAACTCCAAAG 
Hif1a R ACTGTTAGGCTCAGGTGAACT 
Picalm F GTCTGTCCACGCCATGTCG 
Picalm R TAGCAGAGAAAGGATCTCCCC  
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Abstract 
MicroRNA-155 (miR-155) has emerged as a critical regulator of immune cell 
development, function and disease. However, the mechanistic basis for its impact on the 
hematopoietic system remains largely unresolved. Because miRNAs function by 
repressing expression of specific mRNAs through direct 3’UTR interactions, we have 
searched for targets of miR-155 implicated in the regulation of hematopoiesis. In the 
present study, we identify Src homology 2 domain-containing inositol 5-phosphatase 1 
(SHIP1) as a direct target of miR-155, and show using gain and loss of function 
approaches that miR-155 represses SHIP1 through direct 3’UTR interactions that have 
been highly conserved throughout evolution. Repression of endogenous SHIP1 by miR-
155 occurred following sustained overexpression of either mouse or human miR-155 in 
hematopoietic cells both in vitro and in vivo, and resulted in increased activation of the 
kinase Akt during the cellular response to LPS. Furthermore, SHIP1 was also repressed 
by physiologically regulated miR-155, which was observed in LPS treated wt versus 
miR-155-/- primary macrophages. In mice, specific knockdown of SHIP1 in the 
hematopoietic system following retroviral delivery of a miR-155 formatted siRNA against 
SHIP1 resulted in a myeloproliferative disorder (MPD) with striking similarities to that 
observed in miR-155 expressing mice. Our study unveils a molecular link between miR-
155 and SHIP1 and provides evidence that repression of SHIP1 is an important 
component of miR-155 biology.  
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Introduction 
 In recent years, microRNAs have emerged as critical regulators of gene 
expression in a variety of mammalian cell types, including cells of the immune system 
(Bartel and Chen 2004; Baltimore, Boldin et al. 2008; Lodish, Zhou et al. 2008). Through 
their ability to repress expression of specific target genes via direct 3’UTR interactions, 
several miRNAs have been shown to impact both physiological and pathological immune 
processes (He, Thomson et al. 2005; Costinean, Zanesi et al. 2006; Rodriguez, Vigorito 
et al. 2007; Thai, Calado et al. 2007; Xiao, Calado et al. 2007; Johnnidis, Harris et al. 
2008; O'Connell, Rao et al. 2008; Ventura, Young et al. 2008; Xiao, Srinivasan et al. 
2008). Among the most prominent and well studied immune system miRNAs to date, 
miR-155 clearly is involved in protective immunity when properly regulated, yet 
contributes to malignant conditions upon its dysregulated expression.  
 MiRNA-155 is expressed in a variety of immune cell types including B cells (Tam, 
Ben-Yehuda et al. 1997; van den Berg, Kroesen et al. 2003; Eis, Tam et al. 2005; 
Kluiver, Poppema et al. 2005; Fulci, Chiaretti et al. 2007; Rodriguez, Vigorito et al. 2007; 
Thai, Calado et al. 2007), T cells (Haasch, Chen et al. 2002), macrophages (Taganov, 
Boldin et al. 2006; O'Connell, Taganov et al. 2007), dendritic cells (Rodriguez, Vigorito et 
al. 2007) and progenitor/stem cell populations (Georgantas, Hildreth et al. 2007; 
O'Connell, Rao et al. 2008). Interestingly, miR-155 is found at low levels in most of these 
cells types until their activation by immune stimuli such as antigen, Toll-like Receptor 
ligands and/or inflammatory cytokines, which rapidly increase miR-155 expression 
(Haasch, Chen et al. 2002; Taganov, Boldin et al. 2006; O'Connell, Taganov et al. 2007; 
Rodriguez, Vigorito et al. 2007; Thai, Calado et al. 2007). Consistent with its expression 
pattern, miR-155 appears to function in hematopoiesis and the immune response 
(Rodriguez, Vigorito et al. 2007; Thai, Calado et al. 2007; O'Connell, Rao et al. 2008). 
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For example, defective germinal center formation and antibody isotype class switching 
have been observed in miR-155-/- mice following infection or vaccination (Rodriguez, 
Vigorito et al. 2007; Thai, Calado et al. 2007; Vigorito, Perks et al. 2007). In T cells, miR-
155 promotes skewing towards the Th1 subset (Rodriguez, Vigorito et al. 2007; Thai, 
Calado et al. 2007). In dendritic cells, miR-155 is necessary for proper activation of 
responder T cells in the context of antigen presentation (Rodriguez, Vigorito et al. 2007).  
Enhanced expression of miR-155 occurs constitutively in a subset of cancer cells 
of lymphoid (Tam, Ben-Yehuda et al. 1997; van den Berg, Kroesen et al. 2003; Eis, Tam 
et al. 2005; Kluiver, Poppema et al. 2005; Fulci, Chiaretti et al. 2007) and myeloid origin 
(Garzon, Garofalo et al. 2008; O'Connell, Rao et al. 2008). We and others have recently 
demonstrated that sustained expression of miR-155 in the hematopoietic system leads 
to pathological outcomes. Our group expressed miR-155 ubiquitously in the 
hematopoietic compartment via bone marrow transfer of HSCs infected with a retroviral 
vector. This caused a myeloproliferative disorder (MPD) characterized by increased 
granulocyte/monocyte (GM) populations in the bone marrow, peripheral blood and 
spleen, impaired erythropoiesis, and severe splenomegaly due to extramedullary 
hematopoiesis (O'Connell, Rao et al. 2008). Costinean et al. found that transgenic 
expression of miR-155 from a B cell–specific promoter can trigger a B cell malignancy 
(Costinean, Zanesi et al. 2006).  
While much has been learned about miR-155 expression patterns and functions, 
the molecular basis underlying its biology is relatively uncharacterized. As a result, we 
have been searching for novel targets of miR-155 implicated in overlapping biological 
processes. Using microarray technology, bioinformatics, and an extensive review of the 
literature we have identified the inositol phosphatase SHIP1 as a target of miR-155. 
Through both gain and loss of function approaches we demonstrate that miR-155 
represses SHIP1 through direct 3’UTR interactions during both sustained and 
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physiological expression of miR-155. Furthermore, specific knockdown of SHIP1 in the 
hematopoietic system using a miR-155 formatted siRNA against SHIP1 largely 
recapitulated the MPD phenotype we previously described in miR-155 expressing mice. 
Together, our data demonstrate a novel molecular link between miR-155 and SHIP1 in 
the immune system, and suggest that repression of SHIP1 is a critical aspect of miR-155 
function. 
 
Results 
MicroRNA-155 represses SHIP1 through 3’UTR interactions 
We previously performed a mRNA microarray analysis using RAW 264.7 
macrophages stably expressing miR-155 to identify possible targets of miR-155 
(O'Connell, Rao et al. 2008). Among the targets was SHIP1 (INPP5D), a gene that is 
repressed by miR-155 and which has a conserved 8-mer target “seed” in its 3’UTR 
(Figure 1A). SHIP1 was of particular interest because miR-155 is the only miRNA with a 
highly conserved binding site located in the SHIP1 3’UTR according to the Targetscan 
algorithm (Lewis, Burge et al. 2005), and because mice deficient in SHIP1 suffer from a 
myeloproliferative condition resembling that which we previously described for mice 
expressing miR-155 (Helgason, Damen et al. 1998; Liu, Sasaki et al. 1999; Helgason, 
Antonchuk et al. 2003; Harder, Quilici et al. 2004; O'Connell, Rao et al. 2008).  
To directly test whether miR-155 can repress SHIP1 through direct 3’UTR 
interactions, we cloned the 3’UTR of SHIP1 into a reporter plasmid downstream from 
luciferase and performed reporter assays using 293T cells. While miR-155 produced 
from a co-transfected plasmid repressed expression of luciferase fused to the wild-type 
(wt) SHIP1 3’UTR, it failed to repress the SHIP1 3’UTR containing a mutated miR-155 
seed sequence (Figure 1B). As controls, miR-155 repressed the Picalm 3’UTR and 2-
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mer control constructs, but not the control UTR without miR-155 sites (Figure 1B). These 
data reveal that miR-155 directly targets the SHIP1 3’UTR leading to repressed 
expression. 
To determine whether miR-155 can repress endogenous SHIP1, we assayed 
SHIP1 expression in RAW 264.7 cells expressing wt human miR155, human miR-155 
containing a mutated seed region, or vector control. SHIP1 was measured at the mRNA 
and protein levels by qPCR and Western blotting, respectively. Wt miR-155 repressed 
SHIP1 mRNA and protein below control levels, while the miR-155 seed mutant had little 
impact on SHIP1 expression compared with the vector control (Figures 1C and 1D). The 
wt miR-155 was overexpressed in cells receiving the wt miR-155 vector (Figure 1E) and 
the mature miR-155 seed mutant was produced in cells receiving the miR-155 seed 
mutant vector (Figure 1F), indicating that the specificity of the repression was 
determined by the seed region of miR-155.  
SHIP1 is well known to be a negative regulator of the kinase Akt, a downstream 
target of the phosphatidylinositol-3-kinase (PI3K) pathway. Therefore, we assayed Akt 
activation following LPS treatment of the different RAW 264.7 derivatives. Consistent 
with reduced SHIP1 levels, cells expressing wt human miR-155 exhibited increased 
activation of Akt following LPS treatment, while Akt activation was similar in the control 
and human miR-155 seed–mutant expressing cells (Figure 1G). Demonstrating 
conservation of function, mouse miR-155-expressing RAW 264.7 cells also had reduced 
SHIP1 expression (Figure 1H) and increased LPS-mediated Akt activation compared to 
control cells (Figure 1I). The data show that enforced expression of human or mouse 
miR-155 can directly repress expression of endogenous SHIP1 and lead to increased 
Akt activation in response to cellular activation. 
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Enhanced expression of SHIP1 in miR-155-/- macrophages following LPS treatment 
We next evaluated whether SHIP1 is regulated by miR-155 under physiological 
conditions. To achieve this we generated bone marrow-derived macrophages (BMMs) 
from either wt or miR-155-/- mice. As LPS has been shown to be a potent inducer of miR-
155 in macrophages (O'Connell, Taganov et al. 2007), we stimulated these cells with 
LPS over a time course. In wild-type cells, rapid induction of the miR-155 precursor, BIC, 
was followed shortly after by elevated expression of mature miR-155 (Figures 2A and 
2B), as previously seen with poly (I:C) treated BMMs (O'Connell, Taganov et al. 2007). 
We also noticed that while BIC levels fall considerably by 24h, miR-155 expression 
peaks at this timepoint. Protein levels of SHIP1 were assayed at 0h, 4h and 24h after 
LPS treatment of both wt and miR-155-/- BMMs. We observed no change in SHIP1 
protein levels up to 4h following LPS treatment in cells of both genotypes (Figure 2C). 
After 24h, both Wt and miR-155-/- BMMs demonstrated an increase in SHIP1 expression 
compared with earlier time points. However, miR-155-/- BMMs had an enhanced level of 
SHIP1 protein compared to wt control cells at this timepoint (Figure 2C). SHIP1 mRNA 
levels reflected similar differences between wt and miR-155-/- BMMs following 24h of 
LPS treatment (Figure 2D). These results are consistent with miR-155 repressing SHIP1 
expression after their induced coexpression by LPS, and demonstrate that this can occur 
under physiologically relevant conditions in primary cells. 
 
Knockdown of SHIP1 in vivo using siRNA in the context of miR-155 processing 
 Having identified SHIP1 as a direct target of miR-155, we next determined if 
specific knockdown of SHIP1 levels could recapitulate the miR-155 MPD phenotype in 
mice that we recently described (O'Connell, Rao et al. 2008). Although this phenotype is 
predicted by the MPD observed in SHIP1-/- mice (Helgason, Damen et al. 1998; Liu, 
Sasaki et al. 1999; Helgason, Antonchuk et al. 2003), we wanted to perform a specific 
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reduction in SHIP1 using the same retroviral vector and bone marrow reconstitution 
context we used to promote sustained miR-155 expression in the hematopoietic system. 
To accomplish this, we built a retroviral vector that expresses a miR-155 formatted 
SHIP1 siRNA cassette (Figure 3A). The cassette is driven by a RNA Polymerase II 
promoter and the hairpin arms and loop are comprised of mouse miR-155 sequences, 
while the stem structure contains an antisense sequence designed to target the SHIP1 
coding sequence (Figure 3A). Knockdown of other genes in vitro has been shown using 
this approach (Chung, Hart et al. 2006). Following construction of this vector, we stably 
infected RAW 264.7 cells and assayed SHIP1 expression. SHIP1 protein levels were 
markedly reduced in cells expressing the siRNA cassette, compared to the control vector 
(Figure 3B).  
We next tested whether we could achieve knockdown of SHIP1 expression in 
vivo by expressing miR-155 or the siRNA against SHIP1. To this end, HSC enriched 
bone marrow cells were infected with retroviral vectors encoding miR-155, siSHIP1 or 
controls and used to reconstitute lethally irradiated mice as we previously described for 
delivery of miR-155. Following 2 months of reconstitution, we analyzed SHIP1 
expression in the total bone marrow by qPCR. We observed a reduction in SHIP1 mRNA 
levels in mice expressing miR155 or siSHIP1 compared to control vectors (Figure 3C).  
 
Knockdown of SHIP1 in the hematopoietic compartment causes a MPD similar to 
that observed in mice expressing miR-155 
 Mice expressing miR-155, siSHIP1 or control vectors were next studied to 
determine their impact on hematopoietic populations after two months of reconstitution. 
Both miR-155 (human and mouse sequences) and siSHIP1 caused similar MPD 
phenotypes in the bone marrow and spleen compared to control vectors (Figures 4 and 
5). Gross analysis revealed a miR-155 or siSHIP1 dependent splenomegaly and pale 
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coloring of the bone marrow (Figure 5A and unpublished observations). Flow cytometry 
(FCM) detected an increase in CD11b+ (Mac1+) myeloid populations in the bone 
marrow and spleen (Figures 4A and 5A). The percentage of Ter119+ erythroid precursor 
cells was increased in the spleen and decreased in the bone marrow, while the 
percentage of B220+ B cells was decreased in both the spleen and the bone marrow 
(Figures 4A and 5A).  
Histological analyses of Wright stained bone marrow smears confirmed the 
presence of pathological myeloproliferative conditions in miR-155 and siSHIP1 
expressing mice, characterized by elevated numbers of GM progenitors at various 
stages of development compared to controls (Figure 4B). There was also a reduction in 
developing erythroid precursors and megakaryocytes in both miR-155 and siSHIP1 
mice. Of note, miR-155 mice did exhibit a subtle increase in the number of dysplastic 
granulocytic cells compared with siSHIP1, possibly due to an additional miR-155 target. 
FCM also identified that both miR-155 and siSHIP1 expressing cells, which are GFP 
positive, are responsible for the increased myeloid populations (CD11b+) in the bone 
marrow (Figure 4C).  
H&E staining of fixed spleen sections from miR-155 or siSHIP1 mice revealed 
expanded inter-follicular regions containing developing myeloid populations, erythroid 
precursors and megakaryocytes compared to control mice (Figure 5B). The normal 
follicular architecture of the spleen was disrupted by these expanded myeloid 
populations in both cases. Thus, miR-155 expression and specific SHIP1 knockdown in 
the hematopoietic system triggers marked extramedullary hematopoiesis, a likely 
consequence of the dysregulated blood cell development in the bone marrow.  
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Discussion 
Similar to miRNAs like miR-155, many proteins have evolved to regulate immune 
cell function, and cause disease upon their dysregulated expression. Among such 
proteins, the inositol phosphatase SHIP1 is expressed in the hematopoietic system and 
has a broad impact on the biology of different hematopoietic cell types (Leung, 
Tarasenko et al. 2008). SHIP1 functions at the molecular level by hydrolyzing the 5’ 
phosphate of Phosphatidylinositol (PI)-3, 4, 5-P3 to generate PI-3,4-P2, a process that 
blocks PI3K-mediated membrane localization of certain PH domain containing signaling 
molecules such as Akt and PLCg (Lioubin, Algate et al. 1996; Backers, Blero et al. 2003; 
Sly, Rauh et al. 2003). Consequently, mice with a global SHIP1 deficiency develop a 
MPD characterized by increased GM populations, and decreased B lymphocyte 
numbers. This condition is thought to occur as a result of its role as a negative regulator 
of signaling by growth factors and other immune receptors (Kalesnikoff, Sly et al. 2003; 
Leung, Tarasenko et al. 2008). Furthermore, knockout of SHIP1 in B lymphocytes 
causes spontaneous GC formation and antibody class switching (Liu, Oliveira-Dos-
Santos et al. 1998; Helgason, Kalberer et al. 2000; Leung, Tarasenko et al. 2008), while 
a SHIP deficiency in T cells skews peripheral T lymphocytes towards Th1 and away from 
Th2 in response to an immune challenge (Tarasenko, Kole et al. 2007). Thus, SHIP1 
impacts the same cell types that express miR-155, and plays an opposing role in many 
cases. In the present study, we identify and characterize a direct link between miR-155 
and SHIP1, whereby miR-155 can directly repress expression of SHIP1 and thereby 
impede its function. 
 The connection between miR-155 and SHIP1 has implications for normal 
immune physiology, as described above, as well as pathological conditions such as 
cancer. Our present findings demonstrate a strong correlation between the MPDs 
 
68 
caused by miR-155 expression or specific knockdown of SHIP1. Both perturbed the 
hematopoietic process, resulting in increased GM cell populations, reduced lymphocyte 
numbers, impaired erythropoiesis and extramedullary hematopoiesis in the spleen. 
Therefore, miR-155 repression of SHIP1 may prove to be a contributing factor to human 
MPDs and myeloid leukemias where miR-155 has been shown to be overexpressed 
(Garzon, Garofalo et al. 2008; O'Connell, Rao et al. 2008). Of note, SHIP1 is mutated in 
some AML patients, where loss of function has been implicated in the oncogenic 
process (Luo, Yoshida et al. 2003; Luo, Liu et al. 2004). As miR-155 levels are elevated 
in certain B cell lymphomas (Tam, Ben-Yehuda et al. 1997; van den Berg, Kroesen et al. 
2003; Eis, Tam et al. 2005; Kluiver, Poppema et al. 2005; Fulci, Chiaretti et al. 2007), 
and because SHIP1 is a negative regulator of B cell activation and survival (Liu, Oliveira-
Dos-Santos et al. 1998; Helgason, Kalberer et al. 2000; Leung, Tarasenko et al. 2008), 
the miR-155-SHIP1 axis should also prove to be of relevance to B cell malignancies. 
Two recent abstracts suggest that this is the case (Chen L 2008; Pedersen IM 2008). It 
is also plausible that virally encoded orthologs of miR-155 (Gottwein, Mukherjee et al. 
2007; Skalsky, Samols et al. 2007; Zhao, Yao et al. 2009), or miR-155 induction by 
viruses such as Epstein-Bar virus (Yin, McBride et al. 2008), can decrease SHIP1 
expression en route to B cell activation and transformation. Interestingly, the seed region 
of these orthologs is identical to that of miR-155, while the flanking regions have 
diverged dramatically from the mature mammalian miR-155 sequence. This would 
indicate that certain viral miRNAs have specifically evolved to repress seed-dependent 
targets of miR-155 including SHIP1.   
An important question in the field is whether miRNAs function through repression 
of a single or a few targets, or via the cumulative impact of repressing large sets of 
targets. To date, several putative targets of miR-155 have been predicted through 
bioinformatic and proteomic approaches (Selbach, Schwanhausser et al. 2008), 
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indicating that there may be great complexity underlying miR-155 function. It may be that 
the MPD caused by miR-155 also involves other targets than SHIP1 but our studies 
show that SHIP 1 alone can phenocopy the effects of miR-155. MiR-155 has various 
roles in different cell types and physiological situations and analysis of particular specific 
targets such as PU.1 (Vigorito, Perks et al. 2007), AID (Dorsett, McBride et al. 2008; 
Teng, Hakimpour et al. 2008), SOCS1 (Lu, Thai et al. 2009) and now SHIP1 suggest 
that individual targets likely make significant contributions to miR-155 function in a 
context-dependent manner. For instance, PU.1 is repressed by miR-155 and its 
overexpression has been shown to recapitulate the immunoglobulin class switching 
defect observed in miR-155-/- B cells (Vigorito, Perks et al. 2007). AID is repressed by 
miR-155 in B lymphocytes, which has been elegantly demonstrated via germline 
mutation of the miR-155 seed in the 3’UTR of AID (Dorsett, McBride et al. 2008; Teng, 
Hakimpour et al. 2008). The AID studies also provide evidence that miR-155 targeting of 
AID impacts Ig class switching and the rate of c-myc translocations in B lymphocytes. 
SOCS1 targeting by miR-155 has just recently been shown to impact T-regulatory cell 
homeostasis (Lu, Thai et al. 2009). Similar observations have been made for specific 
targets of miR-150 (Xiao, Calado et al. 2007; Lu, Guo et al. 2008), miR-223 (Johnnidis, 
Harris et al. 2008) and miR-17-92 (Ventura, Young et al. 2008; Xiao, Srinivasan et al. 
2008), suggesting a common theme of a few significant targets making dominant 
contributions to miRNA function. Ultimately, germline mutation of miRNA target seed/s 
sequences within the 3’UTR regions of specific targets, as has been done for AID 
(Dorsett, McBride et al. 2008; Teng, Hakimpour et al. 2008), will provide the strongest 
argument for relevance. 
As both miR-155 and SHIP1 regulate critical and overlapping functions of a 
variety of cell types of the immune system, therapeutic manipulation of this novel 
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molecular interaction may prove to be useful in the treatment of diverse pathological 
conditions including infection, cancer and autoimmunity. 
 
Materials and Methods 
Cell Culture. Raw 264.7 macrophage and 293T cells were cultured in complete DMEM 
with 10% FBS, 100 units/ml penicillin, 100 units/ml streptomycin. For generation of 
BMMs, bone marrow cells were isolated from the tibias and femurs of mice as previously 
described (O'Connell, Taganov et al. 2007). All cells were cultured in a humidified 
incubator with 5% CO2 at 37°C. Primary macrophages were stimulated using fresh 
DMEM containing 10 ng/ml 055-B5 LPS (Sigma, St. Louis, MO), while Raw 264.7 cells 
were treated with LPS at 200 ng/ml.  
Sequence alignments. SHIP1 3’UTR sequences from human, mouse, rat and dog were 
obtained and aligned with each other and with the miR-155 seed region using 
TargetScan (Lewis, Burge et al. 2005). 
DNA constructs. Retroviral constructs MG and MG-155 (human sequence) were 
described previously (O'Connell, Taganov et al. 2007). Oligonucleotide sequences used 
to generate new constructs are provided as supplemental data (Table S1). The MGP-
155 expression cassette containing the mouse miR-155 hairpin sequence and flanking 
regions was cloned from cDNA made from LPS treated BMMs. The cassette was 
subcloned into MGP. MGP is a modified pMSCV vector (Clontech, Mountain View, CA) 
where GFP was placed downstream of the 5’ LTR, and the miR-155 expression cassette 
was cloned downstream of the GFP stop codon (detailed cloning strategy available upon 
request). The h155, m155, h155mut and siSHIP1 oligos, which produce mature human 
miR-155, mouse miR-155, human miR-155 seed mutant and siRNA against mouse 
SHIP1, respectively, were designed using the Invitrogen Block-iT pol II miR RNAi 
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strategy and PCR amplified using Fw NotI- and Rev XhoI- containing primers. The 
Invitrogen Block-iT RNAi Designer was used to predict the siRNA sequence against 
mouse SHIP1. For reporter assays, the Picalm 3’UTR was cloned as described 
previously (O'Connell, Rao et al. 2008). The mouse SHIP1 3’UTR was amplified by PCR 
from cDNA derived from mouse RAW 264.7 cells. This PCR product was cloned into 
pmiReport (Ambion, Austin, TX) using SpeI and HindIII. Assembly PCR was used to 
mutate the 6 nucleotide miR-155 seed region. A 2-mer control insert and the IRAK1 
3’UTR were described previously (O'Connell, Rao et al. 2008). 
Luciferase-Beta Gal reporter assays. Experiments were performed as previously 
described using FUW, FUW-155, Beta-gal expression vector and pmiReport vectors 
transfected into 293T cells (O'Connell, Rao et al. 2008). Transfections were carried out 
with TransIT 293 (Mirus, Madison, WI). Data was normalized for transfection efficiency 
using a Beta-gal reporter and is represented as the ratio of luciferase activity of the 
transfection containing FUW-155 to that of the transfection containing FUW. 
RAW 264.7 stable cell lines. To generate VSV-G-pseudotyped MSCV retroviruses, 2 x 
106 293T cells were transfected with pGag-Pol, pVSV-G, and either MGP, MGP-m155, 
MGP-h155, MGP-h155mut or MGP-siSHIP1. Transfection was performed with TransIT 
293 as per manufacturer’s instructions. After 48 hours, viral supernatant was harvested 
and used to infect 5 x 105 RAW 264.7 cells for 8 hours in the presence of polybrene at 
10 ug/ml. After 48 hours, stably transduced cells were selected using puromycin at 10 
ug/ml for 7-10 days.  
Mice. Wt mice on a C57BL/6 genetic background were bred and housed in the Caltech 
Office of Laboratory Animal Resources (OLAR) facility. Mice deficient in miR-155 and on 
a C57BL/6 genetic background were obtained from Alan Bradley at the Wellcome Trust 
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Sanger Institute, Cambridge, UK. All experiments were approved by the Caltech 
Institutional Animal Care and Use Committee (IACUC). 
Bone marrow reconstitution. Experiments were performed as previously described 
(O'Connell, Rao et al. 2008), with the following modifications: HSC enriched bone 
marrow was cultured for 48 hours before the first spin infection using the respective 
retroviral vector. Transfection of retroviral constructs was performed using TransIT 293. 
Cells were subjected to two spin infections, and transduced cells were delivered to 
recipient mice through retro-orbital injection.  
RNA quantification. SYBR Green based quantitative realtime PCR (qPCR) was 
conducted using the 7300 Realtime PCR system (Applied Biosystems, Foster City, CA) 
to assay BIC, miR-155, 5s, SHIP1 mRNA and L32 mRNA levels as described previously 
(O'Connell, Rao et al. 2008). Mature miR-155 and 5s RNA were assayed using a 
miRVana miRNA detection kit as per manufacturer’s instructions (Ambion). Mouse BIC, 
SHIP1 and L32 mRNA were detected using specific primers (Table S1). Northern 
blotting was performed as described (O'Connell, Taganov et al. 2007) using a probe 
reverse complementary to the human miR-155 seed mutant (Table S1). 
Western blotting. Cell extracts were size fractionated by SDS-PAGE and transferred to 
a nitrocellulose membrane using a semi-dry transfer apparatus (Bio-Rad, Hercules, CA). 
Western blotting was performed using the following antibodies: SHIP1 V-19 (sc-1963), 
SHIP1 M-14 (sc-1964), aTubulin B-7 (sc-5286), donkey anti-goat HRP-conjugated (sc-
2020), goat anti-rabbit HRP-conjugated (sc-2004), goat anti-mouse HRP-conjugated (sc-
2005) (Santa Cruz Biotechnology, Santa Cruz, CA); αActin (A2066), βActin (A1978) 
(Sigma, St. Louis, MO); SHIP1 (D1163), Akt1 (C73H10), Phospho-AKT (Ser473) (Cell 
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Signaling, Boston, MA). Protein expression intensities were determined using Scion 
Image software. 
Flow cytometry. Fluorophore-conjugated monoclonal antibodies specific to CD11b 
(Mac1), Ter-119 or B220 (eBioscience) were used to stain RBC-lysed splenocytes and 
RBC-containing bone marrow cells that were washed and fixed with paraformaldehyde 
(1% final). Stained cells were assayed using a BD FACSCalibur flow cytometer (BD, 
Franklin Lakes, NJ) and further analyzed with FlowJo software. 
Morphological assessment of hematolymphoid tissues. Histological and cytological 
samples were prepared and analyzed as described previously (O'Connell, Rao et al. 
2008).  
Statistical tests. All statistical tests were performed using Microsoft Excel. 
 
Figure Legends 
Figure 1. MicroRNA-155 represses SHIP1 expression through 3’UTR interactions. 
A. Schematic layout of the SHIP1 mRNA coding sequence (CDS) and 3’UTR, with the 
relative location of the miR-155 binding site. Depiction is not to scale. Sequence of 
mouse and human miR-155 and predicted interaction with conserved 8-mer miR-155 
seeds found within the SHIP1 3’UTRs from different species (highlighted) are shown. 
The sequence of the SHIP1 3’UTR seed mutant used for reporter assays and predicted 
disruption of the miR-155 interaction is also shown. B. Luciferase reporter assays were 
performed by transiently transfecting 293T cells with an empty plasmid (FUW) or miR-
155 expressing plasmid (FUW-155), the indicated 3’UTR luciferase reporter plasmids, 
and a plasmid producing beta-galactosidase. Luciferase values have been normalized to 
beta-galactosidase, and the percent repression in cells transfected with miR-155 is 
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presented. Raw 264.7 cells stably infected with a retroviral vector expressing wt human 
miR-155 (MGP-h155), mutant seed human miR-155 (MGP-h155mut), or control (MGP) 
were assayed for SHIP1 levels by qPCR (C) and Western blotting (D). As a loading 
control for the Western blot, aTubulin was also assayed. The fold repression of SHIP1 
by the different constructs is shown. E. Levels of mature human miR-155 in the different 
cell types were assayed by qPCR with primers that detect the wt mature miR-155 
sequence. F. RNA from the different cell types and a probe specific for the human miR-
155 seed mutant sequence was used for Northern blotting. G. The different cell types 
were stimulated with LPS (200 ng/ml) over the indicated timecourse and Ser-473-
phosphorylated-Akt (p-Akt), total Akt and b-Actin were assayed by Western blotting. H. 
SHIP1 levels in Raw 264.7 cells expressing mouse miR-155 or control vector were 
assayed by western blotting. I. p-Akt was assayed in these cells following LPS treatment 
(200 ng/ml). Data represent at least 2 independent experiments. 
 
Figure 2. Enhanced expression of SHIP1 in miR-155-/- macrophages following LPS 
treatment.  Bone marrow derived macrophages from Wt or miR-155-/- mice were 
stimulated with 10 ng/ml LPS from E.coli for the indicated periods of time. Expression of 
BIC (A) or mature miR-155 (B) was assayed by qPCR. Expression of SHIP1 was 
assayed in BMMs by Western blotting (C) and qPCR (D). bActin was assayed as a 
loading control for the Western blot, while qPCR data was normalized to L32. The fold 
increase in SHIP1 expression versus the wt 0h sample is shown. Data represent at least 
two independent experiments.  
 
Figure 3. Knockdown of SHIP1 in vivo using siRNA in the context of miR-155 
processing.  A. Schematic of the retroviral vector (MGP-155f) used to deliver siRNA 
against SHIP1 in miR-155 format. B. Knockdown of SHIP1 was assayed in Raw 264.7 
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cells infected with MGP-siSHIP1 or control vector by Western blotting. aTubulin was 
assayed as a loading control. C. Knockdown of SHIP1 in vivo by retroviral expression of 
miR-155 (MGP-155, n=4 mice) or siSHIP1 (MGP-siSHIP1, n=3 mice) in the 
hematopoietic compartment was assayed by qPCR using RNA isolated from total bone 
marrow following two months of hematopoietic reconstitution. Relative expression values 
have been normalized to L32 mRNA. A p-value of 0.05 or less using a Student’s t test 
was considered statistically significant and indicated with an asterisk. 
 
Figure 4. Knockdown of SHIP1 or expression of miR-155 in the hematopoietic 
compartment cause similar MPDs in the bone marrow.  A. Bone marrow was 
extracted from mice expressing human miR-155 (MG-155, n=3 mice), mouse miR-155 
(MGP-155, n=4 mice), siSHIP1 (MGP-siSHIP1, n=3 mice), or control vectors (MG, n=2 
mice or MGP, n=3 mice) 2 months following bone marrow reconstitution. Total bone 
marrow cells were assayed for expression of CD11b (Mac1), Ter119 or B220 using flow 
cytometry. Each dot represents an individual mouse. A p-value of 0.05 or less using a 
Student’s t test was considered statistically significant and indicated with an asterisk. B. 
Bone marrow from MGP, MGP-155 or MGP-siSHIP1 mice was smeared and Wright 
stained. Photomicrographs are shown (1000x magnification, Scale bar 20 mm). C. 
Representative FCM plots from control, MGP-155 and siSHIP1 vector-containing mouse 
bone marrow analyzing GFP and CD11b expression.  
 
Figure 5. Knockdown of SHIP1 or expression of miR-155 in the hematopoietic 
compartment causes spenomegaly and extramedullary hematopoiesis in the 
spleen.  A. Spleens were extracted from mice expressing human miR-155 (MG-155, 
n=3 mice), mouse miR-155 (MGP-155, n=4 mice), siSHIP1 (MGP-siSHIP1, n=3 mice), 
or control vectors (MG, n=2 or MGP, n=3 mice) 2 months following bone marrow 
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reconstitution. Spleens were weighed and RBC-depleted splenocytes subsequently 
assayed for expression of CD11b, Ter119 or B220 by FACS. Each dot represents an 
individual mouse. A p-value of 0.05 or less using a Student’s t test was considered 
statistically significant and indicated with an asterisk. B. Spleens from MGP, MGP-155 or 
MGP-siSHIP1 mice were fixed, sectioned and H&E stained. Photomicrographs are 
shown (400x magnification, Scale bar 50 mm).  
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Figures 
 
Figure 1.  MicroRNA-155 represses SHIP1 expression through 3’UTR interactions 
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Figure 2.  Enhanced expression of SHIP1 in miR-155-/- macrophages following LPS 
treatment 
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Figure 3.  Knockdown of SHIP1 in vivo using siRNA in the context of miR-155 
processing 
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Figure 4.  Knockdown of SHIP1 or expression of miR-155 in the hematopoietic 
compartment cause similar MPDs in the bone marrow 
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Figure 5.  Knockdown of SHIP1 or expression of miR-155 in the hematopoietic 
compartment causes spenomegaly and extramedullary hematopoiesis in the 
spleen 
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Supplemental Table 
 
Table S1.  Cloning primers and template oligos 
         Primer     Sequence 
m155 from LPS 
BMM Fw 
AAACCAGGAAGGGGAAGTGT 
m155 from LPS 
BMM Rev 
ATCCAGCAGGGTGACTCTTG 
m155 BlockiT 
Template oligo 
GAAGGCTGTATGCTGTTAATGCTAATTGTGATAGGGGTTTT
GGCCACTGACTGACCCCTATCAATTAGCATTAACAGGACAC
AAGGCCTG 
h155 BlockiT 
Template oligo 
GAAGGCTGTATGCTGTTAATGCTAATCGTGATAGGGGTTTT
GGCCACTGACTGACCCCTATCAATTAGCATTAACAGGACAC
AAGGCCTG 
h155mut BlockiT 
Template oligo 
GAAGGCTGTATGCTGTATTACGTAATCGTGATAGGGGTTTT
GGCCACTGACTGACCCCTATCAATTACGTAATACAGGACAC
AAGGCCTG 
siShip1 BlockiT 
Template oligo 
GAAGGCTGTATGCTGTTAAATGTCATGCTGGTGACTGTTTT
GGCCACTGACTGACAGTCACCAATGACATTTAACAGGACAC
AAGGCCTG 
m155 arms NotI 
Fw 
ATCGGCTGAGTCGACGCGGCCGCCTGGAGGCTTGCTGAAG
GCTGTATGCTG 
m155 arms XhoI 
Rev 
ATCGCAATTGCTCGAGTGGGCCATTTGTTCCATGTGAGTGC
TAGTAACAGGCCTTGTGTC 
mShip1 3’UTR 
SpeI Fw 
TTCACTAGTGCTGCTGGTGATCGGAGCCTG 
 
mShip1 3’UTR 
HindIII Rev 
TTCAAGCTTTAGAAAGGCACAATTTTATTGGTCACTCAG 
 
mShip1 UTRmut 
fragment 1 Rev 
GGTTAGCTCTAAGAGACCGATGGTTTTCTTATTACGTTTTTA
AAAACATCTCAGGACCCACC  
mShip1 UTRmut 
fragment 2 Fw 
GTGGGTCCTGAGATGTTTTTAAAAACGTAATAAGAAAACCAT
CGGTCTCTTAGAGCTAACC 
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Abstract 
The production of blood cells depends upon a rare hematopoietic stem cell 
(HSC) population, but the molecular mechanisms underlying HSC biology remain poorly 
understood. Here, we identify a subset of microRNAs (miRNAs) that are enriched in 
HSCs compared to other bone marrow cells. An in vivo gain-of-function screen found 
that three of these miRNAs conferred a competitive advantage to engrafting 
hematopoietic cells, while other HSC miRNAs attenuated production of blood cells. 
Overexpression of the most advantageous miRNA, miR-125b, caused a dose-dependent 
myeloproliferative disorder (MPD) that progressed to a lethal myeloid leukemia in mice, 
and also enhanced hematopoietic engraftment in human immune system (HIS) mice. 
Our study identifies an evolutionarily conserved subset of miRNAs that are expressed in 
HSCs and that function to modulate hematopoietic output. 
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Introduction 
Long-term production of blood cells depends upon proper hematopoietic stem 
cell (HSC) function (Orkin and Zon 2008). This involves a delicate balance between HSC 
self-renewal and differentiation into progenitor populations. The molecular networks that 
control these processes have begun to be elucidated in recent years, and several 
regulatory proteins have been shown to manage stem cell physiology (Ramalho-Santos, 
Yoon et al. 2002; Park, Qian et al. 2003; Zhang, Grindley et al. 2006; Deneault, Cellot et 
al. 2009; Santaguida, Schepers et al. 2009). Additionally, there is a substantial overlap 
between the proteins that regulate HSC biology and those that are dysregulated in 
cancers of immunological origin or other hematopoietic diseases underlying the 
importance of these factors in maintaining homeostasis.  
Mammalian non-coding miRNAs have recently been identified as important 
repressors of gene expression through direct interactions with specific mRNA targets, 
and thus act to modulate gene function (Bartel and Chen 2004; Winter, Jung et al. 
2009). Several reports have found that miRNAs regulate the development of specific 
hematopoietic lineages (O'Connell, Rao et al.). Conditional deletion of Dicer, which 
disrupts miRNA processing, has revealed critical roles for miRNAs during development 
of different hematopoietic lineages, including both B and T lymphocytes (Cobb, 
Nesterova et al. 2005; Muljo, Ansel et al. 2005; Koralov, Muljo et al. 2008). Specific 
miRNAs have also been shown to impact development of distinct blood cell lineages. 
Early B cell development is modulated by miR-150 (Xiao, Calado et al. 2007), miRNAs 
17-5p-20a-106a direct human monocytes development (Fontana, Pelosi et al. 2007), 
and miR-223 functions to restrict the granulocytic compartment in vivo (Johnnidis, Harris 
et al. 2008).  
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Recent studies have demonstrated a causative role for miRNAs in mediating 
malignant diseases in the hematopoietic system. For example, sustained hematopoietic 
expression of miR-155 or miR-29a in the mouse hematopoietic system causes a 
myeloproliferative disorder (O'Connell, Rao et al. 2008) or leukemia (Han, Park et al.), 
respectively, while a B cell malignancy is triggered upon constant expression of miR-155 
in a B cell restricted manner (Costinean, Zanesi et al. 2006). On the other hand, tumor 
suppressor miRNAs like miR-15/16 are deleted in a subset of lymphomas (Calin, 
Dumitru et al. 2002), which has been shown to cause chronic lymphocytic leukemia in 
mice (Klein, Lia et al.).   
Despite their being clearly linked to hematopoietic development and cancer, 
there is little known regarding the expression patterns and function of mammalian 
miRNAs in HSC populations. One study found that mice deficient in Ars2, which is 
required for proper miRNA processing, suffer from bone marrow failure suggesting a 
functional role for miRNAs in HSCs (Gruber, Zatechka et al. 2009). Other groups have 
profiled miRNA expression in human CD34+ cells (Georgantas, Hildreth et al. 2007). 
However, many of the identified miRNAs are broadly expressed outside of HSCs, and 
their functional relevance in stem cells was not investigated in vivo. In the present study, 
we sought to both find specific miRNAs that are enriched in long-term HSCs and 
investigate their impact on long-term hematopoietic reconstitution.   
 
Results   
Identification of miRNAs enriched in Hematopoietic Stem Cells (HSCs) 
To identify miRNAs enriched in hematopoietic stem and progenitor cells 
(HSPCs), we isolated lineage negative (lin-) cKit+Sca1+ (LKS) cells from adult C57BL6 
mouse BM using FACS (Fig. 1A (top)). Total RNA was isolated from LKS cells, and also 
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from RBC-depleted total BM, and used to perform a microarray analysis to identify 
expression of mouse miRNAs. Some 137 miRNAs were expressed at detectable levels 
in the BM and/or LKS populations. Of these, 67 were expressed at higher levels in total 
BM versus LKS cells, 59 were expressed at similar levels in the two cellular populations, 
and 11 were expressed at higher levels in the LKS compartment versus total BM (Fig. 
1A (bottom) and Table S1). Corroborating the microarray results, qPCR detected 
enrichment of these 11 miRNAs in LKS cells. They are miR125a-5p, miR-125b-5p, miR-
155, miR-130a, miR196b, miR-99a, miR-126-3p, miR-181c, miR-193b, miR-542-5p and 
let7e (Fig. 1B). A more extensive cellular fractionation of mouse BM further confirmed 
enrichment of most of these miRNAs in the LKS subset (Fig. 1C and Fig S1). 
Expression of miR-223, known to be enriched in mature myeloid cells, was measured as 
a control (Fig 1C). The LKS population is comprised of both hematopoietic stem cells 
(HSCs), capable of establishing long-term multi-lineage hematopoietic engraftment, and 
multipotent progenitors, with reduced capacity to reconstitute the hematopoietic system. 
LKS cells expressing the HSC marker EPCR (Balazs, Fabian et al. 2006) were first 
analyzed and a higher relative expression of many of the miRNAs under study was 
found in EPCR+ versus EPCR- LKS cells (Fig. 1C). Long-term HSCs have also been 
shown to be CD150+CD48- while other LKS progenitor populations are negative for 
CD150 (Kiel, Yilmaz et al. 2005). Again, qPCR analysis found that most of the HSPC 
miRNAs were further enriched in CD150+CD48- long-term HSCs compared to CD150-
LKS cells (Fig. 1D). These data indicate, using multiple criteria to define HSCs, that this 
subset of miRNAs is largely enriched in long-term HSCs. 
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Gain-of-function approach to assess the impact of HSC miRNAs on long-term 
hematopoietic engraftment 
The expression patterns of these particular miRNAs suggest they have a 
specialized role in regulating hematopoiesis at the stem cell level. To ascertain the 
functional impact of these HSC miRNAs on long-term hematopoietic reconstitution, we 
constructed a series of murine stem cell virus (MSCV)-based miRNA expression vectors 
that carry each of the 11 miRNAs under study. The vectors were formatted with mouse 
miR-155 arms and stem loop sequences, with each miRNA duplex encoded by the 
sense and antisense stem regions (Fig. 2A). This format was chosen due to its 
established ability to be processed in hematopoietic cells (O'Connell, Chaudhuri et al. 
2009), including HSCs where we have found mature miR-155 to be expressed (Fig. 1). 
Production of the different mature miRNAs using this format was confirmed in 293T cells 
by qPCR (Fig. S2).  
Competitive repopulation experiments were performed by combining equal 
numbers of HSC-enriched CD45.1+ bone marrow cells transduced with retroviruses 
encoding a specific HSC miRNA with HSC-enriched CD45.2+ bone marrow transduced 
with a control retrovirus. This cellular mixture was used to reconstitute lethally irradiated 
CD45.2+ C57BL6 recipients. Because the retrovectors coexpress GFP in addition to a 
miRNA, the ability of the CD45.1+ miRNA expressing bone marrow to compete with 
CD45.2+ control vector-containing bone marrow during hematopoietic engraftment could 
be tracked by FACS analysis of peripheral blood cells. Mice were bled at 2 and 4 months 
post-reconstitution. When both vectors lacked a miRNA, there was similar representation 
of the two markers in the bone marrow cells (Fig. S3). In three cases, including miR-
125b-5p, miR-126-3p and miR-155, the miRNA conferred an evident and statistically 
significant (p < 0.05) competitive advantage to the engrafted bone marrow (Fig. 2B and 
Fig. S3). In contrast, overexpression of several of the miRNAs caused a significant (p < 
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0.05) disadvantage to the engrafted bone marrow, with miR-196b, miR-181c, let7e and 
542-5p having the largest impact (Fig. 2B and Fig. S3). FACS analysis of the peripheral 
blood was also used to determine the distribution of different hematopoietic lineages to 
assess whether engraftment was being skewed towards a single lineage or was multi-
lineage at 4 months post reconstitution. The effects of the different miRNAs on 
engraftment were largely multi-lineage, consistent with these miRNAs regulating stem 
cell homeostasis (Fig. 2C).       
 
MiR-125b causes a dose-dependent MPD that progresses to a myeloid leukemia 
 We next focused on further characterization of miR-125b because it had the 
largest positive impact on competitive reconstitution among the miRNAs tested, and is 
overexpressed in certain types of AML suggesting it plays an active role in human 
malignancies (Klusmann, Li et al. ; Bousquet, Quelen et al. 2008). miR-125b is 
expressed from two loci in the genome, and these sequences are referred to as miR-
125b1 and miR-125b2. To assess the impact of expressing miR-125b with its native 
arms and loop sequences, we cloned segments of the miR-125b1 and miR-125b2 pri-
miRNAs into our retroviral expression system (Fig. 3A). We found that these cassettes 
led to substantially increased expression levels of mature miR-125b in K562 cells 
compared to the miR-125b cassette formatted with miR-155 arms and loop sequences 
(used above and now referred to as 125b(f)), likely a result of more efficient processing 
(Fig. 3A). Furthermore, miR-125b1 expression was higher than miR-125b2, providing 
three vectors with conveniently graded expression of miR-125b.   
Mice were subsequently reconstituted with bone marrow expressing either miR-
125b1, miR-125b2 or control vector, and a separate cohort of mice expressing miR-
125b(f) or its vector control was also established. All mice from both groups were bled 
following 2 months of reconstitution and complete blood cell counts (CBCs) were 
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recorded (Fig. 3B). Mice expressing miR-125b, regardless of the construct used, had 
subtly elevated total WBC counts compared to control mice. Reconstitution of mice with 
HSPCs expressing the lowest levels of miR-125b, miR-125b(f), resulted in a general 
increase in all WBC compartments analyzed including myeloid, lymphoid, and platelets, 
but did not impact RBCs. However, mice with the more highly expressed endogenous 
miR-125b1 or b2 vectors exhibited a clear myeloproliferative disorder (MPD) that was 
characterized by increased absolute numbers of monocytes and neutrophils, and 
decreased levels of lymphocytes, RBCs and platelets. Peripheral blood from miR-125b-1 
and -2 expressing mice, compared to control mice, also had dramatic increases in the 
percentage of CD11b+ myeloid cells, many of which were also Gr1+ as assayed by 
FACS (Fig. 3C). We also found that enforced expression of endogenous miR-125a, 
which has the same “seed” sequence as miR-125b, also caused a competitive 
advantage to engrafting BM (RO, AC and DB unpublished observations). Expression of 
endogenous miR-125a was higher than the formatted miR-125a cassette used in our 
gain-of-function screen, which likely accounts for the difference in functional impact 
between the two vectors.  
Analysis of Wright stained bone marrow smears from miR-125b(f) mice two 
months post reconstitution revealed a mild expansion of myeloid cells in the bone 
marrow, while H&E stained spleen sections were similar to those from control mice (Fig. 
S4). However, miR-125b1 and miR-125b2 expressing mice exhibited myeloid-dominated 
BM and spleens as well as myeloid cell infiltration into the liver (Fig. S4). By 3.5 months 
post-reconstitution miR-125b1 and miR-125b2 mice had substantially increased WBCs 
in their peripheral blood consisting mainly of immature granulocytic and monocytic cells 
(Fig. S4). Shortly after, the condition became lethal for most of the mice expressing the 
highest levels of miR-125b with tumor infiltration evident in the spleen and liver (Fig. 4A 
and 4B). The surviving miR-125b2 mice also had progressively increasing WBC counts 
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and higher levels of leukemic blasts in their peripheral blood from 3.5 to 4.5 months post 
reconstitution, and this also became lethal (Fig. 4C and 4A). Furthermore, transfer of 
malignant BM from moribund miR-125b1 expressing mice to immunodeficient Rag2-/-gc-
/- secondary recipients resulted in death within weeks, while transfer of BM from control 
mice had no impact on survival (Fig. 4D). These findings demonstrate a dose-dependent 
sufficiency of miR-125b to drive pathological myeloid cell expansion, a condition that 
progresses to an aggressive myeloid leukemia.    
 
Evolutionarily conserved miRNA expression and function in human CD34+ HSPCs 
We investigated whether the subset of miRNAs enriched in mouse HSCs was 
also enriched in human CD34+ HSPCs. RNA was prepared from CD34+ and CD34- 
umbilical cord blood (CB) PBMCs and analyzed by qPCR. With the exception of miR-
193b, all of the miRNAs showed significant enrichment in the CD34+ HSPC cellular 
subset compared to mature CD34- PBMCs (Fig. 5A). To determine whether miR-125b 
could also impact human hematopoietic engraftment, CD34+ CB cells were transduced 
with control or miR-125b1-expressing lentiviral vector (Fig. 5B), and subsequently 
injected intrahepatically into newborn Rag2-/-gc-/- mice on a Balb/c genetic background 
generating the previously described human immune system (HIS) model (Traggiai, 
Chicha et al. 2004). After 10 weeks, peripheral blood was collected and analyzed for the 
presence of human CD45+ WBCs by FACS, and a dose-dependent enhancement in 
multi-lineage engraftment was again observed in miR-125b1-expressing versus control 
HIS mice (Fig. 5C, 5D and 5E). At 12 weeks post-reconstitution, the high dose (MOI 40) 
groups were harvested and miR-125b-expressing HIS mice had significantly elevated 
levels of hCD45+ cells and hCD34+ HSPCs in their bone marrow (Fig. 5F and 5G). 
These data provide evidence that miR-125b also promotes hematopoietic engraftment of 
human HSCs.    
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Discussion 
In this work, we have identified an evolutionarily conserved subset of miRNAs 
that are enriched in HSCs and have provided evidence that these miRNAs function to 
properly manage hematopoietic output. Because some miRNAs promoted while others 
diminished hematopoietic engraftment, it is possible that these HSC miRNAs work in a 
concerted manner to ensure proper output of blood cells. A similar paradigm has 
recently been shown for embryonic stem (ES) cells, where opposing miRNA families 
modulate ES cell self-renewal and differentiation (Melton, Judson et al.). This suggests 
that regulatory networks involving multiple miRNAs participate in the control of both 
embryonic and adult stem cells.   
Owing to their important developmental roles and ability to target known 
oncogenes and tumor suppressors (O'Connell, Rao et al.), miRNAs are a key part of the 
intricate molecular networks that drive or suppress cancer development and 
progression. Certain hematopoietic cancers, such as CML, are sustained by rare cancer 
stem cell populations that have significant mRNA expression overlap with normal HSCs 
despite producing malignant progeny (Savona and Talpaz 2008). Our newly identified 
set of HSC miRNAs might prove to be useful as novel biomarkers of such cancer stem 
cell populations. In the case of miR-125b, it will also be of interest to assess whether it 
transforms HSCs or a committed myeloid progenitor, and to characterize secondary 
mutations that may assist in this process.  
Many of the miRNAs identified in our study, including miR-125b, miR-155, miR-
126, miR-196b, and miR-99a, have been shown to be dysregulated in different subsets 
of AML (Cammarata, Augugliaro et al.). Because we have demonstrated functional 
relevance for many of these HSC miRNAs in vivo, including the abilities of miR-155 
(O'Connell, Rao et al. 2008) and now miR-125b to trigger aggressive MPDs and myeloid 
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leukemia, respectively, therapeutic targeting of this subset may be effective in combating 
hematopoietic cancers.  
 
Materials and Methods 
Isolation of bone marrow cell subsets and FACS. Hematopoietic stem and progenitor 
cells (HSPCs) were isolated from C57BL6 bone marrow by first depleting lineage 
positive cells using specific biotinylated antibodies (Table S2), magnetic beads and a 
MACS column (Miltenyi). Viable (7-AAD negative) Lin- cells were next stained with 
fluorophore-conjugated antibodies (Table S2) and separated using a FACS Aria (BD) 
into cKit-, cKit+Sca1-, and LKS subpopulations. Hematopoietic stem cells were further 
purified from among the LKS population by sorting out EPCR+ or CD150+CD48- LKS 
cells. CD11b+ and B220+ cells were fractionated from total BM using a MACS column. 
RBC-depleted PBMCs were stained with the indicated antibodies (Table S2), washed 
and analyzed using a FACSCalibur (BD).    
Microarray analysis. For the microarray, total RNA was collected from equal numbers 
of LKS cells and total RBC-depleted BM using the miRNeasy kit (Qiagen) and 
subsequently utilized for a low-input microarray with Agilent mouse miRNA 10.1 chips 
(Asuragen). Data represent miRNA expression levels in LKS and total bone marrow 
taken from 10 mice and pooled before RNA purification. Two biological replicates were 
analyzed in this way and both identified the 11 miRNAs described in this study.   
Quantitative PCR. ABI Taqman was utilized to quantitate microRNA levels in different 
BM cell populations using gene-specific primers according to the manufacturer’s 
instructions.  
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Competitive bone marrow reconstitutions. C57BL6 mice expressing the congenic 
WBC markers CD45.1 or CD45.2 were used as bone marrow donors and CD45.2 mice 
were used as recipients. Equal numbers of HSPC enriched bone marrow cells from each 
group (obtained from mice treated with 5-fluorouracil for 5 days) were infected with a 
miRNA expressing (CD45.1 cells) or control vector (CD45.2 cells) and a 1:1 cell mixture 
was injected i.v. into lethally irradiated mice.  
Retroviral and lentiviral vectors. miRNA expression vectors formatted with miR-155 
loop and arms were constructed as described previously (O'Connell, Chaudhuri et al. 
2009) (Table S3). Endogenous miR-125b-1 and miR-125b-2 sequences were PCR 
cloned into MG and MGP retrovectors (O'Connell, Rao et al. 2008; O'Connell, Chaudhuri 
et al. 2009) or a third generation, replication-deficient lentiviral vector with an EF1a 
promoter. Retroviral transduction of mouse HSPCs and bone marrow transplantation 
were performed as previously described (O'Connell, Rao et al. 2008; O'Connell, 
Chaudhuri et al. 2009). K562 cells were cultured in complete RPMI and infected with 
retrovectors in the presence of polybrene (10 mg/ml). Lentiviral transduction of CD34+ 
cells was achieved using an MOI of 4 or 40, Retronectin (Fisher Scientific) coated plates 
and StemSpan serum free medium (Stem Cell Technologies). Transduced CD34+ cells 
were washed and injected 24 hours after infection. 
Human Immune System (HIS) mouse model. HIS mice were generated by injecting 
2x105 lentivirus transduced CD34+ CB cells i.h. into irradiated newborn Rag2-/-gc-/- 
mice on a Balb/c genetic background as described (Traggiai, Chicha et al. 2004). 
Human hematopoietic cell engraftment was assessed by collecting blood and subjecting 
PBMCs to FACS (Table S2).  
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Histopathology and complete blood cell counts. These procedures were performed 
as described (O'Connell, Rao et al. 2008; O'Connell, Chaudhuri et al. 2009).  
Statistics. For statistical analysis a Student’s two-tailed t-test was used. 
 
Figure Legends 
Figure 1. Identification of miRNAs enriched in Hematopoietic Stem Cells (HSCs).  
A. Microarray experiment comparing miRNA expression in the Lineage-cKit+Sca1+ 
(LKS) compartment (FACS plot on top, subset boxed in red) to total bone marrow from 
C57BL6 mice. Number of miRNAs significantly enriched in total BM versus the LKS 
compartment, unchanged between the two groups, or significantly enriched in LKS 
versus total BM cells are shown (bottom). BM cells were pooled from 10 mice, sorted 
and RNA was extracted for the microarray. B. qPCR was used to determine the fold 
enrichment of the 11 miRNAs preferentially expressed in LKS cells versus total BM. 
Data represent two independent experiments. C. Expression levels of the 11 HSPC 
miRNAs were measured in hematopoietic cells from the different bone marrow 
compartments shown in Fig. S1 and represent different stages of blood cell 
development. D. LKS-gated cells were further sorted by FACS into three groups 
according to their expression of the SLAM markers CD150 and CD48. Total RNA was 
collected from each group and the relative expression levels of miRNAs from each LKS 
subpopulation were assayed by qPCR. Data represent two independent experiments, 
each starting with pooled BM from 20 mice. All data were normalized to sno202 and 
represent the mean + SEM. 
  
Figure 2. Gain-of-function approach to assess the impact of HSC miRNAs on long-
term hematopoietic reconstitution.  A. HSC miRNAs were cloned into an MSCV-
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based retroviral vector (MG) using a miR-155 arms-and-loop format. B. Competitive BM 
reconstitutions were performed using C57BL6 mice to assess the engraftment potential 
of BM expressing each of the 11 HSC miRNAs (CD45.1 cells) compared to control BM 
(CD45.2 cells). GFP was used to identify cells containing a vector. A four month time 
course showing the percentage of CD45.1+GFP+ cells in the peripheral blood of each 
group of mice is shown. The experiment was broken into two batches (top and bottom), 
each with its own negative control. C. Lineage analysis of the CD45.1+GFP+ peripheral 
blood cells at the 4 month time point was assessed by determining the percentages of 
B220+ (B cell), CD3+ (T cell) and CD11b+ (myeloid cell) in each group. Data represent 
the mean + SEM. Experiment had 4 mice per group. 
 
Figure 3. MiR-125b causes a dose-dependent MPD.  A. The three constructs used to 
enforce expression of miR-125b are shown. K562 cells were transduced with each 
retrovector and miR-125b levels were assayed by qPCR B. Blood concentrations of the 
indicated cell types are shown for mice expressing MG, MG-125b1, MG-125b2, and in a 
separate experiment (separated by a dashed line), MG and MG-125b(f) 2 months post-
reconstitution. C. FACS plot showing a representative FACS plot of Gr1+CD11b+ cells in 
the peripheral blood of mice overexpressing miR-125b2, miR-125b1 or control vector 2 
months post-reconstitution. * denotes a p value of < 0.05. 
 
Figure 4. MPDs caused by miR-125b progress to myeloid leukemia in a dose-
dependent manner.  A. Survival of mice expressing different levels of miR-125b. Group 
sizes for the experiment performed were MG=7, MG-125b1=8, MG-125b2=8 and MG-
125b(f)=4. B. Liver and spleen from miR-125b2-expressing mice with leukemia 4.5 
months after reconstitution. Representative H&E stained tissue sections of each 
respective organ taken from miR-125b2 expressing mice are shown on the right. C. 
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Percentage of leukemic blasts in the peripheral blood of control or miR-125b2 
expressing mice 3.5 and 4.5 months post-reconstitution, and representative Wright 
stained blood smears from miR-125b2 mice at each timepoint. Examples of blasts are 
indicated by red arrows. D. Survival of mice following intravenous transfer of malignant 
MG-125b1 (4 different donors) or MG control bone marrow to Rag2-/-gc-/- recipients 
(n=3-6 mice per group). * denotes a p value of < 0.05.  
 
Figure 5. Evolutionarily conserved miRNA expression and function in human 
CD34+ HSPCs.  A. Human CB was sorted into CD34+ (HSPC+) and CD34- (HSPC-) 
fractions. Expression of the miRNAs enriched in mouse HSCs was measured by qPCR. 
Data are normalized to RNU48 and presented as mean + SEM (n=3 different donors). B. 
Human CB CD34+ cells were transduced with a control or miR-125b1 expressing 
lentiviral vectors at an MOI of approximately 4 or 40 and miR-125b levels were assayed 
by qPCR. C. Representative FACS plots showing an increased ratio of human to mouse 
CD45+ WBCs in the peripheral blood of miR-125b expressing HIS mice 10 weeks after 
CD34+ cell injection. D. A gray dot represents each mouse. E. Human cells in the 
peripheral blood of high dose (MOI 40) HIS mice were analyzed by FACS for the 
expression of different lineage markers including CD19 (B cells) and CD33 (myeloid). 
Data are represented as the mean +/- SEM (n=7). F. A representative FACS plot of 
hCD45+ and hCD34+ cells in the BM of miR-125b-expressing and control vector HIS 
mice 12 weeks post CD34+ injection. G. A gray dot represents each mouse. * denotes a 
p value of < 0.05.  
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FIGURES 
 
Figure 1.  Identification of miRNAs enriched in Hematopoietic Stem Cells (HSCs) 
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Figure 2.  Gain-of-function approach to assess the impact of HSC miRNAs on 
long-term hematopoietic reconstitution 
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Figure 3.  MiR-125b causes a dose-dependent MPD 
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Figure 4.  MPDs caused by miR-125b progress to myeloid leukemia in a dose-
dependent manner 
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Figure 5.  Evolutionarily conserved miRNA expression and function in human 
CD34+ HSPCs 
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Supplemental Tables 
	  
Table S1.  Microarray Results 
Probe_ID miRNA_Access
ion 
BM norm. 
exp.(log2) 
LKS norm. 
exp.(log2) 
mghv-miR-M1-1 MIMAT0001564 1.658388461 1.665290958 
mghv-miR-M1-2 MIMAT0001565 5.256874189 4.223724501 
mghv-miR-M1-3 MIMAT0001566 -1.708853573 -2.173177625 
mghv-miR-M1-4 MIMAT0001567 -0.710358547 -0.013548819 
mghv-miR-M1-5 MIMAT0001568 -1.969878595 -2.007085557 
mghv-miR-M1-6 MIMAT0001569 1.633282789 0.589373906 
mghv-miR-M1-7-
3p 
MIMAT0001571 2.829957102 3.036485454 
mghv-miR-M1-7-
5p 
MIMAT0001570 -2.083392945 -2.351914656 
mghv-miR-M1-8 MIMAT0001572 -1.419387204 -2.562143355 
mghv-miR-M1-9 MIMAT0001573 2.759736162 3.0982055 
mmu-let-7a MIMAT0000521 8.570957416 8.679039209 
mmu-let-7a* MIMAT0004620 2.587261983 2.503677901 
mmu-let-7b MIMAT0000522 8.470202955 8.841128627 
mmu-let-7b* MIMAT0004621 3.35166403 3.11776057 
mmu-let-7c MIMAT0000523 7.612216945 8.326368152 
mmu-let-7c-1* MIMAT0004622 2.361676696 2.790416529 
mmu-let-7d MIMAT0000383 8.285647809 8.577517577 
mmu-let-7d* MIMAT0000384 2.091155024 2.255575826 
mmu-let-7e MIMAT0000524 2.161639523 5.283164186 
mmu-let-7f MIMAT0000525 8.24140687 8.296871861 
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mmu-let-7f* MIMAT0004623 3.529436039 3.293028849 
mmu-let-7g MIMAT0000121 8.673913416 8.178103409 
mmu-let-7g* MIMAT0004519 0.265210602 -0.036937031 
mmu-let-7i MIMAT0000122 9.843133718 9.781146766 
mmu-let-7i* MIMAT0004520 0.767609973 0.500773655 
mmu-miR-1 MIMAT0000123 -2.051914345 -2.145095925 
mmu-miR-100 MIMAT0000655 0.700920794 1.858457828 
mmu-miR-101a MIMAT0000133 3.303812581 3.784572525 
mmu-miR-101a* MIMAT0004526 -1.334827797 -1.079448599 
mmu-miR-101b MIMAT0000616 2.177135233 2.646731597 
mmu-miR-103 MIMAT0000546 7.278998257 6.699078213 
mmu-miR-105 MIMAT0004856 1.062895698 0.4294107 
mmu-miR-106a MIMAT0000385 3.221552804 3.197113759 
mmu-miR-106b MIMAT0000386 9.210931934 8.982834438 
mmu-miR-106b* MIMAT0004582 -1.006368027 -1.565898396 
mmu-miR-107 MIMAT0000647 7.280000094 7.887308234 
mmu-miR-10a MIMAT0000648 6.884504703 7.564515559 
mmu-miR-10a* MIMAT0004659 -0.46024917 -1.355543349 
mmu-miR-10b MIMAT0000208 2.082494391 2.261888041 
mmu-miR-10b* MIMAT0004538 -1.622835747 -1.389145991 
mmu-miR-122 MIMAT0000246 -0.740334399 -0.916109473 
mmu-miR-1224 MIMAT0005460 12.7606169 8.446866526 
mmu-miR-124 MIMAT0000134 -2.000059207 -2.16854943 
mmu-miR-124* MIMAT0004527 -0.596132072 -0.326864855 
mmu-miR-125a-
3p 
MIMAT0004528 5.177242285 0.735169955 
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mmu-miR-125a-
5p 
MIMAT0000135 1.352220013 3.294244495 
mmu-miR-125b* MIMAT0004529 0.047237385 -0.733528529 
mmu-miR-125b-
3p 
MIMAT0004669 -0.879596767 -1.779341919 
mmu-miR-125b-
5p 
MIMAT0000136 1.841177399 4.787841208 
mmu-miR-126-3p MIMAT0000138 4.499607206 6.300321724 
mmu-miR-126-5p MIMAT0000137 2.45076993 2.53113059 
mmu-miR-127 MIMAT0000139 1.237437665 1.783334631 
mmu-miR-127* MIMAT0004530 -1.760682866 -2.353193503 
mmu-miR-128 MIMAT0000140 5.035404172 5.104355573 
mmu-miR-129-3p MIMAT0000544 2.227605188 2.030993851 
mmu-miR-129-5p MIMAT0000209 -0.181649448 -0.808316819 
mmu-miR-130a MIMAT0000141 4.049473473 6.997191837 
mmu-miR-130b MIMAT0000387 7.705293666 7.820178624 
mmu-miR-130b* MIMAT0004583 2.382753309 2.864926957 
mmu-miR-132 MIMAT0000144 -0.544875578 -0.527459329 
mmu-miR-133a MIMAT0000145 2.520005032 1.814748859 
mmu-miR-133a* MIMAT0003473 -0.873382446 -1.673773178 
mmu-miR-133b MIMAT0000769 2.346762852 1.547889843 
mmu-miR-134 MIMAT0000146 4.833960157 -2.35622959 
mmu-miR-135a MIMAT0000147 2.725493305 2.769002398 
mmu-miR-135a* MIMAT0004531 3.7836828 0.821810284 
mmu-miR-135b MIMAT0000612 2.412313953 2.630017575 
mmu-miR-136 MIMAT0000148 2.75740244 2.968331013 
mmu-miR-136* MIMAT0004532 1.862550274 2.060017043 
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mmu-miR-137 MIMAT0000149 -0.046888883 0.39198953 
mmu-miR-138 MIMAT0000150 -1.096545113 -2.017948042 
mmu-miR-138* MIMAT0004668 1.530756215 -0.850505257 
mmu-miR-139-3p MIMAT0004662 4.018224922 0.983550583 
mmu-miR-139-5p MIMAT0000656 6.497248529 2.508369355 
mmu-miR-140 MIMAT0000151 6.240944023 5.204460731 
mmu-miR-140* MIMAT0000152 6.449992011 5.254834451 
mmu-miR-141 MIMAT0000153 2.415705785 -0.849415781 
mmu-miR-141* MIMAT0004533 -1.702043853 -1.676988782 
mmu-miR-142-3p MIMAT0000155 9.161768446 6.796280308 
mmu-miR-142-5p MIMAT0000154 7.581383502 5.164116308 
mmu-miR-143 MIMAT0000247 -1.26427378 -1.733964582 
mmu-miR-144 MIMAT0000156 4.120191326 -0.472270581 
mmu-miR-145 MIMAT0000157 -0.153210571 -1.147551652 
mmu-miR-145* MIMAT0004534 0.924352865 1.494256717 
mmu-miR-146a MIMAT0000158 3.742598318 3.135766676 
mmu-miR-146b MIMAT0003475 2.639176537 2.881054651 
mmu-miR-146b* MIMAT0004826 -1.710814725 -1.428064795 
mmu-miR-147 MIMAT0004857 -0.994965136 -1.098060866 
mmu-miR-148a MIMAT0000516 5.787231851 5.590756677 
mmu-miR-148a* MIMAT0004617 -1.302380866 -1.068369298 
mmu-miR-148b MIMAT0000580 2.725218546 1.768801264 
mmu-miR-149 MIMAT0000159 4.409232295 3.358487225 
mmu-miR-150 MIMAT0000160 4.125205905 1.282416944 
mmu-miR-150* MIMAT0004535 1.062115295 -2.55866226 
mmu-miR-151-3p MIMAT0000161 -2.002359842 -2.340844057 
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mmu-miR-151-5p MIMAT0004536 3.909798203 4.042815192 
mmu-miR-152 MIMAT0000162 -0.054644158 1.543063844 
mmu-miR-153 MIMAT0000163 -1.468330644 -1.381496025 
mmu-miR-154 MIMAT0000164 2.177288744 2.662636656 
mmu-miR-154* MIMAT0004537 1.755273878 2.202125843 
mmu-miR-155 MIMAT0000165 4.422819897 5.768249292 
mmu-miR-15a MIMAT0000526 10.23390111 8.651660027 
mmu-miR-15a* MIMAT0004624 1.173171068 1.478342572 
mmu-miR-15b MIMAT0000124 11.47561437 10.28767092 
mmu-miR-15b* MIMAT0004521 2.500218212 2.517997125 
mmu-miR-16 MIMAT0000527 9.19874769 7.436168072 
mmu-miR-16* MIMAT0004625 -0.370846328 -0.895292388 
mmu-miR-17 MIMAT0000649 3.239623207 3.185039163 
mmu-miR-17* MIMAT0000650 4.412769463 4.836391266 
mmu-miR-181a MIMAT0000210 4.801976077 4.376353131 
mmu-miR-181a-1* MIMAT0000660 2.059528469 2.284338273 
mmu-miR-181a-2* MIMAT0005443 1.743116713 1.685219535 
mmu-miR-181b MIMAT0000673 5.057947445 5.045742966 
mmu-miR-181c MIMAT0000674 4.280591189 5.893362241 
mmu-miR-181d MIMAT0004324 3.294005289 4.175622359 
mmu-miR-182 MIMAT0000211 -1.050156563 -1.493859796 
mmu-miR-183 MIMAT0000212 0.078256258 -0.225907481 
mmu-miR-183* MIMAT0004539 -1.94483673 -2.530740598 
mmu-miR-184 MIMAT0000213 -0.27532556 -1.760953352 
mmu-miR-185 MIMAT0000214 3.630088193 1.669398165 
mmu-miR-186 MIMAT0000215 2.232988751 2.329861338 
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mmu-miR-186* MIMAT0004540 1.75291291 1.710618073 
mmu-miR-187 MIMAT0000216 -2.188776372 -2.302653393 
mmu-miR-188-3p MIMAT0004541 -1.400770678 -1.444831809 
mmu-miR-188-5p MIMAT0000217 7.843171881 1.579374152 
mmu-miR-18a MIMAT0000528 7.939678386 7.405437282 
mmu-miR-18a* MIMAT0004626 2.217775477 2.232559728 
mmu-miR-18b MIMAT0004858 0.797327511 0.727389414 
mmu-miR-190 MIMAT0000220 0.443652989 1.343690047 
mmu-miR-190b MIMAT0004852 1.110561455 0.954677247 
mmu-miR-191 MIMAT0000221 -0.845089515 -1.105883172 
mmu-miR-191* MIMAT0004542 3.452748603 3.169133117 
mmu-miR-192 MIMAT0000517 4.675931411 2.95792509 
mmu-miR-193 MIMAT0000223 2.782529581 1.569438768 
mmu-miR-193* MIMAT0004544 -2.578498652 -2.953928263 
mmu-miR-193b MIMAT0004859 1.843034952 3.489505936 
mmu-miR-194 MIMAT0000224 1.682782517 -0.672953815 
mmu-miR-195 MIMAT0000225 2.969137293 1.398178221 
mmu-miR-196a MIMAT0000518 1.879684462 1.968028908 
mmu-miR-196a* MIMAT0004618 -1.645255355 -1.722601402 
mmu-miR-196b MIMAT0001081 3.476265536 7.162135464 
mmu-miR-197 MIMAT0004860 2.715058309 2.630409308 
mmu-miR-199a-
3p 
MIMAT0000230 1.840477398 1.430219551 
mmu-miR-199a-
5p 
MIMAT0000229 1.848303397 1.788343381 
mmu-miR-199b* MIMAT0000672 2.350366793 2.855465299 
mmu-miR-19a MIMAT0000651 6.724914206 6.600309357 
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mmu-miR-19a* MIMAT0004660 1.633819453 1.553399055 
mmu-miR-19b MIMAT0000513 9.710523812 10.17340111 
mmu-miR-200a MIMAT0000519 -0.301816008 0.122107874 
mmu-miR-200a* MIMAT0004619 -1.147725578 -1.86256567 
mmu-miR-200b MIMAT0000233 0.959697492 0.305107657 
mmu-miR-200b* MIMAT0004545 -1.663379465 -2.504404298 
mmu-miR-200c MIMAT0000657 4.131889218 -1.460538318 
mmu-miR-200c* MIMAT0004663 -0.735794111 -0.1467394 
mmu-miR-201 MIMAT0000234 1.703561679 2.088463562 
mmu-miR-202-3p MIMAT0000235 6.687775808 5.501978128 
mmu-miR-202-5p MIMAT0004546 2.640725959 2.8560065 
mmu-miR-203 MIMAT0000236 0.491668004 2.085646657 
mmu-miR-203* MIMAT0004547 1.306030495 1.814668824 
mmu-miR-204 MIMAT0000237 2.586888005 3.008958105 
mmu-miR-205 MIMAT0000238 1.03673243 0.232158035 
mmu-miR-206 MIMAT0000239 1.387947102 -2.572455723 
mmu-miR-207 MIMAT0000240 2.733329261 2.307126513 
mmu-miR-208a MIMAT0000520 -1.509493029 -1.712806626 
mmu-miR-208b MIMAT0004939 -0.855139847 -2.000846052 
mmu-miR-20a MIMAT0000529 10.36877283 10.69474225 
mmu-miR-20a* MIMAT0004627 0.599184036 1.541637123 
mmu-miR-20b MIMAT0003187 8.332200953 8.544882975 
mmu-miR-20b* MIMAT0004788 -1.046388241 -1.046779961 
mmu-miR-21 MIMAT0000530 9.898689484 9.582774789 
mmu-miR-21* MIMAT0004628 0.075141825 -1.58768218 
mmu-miR-210 MIMAT0000658 4.207419745 1.426015712 
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mmu-miR-211 MIMAT0000668 2.978999696 3.35678187 
mmu-miR-212 MIMAT0000659 6.049774949 4.863992782 
mmu-miR-214 MIMAT0000661 -1.88234125 -2.511237698 
mmu-miR-214* MIMAT0004664 0.265593297 0.634005822 
mmu-miR-215 MIMAT0000904 1.006194936 0.405080732 
mmu-miR-216a MIMAT0000662 -1.444438118 -1.939866315 
mmu-miR-216b MIMAT0003729 -2.454137681 -2.552058149 
mmu-miR-217 MIMAT0000679 -2.410287725 -2.765869889 
mmu-miR-218 MIMAT0000663 1.116285369 1.159395757 
mmu-miR-218-1* MIMAT0004665 0.171686192 -0.119379179 
mmu-miR-218-2* MIMAT0005444 -1.556523082 -2.117326656 
mmu-miR-219 MIMAT0000664 2.943723986 2.390491951 
mmu-miR-22 MIMAT0000531 7.434630287 4.776519621 
mmu-miR-22* MIMAT0004629 1.296062306 0.840833637 
mmu-miR-220 MIMAT0004863 -1.231172448 -0.7506906 
mmu-miR-221 MIMAT0000669 4.261505693 4.981167266 
mmu-miR-222 MIMAT0000670 2.039909462 3.010867136 
mmu-miR-223 MIMAT0000665 12.50118568 9.443498237 
mmu-miR-224 MIMAT0000671 1.132369414 1.734184404 
mmu-miR-23a MIMAT0000532 7.522132996 6.510298105 
mmu-miR-23b MIMAT0000125 5.902042877 5.943614826 
mmu-miR-24 MIMAT0000219 7.981965747 7.702525826 
mmu-miR-24-1* MIMAT0000218 1.981751982 2.075154364 
mmu-miR-24-2* MIMAT0005440 -1.289708343 -1.661816579 
mmu-miR-25 MIMAT0000652 8.569601536 8.054393963 
mmu-miR-26a MIMAT0000533 7.437286973 6.922694833 
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mmu-miR-26b MIMAT0000534 6.404881732 5.880268364 
mmu-miR-26b* MIMAT0004630 2.159684471 2.338060832 
mmu-miR-27a MIMAT0000537 8.34395871 7.147290458 
mmu-miR-27a* MIMAT0004633 -1.327779917 -1.362619053 
mmu-miR-27b MIMAT0000126 4.869923068 4.401926709 
mmu-miR-27b* MIMAT0004522 -1.65399201 -1.515242407 
mmu-miR-28 MIMAT0000653 3.728616144 3.385467861 
mmu-miR-28* MIMAT0004661 -0.25686275 -2.487928105 
mmu-miR-290-3p MIMAT0004572 3.298101834 2.858803147 
mmu-miR-290-5p MIMAT0000366 2.99444746 0.93436425 
mmu-miR-291a-
3p 
MIMAT0000368 2.267744877 2.771238707 
mmu-miR-291a-
5p 
MIMAT0000367 0.669770001 -1.565233523 
mmu-miR-291b-
3p 
MIMAT0003190 2.21722441 2.719901416 
mmu-miR-291b-
5p 
MIMAT0003189 2.306892202 1.389820097 
mmu-miR-292-3p MIMAT0000370 0.522906183 1.061132635 
mmu-miR-292-5p MIMAT0000369 1.057076981 -1.043947967 
mmu-miR-293 MIMAT0000371 -0.22920919 0.222917244 
mmu-miR-293* MIMAT0004573 1.169131697 1.394372936 
mmu-miR-294 MIMAT0000372 2.778531971 2.929921536 
mmu-miR-294* MIMAT0004574 0.020834441 -1.521020443 
mmu-miR-295 MIMAT0000373 2.290450521 2.762753077 
mmu-miR-295* MIMAT0004575 -1.07261849 -1.829930058 
mmu-miR-296-3p MIMAT0004576 -1.750107888 -2.614857506 
mmu-miR-296-5p MIMAT0000374 7.071013822 4.492672982 
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mmu-miR-297a* MIMAT0004864 0.957832791 0.773661326 
mmu-miR-297b-
5p 
MIMAT0003480 -0.927298172 -1.230789068 
mmu-miR-297c MIMAT0004865 1.475204114 1.48071467 
mmu-miR-298 MIMAT0000376 2.520554011 2.122699227 
mmu-miR-299 MIMAT0004577 -2.059632344 -2.185803058 
mmu-miR-299* MIMAT0000377 2.142223924 2.289863617 
mmu-miR-29a MIMAT0000535 9.683604277 9.43547056 
mmu-miR-29a* MIMAT0004631 2.221658351 2.416427941 
mmu-miR-29b MIMAT0000127 6.465729808 6.391739525 
mmu-miR-29b* MIMAT0004523 1.491287588 1.461550223 
mmu-miR-29c MIMAT0000536 6.347390129 5.316474604 
mmu-miR-29c* MIMAT0004632 2.865640841 2.683015141 
mmu-miR-300 MIMAT0000378 0.505734222 -0.239365496 
mmu-miR-300* MIMAT0004578 0.133684087 -0.086570165 
mmu-miR-301a MIMAT0000379 5.729233319 4.263606223 
mmu-miR-301b MIMAT0004186 1.136619573 1.100979145 
mmu-miR-302a MIMAT0000380 2.153555029 2.436370949 
mmu-miR-302a* MIMAT0004579 0.065564738 0.608842304 
mmu-miR-302b MIMAT0003374 2.300635929 2.223797035 
mmu-miR-302b* MIMAT0003373 -0.186369499 0.113240479 
mmu-miR-302c MIMAT0003376 1.693402104 2.031934025 
mmu-miR-302c* MIMAT0003375 -1.966154934 -1.938587373 
mmu-miR-302d MIMAT0003377 1.041903257 1.744703134 
mmu-miR-30a MIMAT0000128 4.699643595 4.384524502 
mmu-miR-30a* MIMAT0000129 -0.749010286 -0.434192407 
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mmu-miR-30b MIMAT0000130 4.541239815 4.165520656 
mmu-miR-30b* MIMAT0004524 3.754281743 3.209747541 
mmu-miR-30c MIMAT0000514 4.817840148 4.770854246 
mmu-miR-30c-1* MIMAT0004616 0.688556741 -0.758332184 
mmu-miR-30c-2* MIMAT0005438 1.886562666 -1.18036058 
mmu-miR-30d MIMAT0000515 6.71978252 5.876613778 
mmu-miR-30e MIMAT0000248 6.042287113 5.373582361 
mmu-miR-30e* MIMAT0000249 1.527931525 1.208410627 
mmu-miR-31 MIMAT0000538 -0.517818571 1.576330623 
mmu-miR-31* MIMAT0004634 1.118993532 1.825989417 
mmu-miR-32 MIMAT0000654 1.470984924 1.956119872 
mmu-miR-320 MIMAT0000666 4.063629973 0.581128823 
mmu-miR-322 MIMAT0000548 7.076123846 7.66167582 
mmu-miR-322* MIMAT0000549 -1.196525163 -1.300491042 
mmu-miR-323-3p MIMAT0000551 1.206719081 1.01570116 
mmu-miR-323-5p MIMAT0004638 -2.234566894 -2.407612056 
mmu-miR-324-3p MIMAT0000556 3.180002342 2.988025597 
mmu-miR-324-5p MIMAT0000555 4.292625136 4.274899681 
mmu-miR-325 MIMAT0004640 0.768033811 0.266307619 
mmu-miR-325* MIMAT0000558 -1.74761927 -1.654879197 
mmu-miR-326 MIMAT0000559 2.788969138 2.972614248 
mmu-miR-327 MIMAT0004867 4.01313231 -2.943221731 
mmu-miR-328 MIMAT0000565 2.922188693 3.372306431 
mmu-miR-329 MIMAT0000567 2.66925663 2.616411319 
mmu-miR-33 MIMAT0000667 3.336779161 3.292651586 
mmu-miR-33* MIMAT0004666 -0.127515718 -0.667332308 
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mmu-miR-330 MIMAT0004642 -0.961083432 -1.352853783 
mmu-miR-330* MIMAT0000569 -0.064296153 -1.950341535 
mmu-miR-331-3p MIMAT0000571 4.869501564 4.654473368 
mmu-miR-331-5p MIMAT0004643 -1.12037785 -1.924076214 
mmu-miR-335-3p MIMAT0004704 3.040406892 3.00440183 
mmu-miR-335-5p MIMAT0000766 -1.90264476 -1.930265935 
mmu-miR-337-3p MIMAT0000578 1.617907362 1.758553047 
mmu-miR-337-5p MIMAT0004644 -1.758229153 -1.921587586 
mmu-miR-338-3p MIMAT0000582 4.083145513 2.159044868 
mmu-miR-338-5p MIMAT0004647 0.579561288 -1.250811373 
mmu-miR-339-3p MIMAT0004649 -1.771383779 -2.484097372 
mmu-miR-339-5p MIMAT0000584 -1.789969543 -2.497892065 
mmu-miR-340-3p MIMAT0000586 4.103118032 3.46300419 
mmu-miR-340-5p MIMAT0004651 4.256147243 2.534558017 
mmu-miR-341 MIMAT0000588 3.718084395 -1.918968957 
mmu-miR-342-3p MIMAT0000590 7.990586605 5.231568983 
mmu-miR-342-5p MIMAT0004653 0.943001627 -0.626352469 
mmu-miR-343 MIMAT0004868 1.352476363 0.910744544 
mmu-miR-344 MIMAT0000593 -0.873271078 -1.155110301 
mmu-miR-345-3p MIMAT0004656 -0.129699546 -2.909411968 
mmu-miR-345-5p MIMAT0000595 4.526128484 4.148004071 
mmu-miR-346 MIMAT0000597 0.150218706 -0.85608024 
mmu-miR-34a MIMAT0000542 6.114063807 5.801020131 
mmu-miR-34b-3p MIMAT0004581 0.597539522 1.198774658 
mmu-miR-34b-5p MIMAT0000382 1.381707917 0.883363401 
mmu-miR-34c MIMAT0000381 0.243985027 0.117839131 
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mmu-miR-34c* MIMAT0004580 -0.693125968 -1.24480953 
mmu-miR-350 MIMAT0000605 4.826754759 3.813329761 
mmu-miR-351 MIMAT0000609 0.672085619 0.698779389 
mmu-miR-361 MIMAT0000704 6.373503853 4.910143779 
mmu-miR-362-3p MIMAT0004684 4.629616935 3.834230842 
mmu-miR-362-5p MIMAT0000706 0.496724185 -1.983564586 
mmu-miR-363 MIMAT0000708 2.833489847 2.548691952 
mmu-miR-365 MIMAT0000711 3.541256436 3.226034253 
mmu-miR-367 MIMAT0003181 2.057235684 2.150545508 
mmu-miR-369-3p MIMAT0003186 1.422130781 1.238364289 
mmu-miR-369-5p MIMAT0003185 1.933147912 2.364489982 
mmu-miR-370 MIMAT0001095 6.787242731 -1.500324573 
mmu-miR-374 MIMAT0003727 2.85414028 2.954729655 
mmu-miR-374* MIMAT0003728 1.212679725 1.634194605 
mmu-miR-375 MIMAT0000739 -1.202063908 -1.342107049 
mmu-miR-376a MIMAT0000740 -1.976262496 -2.175824022 
mmu-miR-376a* MIMAT0003387 1.981685648 1.759241273 
mmu-miR-376b MIMAT0001092 -0.92207293 -1.116804283 
mmu-miR-376b* MIMAT0003388 1.890961488 1.950129725 
mmu-miR-376c MIMAT0003183 -0.689595781 -0.526097376 
mmu-miR-376c* MIMAT0005295 1.701197374 1.82372057 
mmu-miR-377 MIMAT0000741 1.148312181 1.069113678 
mmu-miR-378 MIMAT0003151 3.232228115 1.92641787 
mmu-miR-378* MIMAT0000742 1.879463913 1.998036894 
mmu-miR-379 MIMAT0000743 -1.885251535 -1.986326047 
mmu-miR-380-3p MIMAT0000745 1.650270235 1.442055047 
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mmu-miR-380-5p MIMAT0000744 -1.073629112 -1.68954064 
mmu-miR-381 MIMAT0000746 -0.660974513 -0.804802988 
mmu-miR-382 MIMAT0000747 -0.485197893 -0.97553247 
mmu-miR-382* MIMAT0004691 2.268506147 2.685944565 
mmu-miR-383 MIMAT0000748 -1.629670515 -2.088843579 
mmu-miR-384-3p MIMAT0001076 1.802313222 1.1779027 
mmu-miR-384-5p MIMAT0004745 0.619398332 1.142050841 
mmu-miR-409-3p MIMAT0001090 -0.059173823 -0.357383475 
mmu-miR-409-5p MIMAT0004746 1.757754085 1.512966747 
mmu-miR-410 MIMAT0001091 -0.318842633 0.585768695 
mmu-miR-411 MIMAT0004747 -1.139840596 -0.995712884 
mmu-miR-411* MIMAT0001093 0.725737201 1.227354101 
mmu-miR-412 MIMAT0001094 -1.103607361 -0.982302846 
mmu-miR-421 MIMAT0004869 1.887362208 0.605019628 
mmu-miR-423-3p MIMAT0003454 -0.776151839 -1.868308923 
mmu-miR-423-5p MIMAT0004825 6.194049441 5.236998224 
mmu-miR-425 MIMAT0004750 6.377121411 6.016649306 
mmu-miR-425* MIMAT0001342 -0.049989842 -0.055794443 
mmu-miR-429 MIMAT0001537 1.871783878 1.988485624 
mmu-miR-431 MIMAT0001418 -1.560844517 -1.292709481 
mmu-miR-431* MIMAT0004753 0.948625779 0.712166411 
mmu-miR-433 MIMAT0001420 -1.473296767 -1.851602188 
mmu-miR-433* MIMAT0001419 1.494513346 1.667710392 
mmu-miR-434-3p MIMAT0001422 2.040616439 2.155893125 
mmu-miR-434-5p MIMAT0001421 0.558199756 0.286247162 
mmu-miR-448 MIMAT0001533 0.462340558 -0.450014378 
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mmu-miR-449a MIMAT0001542 0.685271571 0.78803702 
mmu-miR-449b MIMAT0005447 -0.60450622 -0.96540453 
mmu-miR-449c MIMAT0003460 -0.978285465 -1.173659785 
mmu-miR-450a-
3p 
MIMAT0004789 1.821344374 0.779719862 
mmu-miR-450a-
5p 
MIMAT0001546 2.11821949 2.617587165 
mmu-miR-450b-
3p 
MIMAT0003512 1.358551759 1.508485551 
mmu-miR-450b-
5p 
MIMAT0003511 1.651182313 1.808247237 
mmu-miR-451 MIMAT0001632 7.71938396 3.061462669 
mmu-miR-452 MIMAT0001637 4.110342831 -2.047833805 
mmu-miR-453 MIMAT0004870 -0.450543831 -0.251091746 
mmu-miR-455 MIMAT0003742 -0.212877633 -1.361733274 
mmu-miR-455* MIMAT0003485 1.204019058 1.309826675 
mmu-miR-463 MIMAT0004758 -0.798814279 -1.043753736 
mmu-miR-463* MIMAT0002104 2.521524498 2.657769524 
mmu-miR-464 MIMAT0002105 1.746393436 1.947614051 
mmu-miR-465a-
3p 
MIMAT0004217 -0.066952062 0.215537754 
mmu-miR-465a-
5p 
MIMAT0002106 -2.106553585 -2.375916786 
mmu-miR-465b-
5p 
MIMAT0004871 -0.878803691 -1.475727464 
mmu-miR-465c-
5p 
MIMAT0004873 -1.758387561 -1.779064239 
mmu-miR-466a-
3p 
MIMAT0002107 0.902656131 0.816782749 
mmu-miR-466a- MIMAT0004759 -0.49565446 -0.482459958 
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5p 
mmu-miR-466b-
5p 
MIMAT0004875 -0.928895466 -0.987271867 
mmu-miR-466c-
5p 
MIMAT0004877 3.423269611 1.988355934 
mmu-miR-466d-
3p 
MIMAT0004931 -1.132151308 -1.077176029 
mmu-miR-466d-
5p 
MIMAT0004930 -1.867320825 -1.880745326 
mmu-miR-466f-3p MIMAT0004882 1.563923008 1.373608292 
mmu-miR-466f-5p MIMAT0004881 -1.067558856 -1.650000682 
mmu-miR-466g MIMAT0004883 -0.552965501 -0.294476078 
mmu-miR-466h MIMAT0004884 1.15661067 0.407530664 
mmu-miR-467a MIMAT0003409 1.836333002 1.427897647 
mmu-miR-467a* MIMAT0002108 2.025403395 1.385790226 
mmu-miR-467b MIMAT0005448 2.315793721 2.167885533 
mmu-miR-467b* MIMAT0003478 0.465266856 -0.285644099 
mmu-miR-467c MIMAT0004885 1.771954119 1.63963448 
mmu-miR-467d MIMAT0004886 -1.138267545 -1.592034643 
mmu-miR-467e MIMAT0005293 -0.028176294 0.426007032 
mmu-miR-467e* MIMAT0005294 1.831928249 2.096003299 
mmu-miR-468 MIMAT0002109 2.692323328 0.526672911 
mmu-miR-469 MIMAT0002110 2.942035607 3.215554929 
mmu-miR-470 MIMAT0002111 -1.423843237 -1.750720359 
mmu-miR-470* MIMAT0004760 1.614855034 1.864640269 
mmu-miR-471 MIMAT0002112 1.645279907 1.636128189 
mmu-miR-483 MIMAT0004782 6.51562285 -2.447984229 
mmu-miR-483* MIMAT0003120 3.75005955 3.188756058 
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mmu-miR-484 MIMAT0003127 3.205766806 2.320316803 
mmu-miR-485 MIMAT0003128 -0.689757057 -0.349758767 
mmu-miR-485* MIMAT0003129 1.179976387 0.559317932 
mmu-miR-486 MIMAT0003130 4.859086533 -0.80771241 
mmu-miR-487b MIMAT0003184 1.86898684 1.44175839 
mmu-miR-488 MIMAT0003450 -0.05942876 0.56253181 
mmu-miR-488* MIMAT0003449 0.097308517 -0.220885905 
mmu-miR-489 MIMAT0003112 -0.735539623 -0.925805061 
mmu-miR-490 MIMAT0003780 -0.382038408 -1.657148105 
mmu-miR-491 MIMAT0003486 -0.878045761 -0.951501854 
mmu-miR-493 MIMAT0004888 -1.071972588 -1.966223199 
mmu-miR-494 MIMAT0003182 10.10949515 5.987053374 
mmu-miR-495 MIMAT0003456 1.543038523 1.616498479 
mmu-miR-496 MIMAT0003738 0.533893282 0.686751906 
mmu-miR-497 MIMAT0003453 3.155951215 1.579564888 
mmu-miR-499 MIMAT0003482 0.54593222 0.563951662 
mmu-miR-500 MIMAT0003507 5.720212156 4.536301688 
mmu-miR-501-3p MIMAT0003509 -2.131802467 -2.388983559 
mmu-miR-501-5p MIMAT0003508 -1.532709532 -2.071493069 
mmu-miR-503 MIMAT0003188 3.93569992 3.356310351 
mmu-miR-503* MIMAT0004790 -0.509033262 -1.298251089 
mmu-miR-504 MIMAT0004889 0.006892847 0.316355261 
mmu-miR-505 MIMAT0003513 2.544898372 2.492359424 
mmu-miR-509-3p MIMAT0004891 1.275781545 1.640938677 
mmu-miR-509-5p MIMAT0004890 -1.349072372 -0.84062569 
mmu-miR-511 MIMAT0004940 2.465797589 2.543205161 
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mmu-miR-532-3p MIMAT0004781 0.041117084 -0.754167353 
mmu-miR-532-5p MIMAT0002889 3.982559465 2.680791699 
mmu-miR-539 MIMAT0003169 0.613160326 0.996872391 
mmu-miR-540-3p MIMAT0003167 -1.847152893 -2.244477781 
mmu-miR-540-5p MIMAT0004786 1.407910865 1.220692805 
mmu-miR-541 MIMAT0003170 -0.145110458 0.947450677 
mmu-miR-542-3p MIMAT0003172 1.129246693 2.613189074 
mmu-miR-542-5p MIMAT0003171 3.211739149 5.086370973 
mmu-miR-543 MIMAT0003168 1.865024892 2.297631033 
mmu-miR-544 MIMAT0004941 2.354578244 2.779898184 
mmu-miR-546 MIMAT0003166 4.869891558 -2.496529131 
mmu-miR-547 MIMAT0003173 -1.192068874 -0.529504421 
mmu-miR-551b MIMAT0003890 2.229749041 1.674180581 
mmu-miR-568 MIMAT0004892 -0.051709285 0.129960117 
mmu-miR-574-3p MIMAT0004894 0.436730115 0.350750089 
mmu-miR-574-5p MIMAT0004893 8.104836175 4.632877086 
mmu-miR-582-3p MIMAT0005292 -1.062211027 -1.568540049 
mmu-miR-582-5p MIMAT0005291 2.148531164 2.399912573 
mmu-miR-590-3p MIMAT0004896 0.947696475 1.592731227 
mmu-miR-590-5p MIMAT0004895 0.898244503 1.057822295 
mmu-miR-592 MIMAT0003730 1.646095146 -0.408239422 
mmu-miR-598 MIMAT0004942 1.694893349 2.066414835 
mmu-miR-615-3p MIMAT0003783 0.995151624 0.757380504 
mmu-miR-615-5p MIMAT0004837 -1.926719049 -2.013241824 
mmu-miR-652 MIMAT0003711 7.600822806 6.608058956 
mmu-miR-653 MIMAT0004943 0.202331488 0.808710774 
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mmu-miR-654-3p MIMAT0004898 1.114021548 0.999129498 
mmu-miR-654-5p MIMAT0004897 -1.364372899 -1.539048079 
mmu-miR-665 MIMAT0003733 -1.113123435 -2.31102536 
mmu-miR-666-3p MIMAT0004823 -1.254053829 -0.884049522 
mmu-miR-666-5p MIMAT0003737 0.387382856 -1.902979354 
mmu-miR-667 MIMAT0003734 0.820572937 -1.300495475 
mmu-miR-668 MIMAT0003732 0.80595443 0.477230019 
mmu-miR-669a MIMAT0003477 3.222134735 2.802570483 
mmu-miR-669b MIMAT0003476 0.272808302 -1.872514343 
mmu-miR-669c MIMAT0003479 4.100681658 1.911714977 
mmu-miR-670 MIMAT0003736 -1.556016837 -2.323365098 
mmu-miR-671-3p MIMAT0004821 -0.444147193 -1.557061511 
mmu-miR-671-5p MIMAT0003731 7.34674841 1.469139308 
mmu-miR-672 MIMAT0003735 0.689332917 -1.747640427 
mmu-miR-673-3p MIMAT0004824 0.446844117 -0.257923679 
mmu-miR-673-5p MIMAT0003739 -0.945490272 -1.286728997 
mmu-miR-674 MIMAT0003740 1.46456685 -2.835283756 
mmu-miR-674* MIMAT0003741 2.929659873 2.994063232 
mmu-miR-675-3p MIMAT0003726 0.236036424 0.723499632 
mmu-miR-675-5p MIMAT0003725 -1.980950405 -2.388535612 
mmu-miR-676 MIMAT0003782 0.224920134 0.317183772 
mmu-miR-676* MIMAT0003781 -0.053944537 0.120534364 
mmu-miR-677 MIMAT0003451 1.201898173 0.631407583 
mmu-miR-678 MIMAT0003452 4.240000754 -1.987599011 
mmu-miR-679 MIMAT0003455 -1.666960065 -1.759088458 
mmu-miR-680 MIMAT0003457 5.093257629 -1.49429763 
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mmu-miR-681 MIMAT0003458 2.971135575 -1.967573056 
mmu-miR-682 MIMAT0003459 0.873528133 -1.556447827 
mmu-miR-683 MIMAT0003461 -0.48058979 -0.65310516 
mmu-miR-684 MIMAT0003462 1.221700059 2.056500506 
mmu-miR-685 MIMAT0003463 2.49452262 -2.615671678 
mmu-miR-686 MIMAT0003464 -2.152071139 -2.774343134 
mmu-miR-687 MIMAT0003466 -2.167599964 -2.507442682 
mmu-miR-688 MIMAT0003467 0.258823457 0.596369031 
mmu-miR-689 MIMAT0003468 9.726739807 5.210869472 
mmu-miR-690 MIMAT0003469 5.420678522 3.407647344 
mmu-miR-691 MIMAT0003470 0.70617163 -2.809452262 
mmu-miR-692 MIMAT0003471 -0.490315993 -0.823923112 
mmu-miR-693-3p MIMAT0004189 -2.08977265 -2.063471207 
mmu-miR-693-5p MIMAT0003472 1.426767337 1.701489791 
mmu-miR-694 MIMAT0003474 -1.582511905 -1.629072805 
mmu-miR-695 MIMAT0003481 -2.34402177 -2.501798323 
mmu-miR-696 MIMAT0003483 0.044165587 -1.570295187 
mmu-miR-697 MIMAT0003487 4.715060256 3.178714499 
mmu-miR-698 MIMAT0003488 2.102187095 2.610073065 
mmu-miR-699 MIMAT0003489 -0.805705312 -1.413578357 
mmu-miR-700 MIMAT0003490 1.603788317 -0.067643873 
mmu-miR-701 MIMAT0003491 -2.239005445 -2.483786954 
mmu-miR-702 MIMAT0003492 3.445071146 3.386831197 
mmu-miR-703 MIMAT0003493 -1.070600626 -1.667620425 
mmu-miR-704 MIMAT0003494 -0.030358196 -0.372394071 
mmu-miR-705 MIMAT0003495 7.412657583 -0.751162155 
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mmu-miR-706 MIMAT0003496 3.136663208 1.119140491 
mmu-miR-707 MIMAT0003497 -1.14080843 -0.688497804 
mmu-miR-708 MIMAT0004828 -0.518290539 -1.602512569 
mmu-miR-708* MIMAT0003498 -0.681155897 -1.211122556 
mmu-miR-709 MIMAT0003499 11.2903681 8.837902863 
mmu-miR-710 MIMAT0003500 3.116663449 -2.942451696 
mmu-miR-711 MIMAT0003501 2.090303443 -3.01830248 
mmu-miR-712 MIMAT0003502 5.66109448 2.949098681 
mmu-miR-712* MIMAT0003743 4.44497163 -2.133835117 
mmu-miR-713 MIMAT0003504 -2.348685259 -2.37520349 
mmu-miR-714 MIMAT0003505 9.406839601 4.176204167 
mmu-miR-715 MIMAT0003506 4.542114524 1.315087414 
mmu-miR-717 MIMAT0003510 0.056142713 -0.097478839 
mmu-miR-718 MIMAT0003514 0.712693786 -2.357071903 
mmu-miR-719 MIMAT0003465 -0.977779468 -1.360571704 
mmu-miR-720 MIMAT0003484 11.04883202 11.09337948 
mmu-miR-721 MIMAT0003515 8.290759783 4.560899922 
mmu-miR-741 MIMAT0004236 -0.241401107 0.31881022 
mmu-miR-742 MIMAT0004237 -1.674106656 -1.413448489 
mmu-miR-742* MIMAT0004838 0.333766293 0.516142371 
mmu-miR-743a MIMAT0004238 -1.487059605 -2.001447034 
mmu-miR-743b-
3p 
MIMAT0004840 0.010306123 -0.475734955 
mmu-miR-743b-
5p 
MIMAT0004839 -1.091499999 -1.161749258 
mmu-miR-744 MIMAT0004187 -2.159191948 -2.283935697 
mmu-miR-744* MIMAT0004820 1.888058504 1.571540064 
 
132 
mmu-miR-758 MIMAT0003889 -0.909594115 -0.973196472 
mmu-miR-759 MIMAT0003897 0.881543937 0.127403106 
mmu-miR-760 MIMAT0003898 4.666251402 -0.023303787 
mmu-miR-761 MIMAT0003893 -2.087055121 -2.226832348 
mmu-miR-762 MIMAT0003892 3.783791091 -2.74846252 
mmu-miR-763 MIMAT0003896 -2.198099075 -2.457531752 
mmu-miR-764-3p MIMAT0003895 -1.192264167 -1.230734065 
mmu-miR-764-5p MIMAT0003894 1.159029667 1.29997425 
mmu-miR-770-3p MIMAT0003891 3.674632664 -2.60238728 
mmu-miR-770-5p MIMAT0004822 -1.538385739 -2.106602075 
mmu-miR-7a MIMAT0000677 2.455965976 1.661881292 
mmu-miR-7a* MIMAT0004670 1.946233186 2.15315134 
mmu-miR-7b MIMAT0000678 1.216867688 1.459788143 
mmu-miR-
801_v10.1 
NA 8.71539989 2.585106601 
mmu-miR-802 MIMAT0004188 1.433736656 1.343706708 
mmu-miR-804 MIMAT0004210 1.46402044 1.344489583 
mmu-miR-805 MIMAT0004211 -2.121875539 -2.498902496 
mmu-miR-871 MIMAT0004841 -0.044368961 -0.733110154 
mmu-miR-872 MIMAT0004934 2.128865836 2.543765753 
mmu-miR-872* MIMAT0004935 0.380951621 0.70159221 
mmu-miR-873 MIMAT0004936 0.975218191 0.955851275 
mmu-miR-874 MIMAT0004853 3.730630464 -0.099422265 
mmu-miR-875-3p MIMAT0004938 -1.403211621 -1.85224945 
mmu-miR-875-5p MIMAT0004937 2.027193548 1.927198946 
mmu-miR-876-3p MIMAT0004855 -0.193717862 0.323874124 
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mmu-miR-876-5p MIMAT0004854 1.628394516 2.118435435 
mmu-miR-877 MIMAT0004861 5.035930978 0.364372925 
mmu-miR-877* MIMAT0004862 3.605165028 3.396426006 
mmu-miR-878-3p MIMAT0004933 2.817789671 0.957953104 
mmu-miR-878-5p MIMAT0004932 -1.350981586 -1.729419693 
mmu-miR-879 MIMAT0004842 0.209437555 0.13780115 
mmu-miR-879* MIMAT0004843 -0.05532006 0.514547868 
mmu-miR-880 MIMAT0004844 1.817568569 1.519679311 
mmu-miR-881 MIMAT0004846 2.017091911 2.303689989 
mmu-miR-881* MIMAT0004845 -0.869948224 -0.548231101 
mmu-miR-882 MIMAT0004847 -1.364515877 -1.521337183 
mmu-miR-883a-
3p 
MIMAT0004849 1.097572712 1.664724891 
mmu-miR-883a-
5p 
MIMAT0004848 -2.108245969 -2.445372177 
mmu-miR-883b-
3p 
MIMAT0004851 1.606834715 2.270051144 
mmu-miR-883b-
5p 
MIMAT0004850 -2.180778495 -2.148255735 
mmu-miR-9 MIMAT0000142 -0.376366927 -0.396352929 
mmu-miR-9* MIMAT0000143 -0.680622327 -0.693802823 
mmu-miR-92a MIMAT0000539 10.13288125 10.75573482 
mmu-miR-92a* MIMAT0004635 -0.850713721 -1.556307971 
mmu-miR-92b MIMAT0004899 1.48953729 1.505732696 
mmu-miR-93 MIMAT0000540 7.381950317 6.531666564 
mmu-miR-93* MIMAT0004636 0.075135915 0.266502674 
mmu-miR-96 MIMAT0000541 2.157092901 2.27894918 
mmu-miR-98 MIMAT0000545 4.309986394 3.981152229 
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mmu-miR-99a MIMAT0000131 4.114316795 7.134121736 
mmu-miR-99b MIMAT0000132 -0.503073082 1.139445639 
mmu-miR-99b* MIMAT0004525 2.566953382 -1.780003374 
 
 
 
 
Table S2.  Antibodies for Flow Cytometry and Western Blotting 
 
Target Antigen Antibody Clone 
Gr1 (Ly-6G) RB6-8C5 
CD11b M1/70 
Ter-119 TER-119 
B220 (CD45R) RA3-6B2 
CD45.1 A20 
CD45.2 104 
cKit 2B8 
Sca1 (Ly6A/E) D7 
CD150 TC15-12F12.2 
CD48 HM48-1 
EPCR (CD201) eBio1560 
CD4 (L3T4) GK1.5 
CD8a (Ly-2) 53-6.7 
CD11c (p150/90) N418 
NK-1.1 (Ly-55) PK136 
CD3e 145-2C11 
CD19 MB19-1 
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Table S3.  Oligonucleotide and PCR Primer Sequences 
         Primer     Sequence 
miR-125a 
155-formatted 
template 
GAAGGCTGTATGCTGTCCCTGAGACCCTTTAACCTGTGAGTTTT
GGCCACTGACTGACTCACAGGTAAGGGTCTCAGGGACAGGACA
CAAGGCCTG 
miR-125b 
155-formatted 
template 
GAAGGCTGTATGCTGTCCCTGAGACCCTAACTTGTGAGTTTTGG
CCACTGACTGACTCACAAGTGGGTCTCAGGGACAGGACACAAG
GCCTG 
miR-155 
155-formatted 
template 
GAAGGCTGTATGCTGTTAATGCTAATTGTGATAGGGGTTTTGGC
CACTGACTGACCCCTATCAATTAGCATTAACAGGACACAAGGCC
TG 
miR-99a 
155-formatted 
template 
GAAGGCTGTATGCTGAACCCGTAGATCCGATCTTGTGGTTTTGG
CCACTGACTGACCACAAGATGATCTACGGGTTCAGGACACAAG
GCCTG 
miR-126 
155-formatted 
template 
GAAGGCTGTATGCTGCATTATTACTTTTGGTACGCGGTTTTGGC
CACTGACTGACCGCGTACCAAGTAATAATGCAGGACACAAGGC
CTG 
miR-196b 
155-formatted 
template 
GAAGGCTGTATGCTGTAGGTAGTTTCCTGTTGTTGGGGTTTTGG
CCACTGACTGACCCCAACAAGGAAACTACCTACAGGACACAAG
GCCTG 
miR-130a 
155-formatted 
template 
GAAGGCTGTATGCTGCAGTGCAATGTTAAAAGGGCATGTTTTGG
CCACTGACTGACATGCCCTTAACATTGCACTGCAGGACACAAG
GCCTG 
miR-542-5p 
155-formatted 
template 
GAAGGCTGTATGCTGCTCGGGGATCATCATGTCACGAGTTTTG
GCCACTGACTGACTCGTGACAATGATCCCCGAGCAGGACACAA
GGCCTG 
miR-181c 
155-formatted 
template 
GAAGGCTGTATGCTGAACATTCAACCTGTCGGTGAGTGTTTTGG
CCACTGACTGACACTCACCGAGGTTGAATGTTCAGGACACAAG
GCCTG 
miR-193b 
155-formatted 
template 
GAAGGCTGTATGCTGAACTGGCCCACAAAGTCCCGCTGTTTTG
GCCACTGACTGACAGCGGGACTGTGGGCCAGTTCAGGACACAA
GGCCTG 
let7e 
155-formatted 
template 
GAAGGCTGTATGCTGTGAGGTAGGAGGTTGTATAGTTGTTTTGG
CCACTGACTGACAACTATACCCTCCTACCTCACAGGACACAAGG
CCTG 
miR-125b-1 
NotI Fw TTCGCGGCCGCGAGTTTTCTCTGATGTACTCGTGATCGTATGT 
miR-125b-1 
XhoI Rev TTCCTCGAGAACAGAAATCCAGGAGCTGCCACTC 
miR-125b-2 
NotI Fw TTCGCGGCCGCGCCCTTGCTAGCGAAGCAGATTTT 
miR125b-2 
XhoI Rev TTCCTCGAGAGTATTTTTGGGGATGGGTCATGGTG 
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Abstract 
 MicroRNA-125b expression is modulated in macrophages in response to 
stimulatory cues. Here we report a functional role of miR-125b in macrophages. We 
found that miR-125b is enriched in macrophages compared to lymphoid cells and whole 
immune tissues. Enforced expression of miR-125b drives macrophages to adapt an 
activated morphology that is accompanied by increased co-stimulatory factor expression 
and elevated responsiveness to interferon gamma, while anti-miR-125b treatment 
decreases CD80 surface expression. To determine whether these alterations in cell 
signaling, gene expression and morphology have functional consequences, we 
examined the ability of macrophages with enhanced miR-125b expression to present 
antigens and found that they better stimulate T cell activation than control macrophages. 
Further indicating increased function, these macrophages were more effective at killing 
EL4 tumor cells in vitro and in vivo. Moreover, miR-125b repressed IRF4 and IRF4 
knockdown in macrophages mimicked the miR-125b overexpression phenotype. In 
summary, our evidence suggests that miR-125b is at least partly responsible for 
generating the activated nature of macrophages, at least partially by reducing IRF4 
levels, and potentiates the functional role of macrophages in inducing immune 
responses. 
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Introduction 
 The mammalian innate immune system provides a critical first line of defense 
against pathogens. Macrophages are key components of this system, acting to release 
cytokines, kill pathogens directly and present antigens to the adaptive immune system. 
The macrophage surface contains sensing proteins, like Toll-like receptors and the 
interferon gamma receptor that, when engaged, lead to a rapid differentiation event 
termed “activation”, where the cell transforms from relative quiescence to an effector 
state characterized by far-heightened microbicidal ability. Macrophages also carry co-
stimulatory proteins such as CD80 and CD86 for interacting with T cells, thus bridging 
innate immunity to adaptive immunity 1,2. 
Recently microRNAs have been shown to be important mediators of the 
macrophage activation process. MicroRNAs-155, 146, 147, 9 and 21 are induced by 
ligands of the Toll-like receptors (TLRs) 3,4. These microRNAs, in turn, inhibit expression 
of protein in the inflammatory signaling cascade, thus modulating immunity through 
feedback regulation 3,4. MiR-125b, a homologue of the C. elegans microRNA lin-4, has 
been shown to be decreased in macrophages in response to TLR4 signaling 5-7.  
We and others found that miR-125b is enriched in hematopoietic stem cells and 
that increased miR-125b enhances hematopoietic engraftment 8,9. Further increased 
levels of miR-125b cause an aggressive myeloproliferative disorder that leads to 
leukemia 8. Here we examine the role miR-125b plays in regulating macrophage 
activation. We find that macrophages express a particularly high concentration of miR-
125b. When miR-125b is overexpressed in macrophages, it enhances surface activation 
markers both basally and in response to interferon gamma. By contrast, treatment of 
RAW264.7 macrophages with anti-miR-125b causes them to express decreased surface 
CD80 both basally and in response to interferon gamma. We demonstrate that 
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macrophages expressing increased miR-125b become more potent stimulators of 
immune responses as shown by increased antigen-specific T cell activation and anti-
tumor immunity. Lastly, we find that IRF4 is an important target of miR-125b in 
macrophages and that IRF4 knockdown mimics the miR-125b overexpression 
phenotype.  
 
Materials and Methods 
Cell culture. 293T cells, RAW264.7 cells and BMMs were cultured at 37°C with 5% CO2 
in DMEM supplemented with 10% FBS, 100 units/ml penicillin and 100 units/ml 
streptomycin. For IFNγ treatment, cells were treated overnight with 200 units/ml of 
recombinant mouse IFNγ (eBioscience). 
Mice. C57Bl/6 and OTI Ovalbumin TCR-transgenic Balb/c mice were bred in the Caltech 
Office of Laboratory Animal Resources (OLAR) facility or purchased from Jackson 
Laboratories. The Caltech Institutional Animal Care and Use Committee (IACUC) 
approved all mouse experimental protocols.  
Isolation of immune cells and tissues. T cells and B cells were purified from the 
spleens of C57Bl/6 mice using magnetic beads (Miltenyi). Peritoneal macrophages were 
isolated four days after injecting mice with 3% Thyoglycollate.  
DNA constructs. The MG, MGP, MG-125b-1 and MGP-125b-1 vector systems have 
been described previously 10-12. The human miR-125b-1 sequence was also cloned into 
the pcDNA3 vector downstream of the CMV promoter. The IRF4 shRNA sequence was 
predicted and cloned into MGP as described previously 11,13. NC1 is a negative control 
shRNA sequence predicted not to target any protein coding genes in the mouse genome 
(Invitrogen). For reporter assays, pMIR-REPORT vector (Ambion) containing Picalm and 
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Cutl1 3’UTRs were constructed previously 10. A 3 kb region of the human IRF4 3’UTR, 
which includes the miR-125b putative binding site, was cloned into pMIR-REPORT 
downstream of luciferase. A positive control 2-mer containing two tandem sites 
complementary to miR-125b was also cloned. Primer sequences are listed in Table S1. 
Retrovirally transduced bone marrow derived macrophages. To generate retrovirus 
for infecting bone marrow, 293T cells were transfected with pCL-Eco and MG, MGP, 
MG-125b-1 or MGP-125b-1 vectors. After 36 h, 10 ug/ml polybrene (Millipore) was 
added to retrovirus-containing culture supernatant, which was used to spin-infect bone 
marrow from C57Bl/6 mice. Cells were counted and 1 million were plated per well in a 6 
well plate with 10 ng/ml M-CSF (eBioscience), and differentiated for 6 days to yield 
retrovirally transduced BMMs 12. 
Stable cell lines. RAW264.7 cells were stably transduced with VSV-G-pseudotyped 
MGP or MGP-125b-1 retrovirus and puromycin selection was subsequently performed 
as described previously 11. 
Electroporation of anti-miRs. RAW264.7 cells were co-electroporated with anti-miR-
125b or a mismatched control (Regulus Therapeutics) and pmaxGFP vector (Lonza) 
using an Amaxa Nucleofector. 36 hours post-electroporation, GFP positive cells were 
analyzed by FACS. Anti-miR-125b or mismatched control compound were chimeric 2′-
fluoro/2′-O-methoxyethyl-modified oligonucleotides with a completely modified 
phosphorothioate backbone 14 (Regulus Therapeutics). The exact chemistry is available 
on request.  
T-cell macrophage co-culture. 50,000 BMMs stably expressing either MG or MG-
125b-1 were co-cultured with 150,000 T cells harvested from OTI Ova TCR-transgenic 
Balb/c mouse in a 48 well flat-bottom plate in the absence or presence of ovalbumin 
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protein. Flow cytometry and ELISAs to assess T cell activation were performed 72 hours 
later. ELISAs were performed with an IL-2 detection kit from eBioscience and carried out 
according to the manufacturer’s instructions. 
EL4 tumor cell experiments. 500,000 BMMs stably expressing either MG or MG-125b-
1 were generated as described above in 6 well plates. One million EL4-Fluc cells were 
added to each well, supplemented with 20 ng/ml LPS. EL4-Fluc apoptosis was 
measured 94 hours later by staining cells in suspension with AnnexinV antibody (BD 
Pharmingen). For the in vivo experiments, 2 million EL4-Fluc cells were co-injected 
with 400,000 BMMs subcutaneously into albino C57Bl/6 mice. Mice were closely 
monitored over the next 12 days. Tumor luminescence was measured using a Xenogen 
imager. At the experimental endpoint, animals were euthanized and tumors were 
removed and weighed. Tumor surface area was assessed using a caliper— tumor length 
and width were measured in cm, and the product was taken to determine surface area. 
Sequence alignment. The miR-125b seed region and IRF4 3’UTR sequences from 
human (Homo sapien), mouse (Mus musculus), cat (Felis catus) and armadillo (Dasypus 
novemcinctus) were obtained and aligned using Targetscan 15-17. 
Luciferase reporter assay. 293T cells were co-transfected with pcDNA-125b, β-gal 
expression vector, and the pMIR-REPORT vectors containing 3’UTRs of Cutl1, Picalm, 
IRF4 or 2-mer. The luciferase activity was quantified 48 hours later and normalized to β-
gal activity as previously described 11,13.  
RNA preparation and quantification. RNA was isolated using TRIzol (Invitrogen), 
RNEasy (Qiagen) or miRNEasy (Qiagen) as per manufacturer’s instructions. 
Quantitative real-type PCR (qPCR) was conducted using a 7300 Real-time PCR 
machine (Applied Biosystems) or a Realplex Real-time PCR machine (Eppendorf). 
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SYBR green was used to assay IRF4 and L32 expression. PCR with previously 
published primer sequences for mouse pri-miR-125b-1 and pri-miR-125b-2 were used to 
assay levels of miR-125b primary transcripts 18. Taqman-based qPCR was conducted to 
assay miR-125b, miR-125a and snoRNA-202 (Applied Biosystems). Primer sequences 
are listed in Table S1. 
Flow cytometry. Cells were stained with the following fluorophore-conjugated 
antibodies: CD80, CD86, CD40 (Biolegend); MHC II (eBioscience); AnnexinV (BD 
Pharmingen). Cell surface receptors were measured using a FACSCalibur (Becton 
Dickinson) and all data was analyzed with FloJo (Treestar). Data was gated on GFP 
positive events when retrovirally transduced cells were analyzed. 
 
Results 
MiR-125b expression is enriched in macrophages 
 To investigate the expression of miR-125b in different immune cells and tissues, 
we harvested RNA from total splenocytes, thymocytes, splenic T cells, splenic B cells, 
and peritoneal macrophages from C57Bl/6 mice. Levels of miR-125b were assessed by 
reverse transcription followed by quantitative PCR. The expression of miR-125b was 
much higher in macrophages compared to the other immune cells and tissues (Fig. 1A). 
Within macrophages, miR-125b levels were also significantly higher than its homologue, 
miR-125a, indicating that miR-125b is the dominant isoform in these cells (Fig. S1). Also, 
miR-125b is expressed from two loci in the mouse genome, each encoding a different 
primary transcript. We performed RT-PCR for each of these primary transcripts and 
determined that macrophages express primarily miR-125b-1 (Fig. 1B). Because miR-
125b-1 is enriched in macrophages, we set out to determine the functional role of miR-
125b-1 (referred from here on as miR-125b) in these cells. 
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Enforced expression of miR-125b enhances macrophage activation status  
 To examine the response of macrophages to miR-125b, we utilized a miR-125b 
overexpression system based on the MG vector (MG-miR-125b), which was originally 
derived from the murine stem cell virus 10 (Fig. 2A). Bone marrow cells isolated from 
C57Bl/6 mice were spin-infected with either MG-miR-125b or MG control vector. These 
cells were then differentiated into bone marrow derived macrophages (BMMs) by 
treatment with macrophage-colony stimulating factor (M-CSF). Using this system, miR-
125b was overexpressed 15-fold above endogenous levels in BMMs (Fig. 2B). 
Interestingly, miR-125b overexpressing BMMs acquired a spread morphology with 
extensive pseudopods that resembled activated macrophages (Fig. 2C). We performed 
flow cytometric analyses and observed increased expression of MHCII and the co-
stimulatory molecules CD40, CD86 and CD80 in these macrophages, indicating that 
these cells were indeed more activated (Fig. 2D). Ectopic expression of miR-125b in 
RAW264.7 macrophages gave similar results (Fig. S2 A), further emphasizing that this 
microRNA promotes activation of macrophages. 
 
MiR-125b increases macrophage response to interferon gamma 
 Next, we assessed the effect of miR-125b on the responsiveness of 
macrophages by stimulating these cells with interferon gamma (IFNγ). IFNγ treatment 
increased the expression of MHCII, CD40, CD86, and CD80 activation markers in 
control macrophages (Fig. 3A) while miR-125b overexpressing macrophages expressed 
significantly higher levels of these markers (Fig. 3A). Similar results were obtained in 
RAW264.7 macrophages with enforced miR-125b expression (Fig. S2 A).  
 To examine whether reducing the concentration of miR-125b had an effect 
inverse to that of overexpression, RAW264.7 macrophages were treated with synthetic 
antisense oligonucleotides (anti-miRs) and surface CD80 levels were monitored as an 
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indication of the activation status of the cells. Anti-miR125b did cause a reduction of both 
basal and IFNγ-induced levels of CD80 compared to cells treated with a control anti-miR 
(Fig3 B). Thus, miR-125b appears to control CD80 expression in macrophages under 
normal, physiological conditions. 
A likely reason for the heightened response to IFNγ in miR-125b-treated cells 
could be an increased expression of the interferon gamma receptor (IFNγR). Indeed, 
miR-125b overexpressing BMMs (Fig. 3C) and RAW264.7 macrophages (Fig. S2 B) had 
significantly higher levels of the receptor. Thus, in addition to potentiating macrophage 
activation, miR-125b promotes enhanced macrophage responsiveness to IFNγ and 
increases surface expression of its cognate receptor. 
 
MiR-125b enhances macrophage-mediated function  
 Because we found that miR-125b drove macrophages to adopt an elevated 
activation status and become more responsive to stimulatory cues, we examined 
whether miR-125b would also potentiate macrophage-mediated immune function. To 
this end, we investigated whether miR-125b would increase the ability of macrophages 
to present antigens and induce activation of T cells. MiR-125b overexpressing 
macrophages were co-cultured with transgenic T cells that express a chicken ovalbumin-
specific T cell receptor (OT1) in the presence of ovalbumin. Indeed, compared to control 
macrophages, miR-125b overexpressing cells were more effective at inducing T cell 
activation, which was indicated by increased CD25 expression and IL-2 secretion by the 
T cells in response to ovalbumin (Fig. 4A). Thus, enforced expression of miR-125b led to 
an elevated ability of macrophages to act as effective antigen presenting cells for 
stimulation of T cell responses. 
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 In addition to serving as antigen presenting cells, another major function of 
macrophages is to eliminate aberrant cells, such as tumor cells. We therefore assessed 
whether miR-125b-stimulated macrophages were more effective at killing tumor cells. 
We used the EL4-Fluc thymoma tumor line 19, which was engineered to express 
luciferase, and co-cultured these cells with either control macrophages or macrophages 
overexpressing miR-125b. Consistent with augmented function, miR-125b expressing 
macrophages were better at inducing apoptosis of EL4-Fluc cells (Fig. 4B). 
Macrophages exposed to LPS gained the ability to induce apoptosis of EL4-Fluc cells, 
with miR-125b-overexpressing macrophages having superior effectiveness (Fig. 4B). To 
test whether miR-125b levels in macrophages affect tumor killing in vivo, we 
subcutaneously co-injected into mice equal numbers of LPS-activated control or miR-
125b overexpressing macrophages with EL4-Fluc cells and tracked growth of the 
resulting tumor by measuring tumor surface area over time. Since EL4-Fluc cells were 
engineered to express luciferase, we also monitored tumor growth by measuring 
luminescence in vivo. Consistent with our in vitro data, macrophages with miR-125b 
ectopic expression suppressed the ability of EL4 cells to expand in vivo (Fig. 4C). At the 
endpoint of the experiment on day 12, animals injected with MG-125b macrophages had 
smaller EL4-derived tumors that were significantly less luminescent than those injected 
with control macrophages (Fig. 4 D-E). Thus, miR-125b expression in macrophages 
appears to aid them in preventing the expansion of tumorigenic cells, further 
demonstrating that miR-125b enhances macrophage function. 
 
IRF4 is a miR-125b target in macrophages  
 To identify targets regulated by miR-125b that modulate macrophage activation, 
we used TargetScan 5.1 to identify transcripts in the mouse genome that contain 
conserved putative miR-125b binding sites in their 3’ untranslated regions (UTRs). 
 
149 
Among these genes, the 3’UTR of IRF4 harbored a conserved miR-125b binding site 
(Fig. 5A) and has been previously validated as a miR-125b target in B cell lines 20-23. We 
found that miR-125b indeed represses via the 3’UTR of IRF4 (Fig. 5B) and that miR-
125b inhibits IRF4 expression in macrophages (Fig. 5C). Next, using the MGP retroviral 
vector system 11, we knocked down the expression of IRF4 using RNAi (Fig. 5D) and 
examined the effect in macrophages. MGP-125b led to a six-fold increase in miR-125b 
in BMMs. Similar to miR-125b overexpression, decreased IRF4 expression resulted in 
increased surface expression of MHCII, CD40, CD86, CD80 and IFNγR (Fig 5E). Thus 
IRF4 knockdown in macrophages enhances activation, mimicking the miR-125b 
overexpression phenotype. This data is consistent with previous reports demonstrating 
that IRF4 is a negative regulator of macrophage pro-inflammatory pathways21,24. 
Collectively, our data suggests that IRF4 is a primary target of miR-125b in regulating 
macrophage activation. 
 
Discussion 
 In this study, we demonstrate that miR-125b is enriched in macrophages and that 
further elevation of miR-125b promotes greater activation, IFNγ response, and immune 
function in these cells. We also performed loss-of-function studies using synthetic 
antisense oligonucleotides designed to inhibit miR-125b, and found that this anti-miR-
125b compound effectively decreased CD80 levels, supporting a physiological role for 
miR-125b in macrophage activation. Other groups have reported that miR-125b levels 
decrease in macrophages 3 hours post-inflammatory stimulation 5,7. Thus, decreasing 
miR-125b may serve as a natural mechanism to limit the inflammatory response. In our 
studies, miR-125b overexpression also promoted the ability of macrophages to present 
antigen and induce T cell activation, demonstrating that miR-125b can enhance the 
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macrophage’s role in mediating adaptive immunity. The increase in activated T cells 
would in theory result in more secretion of IFNγ, which in turn would further magnify the 
activation status of miR-125b-expressing macrophages. In this way, by affecting 
macrophage function alone, miR-125b could amplify both innate and adaptive immune 
responses by orchestrating positive feedback loops between macrophages and T cells. 
In B cells, miR-125b inhibits differentiation of germinal center B cells into plasma 
cells, and does so via repression of the transcription factors IRF4 and BLIMP1 23,25. 
IRF4, a member of the Interferon Response Factor family of transcription factors, also 
has important functions in macrophages where it acts as an inhibitor of the inflammatory 
response 21,24. We demonstrate here that IRF4 is a target of miR-125b and that IRF4 
knockdown mimics the miR-125b mediated activation phenotype in macrophages.  
MiR-125b is upregulated in certain leukemias and downregulated in many non-
hematopoietic solid cancers 12,26-36. We have shown here that increased miR-125b 
expression in tumor macrophages slows tumor growth. Our data suggests that 
supplementing tumor macrophages with miR-125b may be a useful strategy for treating 
certain cancers. 
 
Figure Legends 
Figure 1. MiR-125b expression is enriched in macrophages. A) Relative expression 
of miR-125b in immune tissues and cells assessed by quantitative PCR. Data represents 
the mean with SEM of 3 biological replicates per group. B) Expression of the miR-125b 
primary transcripts, pri-125b-1 and pri-125b-2, in bone marrow derived macrophages 
(BMMs). Data is representative of two independent experiments. 
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Figure 2. MiR-125b enhances basal macrophage activation. A) Retroviral vector 
design for overexpression of miR-125b-1. B) Relative expression of miR-125b in BMMs 
after transduction with MG or MG-miR-125b expressing vector. C) Morphology of control 
MG or miR-125b overexpressing BMMs. Data represent five independent experiments. 
D) Geometric mean fluorescence (GMF) of MHCII, CD40, CD86 and CD80 are shown. 
Representative plots obtained from flow cytrometric analyses are also shown for each 
marker. Data is the mean with SEM of 3-5 samples per group and is representative of 
two independent experiments.  
 
Figure 3. MiR-125b increases macrophage response to IFNγ . A) Surface expression 
of MHCII, CD40, CD86, and CD80 in response to media alone or IFNγ. A representative 
flow cytometric plot of the IFNγ-treated samples is shown for each factor. B) Raw264.7 
macrophages electroporated with control (NC) or anti-miR-125b were subjected to flow 
cytometry for the surface expression of CD80. A representative FACS plot of the media-
treated samples shown. C) Surface expression of IFNγR in control (MG) versus miR-
125b overexpressing macrophages. A representative FACS plot is shown. All data 
shown represents the mean expressed with SEM of three samples per group and is 
representative of two independent experiments. 
 
Figure 4. MiR-125b enhances macrophage function. A) BMMs expressing the vectors 
MG or MG-125b were co-cultured with ovalbumin-specific OT1 T cells with or without 
ovalbumin for 72 hours. The percent CD8+CD25+ T cells are shown in the left panel. 
Concentration of IL-2 (pg/ml) produced by the T cells in the supernatant is shown in the 
right panel. Data represents the mean with SEM of 3 biological replicates per group. B) 
The percent AnnexinV+ EL4-Fluc cells after 94 hours of co-culture with control or miR-
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125 overexpressing macrophages in the presence of media alone or lipopolysaccharide 
(LPS). A representative flow cytometric plot of the LPS-treated group is shown. Data is 
expressed in mean with SEM of 1-3 experimental samples per group. C-E) EL4-Fluc 
cells were subcutaneously co-injected with LPS-activated control or miR-125b 
overexpressing macrophages into albino C57Bl/6 mice. Tumor surface area in cm2 was 
monitored from day 9-12 (C). The relative intensity of luminescence (D) and weight (E) 
of the EL4 tumors were measured on day 12. Data represents the mean plotted with 
SEM of eight mice per group. Representative of two independent experiments. 
 
Figure 5. IRF4 is a target of miR-125b in macrophages. A) IRF4 contains a 
conserved miR-125b target site. B) Luciferase reporters carrying the 3’UTR of IRF4, 
Picalm (negative control), Cutl1 (negative control) or 2-mer (positive control) were co-
transfected into 293T cells with β-gal reporter and +/- miR-125b. The relative luciferase 
activity of each reporter in the presence of miR-125b is shown relative to the no 
microRNA control. C) RAW264.7 macrophages were transduced with either a control 
(MGP) or miR-125b expressing vector, or with D) control (NC1) or IRF4 shRNA 
expressing vector. RNA was harvested and L32-normalized IRF4 levels were 
determined by qPCR. E) BMMs expressing MGP, MGP-125b, or shRNA against IRF4 
were measured for surface expression of the activation markers MHCII, CD40, CD86, 
CD80 and IFNγR. Geometric Mean Fluorescence (GMF) measured by flow cytometry is 
shown. All data represents the mean with SEM of 3 samples per group and is 
representative of two independent experiments. 
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Figures 
 
 
 
Figure 1.  MiR-125b expression is enriched in macrophages 
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Figure 2.  MiR-125b enhances basal macrophage activation 
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Figure 3.  MiR-125b increases macrophage response to IFNγ  
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Figure 4.  MiR-125b enhances macrophage function 
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Figure 5.  IRF4 is a target of miR-125b in macrophages 
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Supplemental Figures 
 
Figure S1.  MiR-125b is expressed higher than miR-125a in macrophages. Relative 
expression of miR-125b and miR-125a in peritoneal macrophages. Data represents the 
mean and SEM of three biological replicates. 
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Figure S2.  MiR-125b enhances basal and IFNγ  mediated activation of RAW264.7 
macrophages. A) Surface expression of the activation markers MHCII, CD86 and CD80 
in media and IFNγ-treated samples. B) Surface expression of IFNγR in MGP control or 
miR-125b overexpressing RAW264.7 macrophages. All data shown is the mean with 
SEM of three samples per group, and is representative of two independent experiments. 
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Supplemental Table 
 
Table S1.  Primer Sequences 
    Primer         Sequence 
 
 
 
 
 
 
 
IRF4 shRNA oligo GAAGGCTGTATGCTGAAACAATGCCCAAGCCTTGAAGTT
TTGGCCACTGACTGACTTCAAGGCGGGCATTGTTTCAGG
ACACAAGGCCTG 
IRF4 3’ UTR NotI Fw TTCGCGGCCGCGAGTTTTCTCTGATGTACTCGTGATCGT
ATGT 
IRF4 3’ UTR XhoI 
Rev 
TTCCTCGAGAACAGAAATCCAGGAGCTGCCACTC 
2-mer SpeI Fw CTAGTTCACAAGTTAGGGTCTCAGGGATCACAAGTTAGG
GTCTCAGGGAA 
2-mer HindIII Rev AGCTTTCCCTGAGACCCTAACTTGTGATCCCTGAGACCC
TAACTTGTGAA 
IRF4 qPCR Fw TCCGACAGTGGTTGATCGAC 
IRF4 qPCR Rev CCTCACGATTGTAGTCCTGCTT 
L32 qPCR Fw AAGCGAAACTGGCGGAAAC 
L32 qPCR Rev TAACCGATGTTGGGCATCAG 
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Chapter 6: MicroRNA-125b targets Lin28 
and physiologically and pathologically 
regulates hematopoiesis 
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Abstract 
MicroRNA-125b (miR-125b) is upregulated in patients with leukemia. We show here that 
overexpression of miR-125b alone in mice is sufficient to promote a highly aggressive 
myeloid leukemia characterized by tumor cell infiltration into peripheral organs, including 
the brain, lungs, kidneys and liver. Prior to leukemia, mice with miR-125b 
overexpression have normal white blood cell counts but the hematopoietic compartment 
is rearranged such that myeloid cell numbers are dramatically increased at the expense 
of B cells. We reveal that miR-125b exerts this effect by upregulating the number of 
common myeloid progenitors while inhibiting the development of pro-B cells. Next we 
applied a miR-125b ‘sponge’ decoy loss-of-function approach to uncouple the role of 
miR-125b in tumorigenesis from its potential physiological function in hematopoiesis; 
indeed, we found that miR-125b physiologically regulates hematopoietic development. 
To investigate the mechanism by which miR-125b regulates hematopoiesis, we 
examined and found that the inducible pluoripotent stem cell (IPS) regulator Lin28 was 
the most repressed by miR-125b in mouse bone marrow cells among a panel of 
computationally derived candidate targets. Of importance, overexpression of Lin28 in the 
mouse hematopoietic system mimicked the phenotype observed upon inhibiting miR-
125b function, leading to a decrease in hematopoietic development. Relevant to the 
miR-125b overexpression pre-cancer phenotype, we revealed that knockdown of Lin28 
also led to a hematopoietic rearrangement with increased myeloid and decreased B cell 
numbers. Thus, Lin28 is an important regulator of hematopoiesis, and is a primary target 
of miR-125b in the hematopoietic system. 
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Introduction 
MicroRNAs are a class of ~ 22 nucleotide RNA species that follow a canonical 
processing pathway generated by sequential cleavage of endogenous PolII-generated 
transcripts by Drosha and Dicer1,2. The first microRNA, lin-4, was discovered in C. 
elegans and was shown to regulate the transition from early larval L1 to later L4 stages 
by repressing its target genes, the transcription factor Lin-14 and the RNA-binding 
protein Lin-283-7. Indeed, as lin-4 levels increase between larval stages L1 and L3, levels 
of its target genes Lin-14 and Lin-28 decrease3. Lin28 itself represses biogenesis of 
another microRNA, let-78-11, a microRNA necessary for late-stage larval 
development12,13. Thus, the lin-4:Lin-28:let7 cascade was shown to be critical for proper 
worm development. This signaling cascade is conserved in vertebrates as the 
mammalian homologue of lin-4, miR-125b, is also able to repress Lin-28. Previously, 
ectopic expression of miR-125b was shown to repress Lin28 expression in the mouse 
P19 embryonic carcinoma cell line14. MiR-125b was also shown to mediate repression 
via specific target sites in the Lin28 3’ untranslated region (UTR)14. This highlights a 
potential critical developmental function of miR-125b:Lin-28 signaling in mammalian 
systems, which has yet to be explored. 
In humans, miR-125b is enriched in hematopoietic stem cells15,16 and is 
upregulated in a range of human leukemias, including acute myeloid leukemia 
(AML)17,18, chronic myeloid leukemia (CML)18, acute megakaryocytic leukemia (AMKL)19, 
childhood acute lymphoblastic leukemia (ALL) with the ETV6/Runx1 fusion protein20, and 
Philadelphia-chromosome positive B-cell precursor ALL18. Indeed, overexpression of 
miR-125b alone in the bone marrow of mice is sufficient to induce leukemia16,18,21, 
showing that constitutive miR-125b upregulation can initiate and subsequently lead to 
cancer. Recent in vitro work has also demonstrated the role of miR-125b in the 
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development of plasma cells22 and effector T cells23, showing that miR-125b regulates 
development of immune cells as well.  
Also demonstrating relevance in mammalian development, Lin-28 has been 
shown to be important for early embryogenesis in mice and humans24. The levels of Lin-
28 are enriched in embryonic stem (ES) cells and decrease as these cells differentiate24.  
Indeed, ectopic expression of Lin-28 along with three other genes (Oct4, Sox2 and 
Nanog) causes de-differentiation of mature human cells into induced pluripotent stem 
(IPS) cells25. This demonstrates the power of Lin28 to endow cells with pluripotent 
qualities. Still, it remains to be seen whether Lin28 also plays developmental roles in 
biological systems arising from adult stem cells, such as hematopoiesis. Given the 
importance of miR-125b in leukemic development and hematopoiesis, it will be 
interesting to investigate whether Lin28 has overlapping functions with miR-125b in 
these events.  
 In this study we seek to better understand how miR-125b and Lin-28 regulate 
hematopoietic development. We began by characterizing that the cancer caused by 
miR-125b overexpression is a highly aggressive myeloid leukemia, which is further 
demonstrated by infiltration of myeloid cells into non-hematopoietic organs including the 
lungs, kidneys and brain. To investigate the cellular changes that lead to leukemia, we 
next examined the impact miR-125b has on the hematopoietic system prior to disease 
onset. We found that miR-125b overexpression dramatically enhances common myeloid 
progenitors (CMPs) and downstream mature myeloid cells. Interestingly, whereas 
common lymphoid progenitors (CLPs) were also modestly increased, downstream pro-B 
and pre-B cells were much lower in the miR-125b overexpressing animals, suggesting 
that miR-125b blocks the transition from CLPs to pro-B cells. In order to determine a 
physiological role for miR-125b in hematopoiesis, we showed through loss-of-function 
that miR-125b decreases output of all examined hematopoietic lineages, thus 
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establishing that miR-125b is necessary for proper hematopoietic output. Finally we 
demonstrate that Lin28 is a primary target of miR-125b in the hematopoietic system. We 
show that Lin28 is efficiently repressed by miR-125b in both mouse and human 
hematopoietic cells. We show that Lin28 knockdown and overexpression mimic miR-
125b gain- and loss-of-function, respectively. Thus, lin-28 is a powerful regulator of 
hematopoiesis. In summary, we show here that miR-125b physiologically and 
pathologically regulates hematopoiesis, and that Lin28 is a primary target gene of miR-
125b in the hematopoietic system. 
 
Experimental Results 
MiR-125b causes an aggressive and highly metastatic myeloid leukemia  
 We and others previously showed that overexpression of miR-125b in bone 
marrow transplanted recipient mice causes leukemia 4-6 months after bone marrow 
reconstitution16,21. Here we interrogated the precise types of cells that were neoplastic in 
the disease and investigated the aggressive nature of the disease. We began by 
performing bone marrow reconstitution experiments into lethally irradiated recipient mice 
with donor hematopoietic stem cell (HSC)-enriched bone marrow that were infected with 
retroviruses harboring the MG control or miR-125b-1 overexpressing vector (MG-
125b)16. These vectors also express green fluorescent protein (GFP)16,26, which provided 
the advantage of tracking cells that ectopically express miR-125b in the recipient 
animals (Fig S1A). Of note, these bone marrow reconstitution experiments allowed the 
study of miR-125b function specifically in the hematopoietic compartment, uncoupling it 
from its potential function in other tissues. In these experiments, the transduction 
efficiency of HSC-enriched bone marrow cells with retro-vectors at the time of 
transplantation into recipients was 40% and 25% GFP+ in MG and MG-125b animals 
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(Fig S1B), respectively. The level of miR-125b overexpression in MG-125b transduced 
bone marrow was 25-fold over MG control (Fig S1C). Five months post-reconstitution, 
consistent with previous reports16,21, MG-125b animals had severely enlarged spleens 
compared to control animals (596 mg compared to 85 mg) (Fig S1D-E) and the white 
blood cell count was four-fold increased (Fig S2A). When we performed flow cytometry 
on these spleens, we observed a dramatic increase in the percent of GFP+ myeloid 
cells, but a decrease in percent GFP+ lymphoid cells, indicating that miR-125b leads to a 
myeloid type of leukemia (Figure S2B). 
In our previous study, we suggested that miR-125b overexpressing mice get a 
myeloid-type of leukemia16. Here we confirmed this finding by showing that miR-125b 
overexpressing mice develop a 33-fold increase in myeloid white blood cells (CD11b+ 
CD45+) in the blood at 4.5 months post-reconstitution (Fig 1A), a time point at which the 
mice appear moribund and some had already died (Fig S3A). Further confirming that the 
leukemia was myeloid, we examined B and T cell numbers and observed those to be 
decreased or only modestly elevated, respectively (Fig S3B-C). Of note, a second cohort 
of ten animals (Fig S4A) delivered similar results with two notable exceptions. At five 
months post-reconstitution (Fig S4B), the seven surviving animals strongly upregulated 
myeloid-type leukocytes (32-fold increase) in their blood (Fig S4C), but one animal also 
showed an 8-fold increase of B cells (Fig S4D) and a second showed a 29-fold increase 
in T cells (Fig S4E). Blood from the other three animals was also measured within two 
weeks of their deaths, and revealed dramatic upregulation of myeloid but not lymphoid 
cells (Data not shown). Still this confirms previous studies that miR-125b is capable of 
producing lymphoid tumor cells18,21 too, although the majority of our animals (86%) 
exhibited myeloid-only types of leukemia.  
In order to probe further into the nature of the miR-125b-driven myeloid leukemia, 
we examined whether neoplastic myeloid cells infiltrate non-hematopoietic organs. The 
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blood-brain barrier normally prevents infiltration of white blood cells into the brain, an 
organ thus referred to as “immunoprivileged”. In miR-125b overexpressing mice, 
however, flow cytometry revealed dramatic infiltration of CD45+ GFP+ white blood cells 
and CD11b+ GFP+ myeloid cells into the brain 5 months post-reconstitution (Fig 1B). The 
kidneys of MG-125b mice were also heavily infiltrated with myeloid leukemic cells as 
indicated by histopathology (Fig 1B) and flow cytometry (Fig S5A). They were 
morphologically larger and pale colored compared to control animals (Fig S5B). Myeloid 
leukemic cells also infiltrated the lungs and livers of miR-125b cancer mice as evidenced 
by histopathology, FACS and gross pathology (Fig 1B, Fig S5C-F). Further indicative of 
miR-125b infiltrating cells in the lung, kidneys and liver, we observed 18-74 fold increase 
of miR-125b levels in these tissues compared to control animals (Fig S6A-C). Displaying 
increased survival, splenocytes taken from miR-125b overexpressing animals, when 
cultured for 204 hours, displayed decreased apoptosis compared to MG controls (Fig 
S7A-B). Interestingly, mice overexpressing miR-125a also developed an aggressive 
leukemia and died by six months post-reconstitution (Fig S8), indicating that the 
capability to cause leukemia is conserved between miR-125 homologues. In summary, 
miR-125b leads to an aggressive myeloid leukemia that efficiently metastasizes into 
non-hematopoietic organs including the brain. 
 
MiR-125b ectopic expression rearranges the hematopoietic system prior to cancer 
onset 
 In order to understand the initial events that lead to miR-125b mediated leukemia 
that occurs 5 months post-reconstitution, we examined the spleen and bone marrow at 
seven weeks post-reconstitution, a time point that falls well before the onset of cancer as 
indicated by similar white blood cell counts in the spleen and bone marrow of MG and 
MG-125b animals (Fig 2A, Fig S10A-B). At this time point, MG-125b animals showed a 
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dramatic increase in all myeloid lineages including granulocytes, macrophages and 
dendritic cells, with T cell numbers being similar between MG and MG-125b animals 
(Figure 2A, Fig S10C-E). However, there was a dramatic decrease in B cell and 
plasmablast numbers (Fig 2A, Fig S10F). Importantly and consistently with decreased B 
and plasmablast cell development, MG-125b animals were severely impaired in the 
ability to produce anti-ovalbumin IgG antibody (Fig 2A). Thus, miR-125b overexpression 
at the pre-cancerous stage causes a rearrangement of the hematopoietic compartment 
that favors myeloid cell development at the expense of B cells and consequently impairs 
humoral immunity. 
 Next, we analyzed hematopoietic stem and progenitor cell numbers in the bone 
marrow at the 7 week time point following bone marrow transplantation. We observed 
that hematopoietic stem cell numbers were similar between MG and MG-125b animals 
(Fig 2C, Figure S11), showing that miR-125b overexpression does not increase HSC 
numbers early in the disease course. Progenitors directly downstream of HSCs, 
however, including multipotent progenitors (MPPs), common myeloid progenitors and 
granulocyte macrophage progenitors (CMP/GMPs), myeloid-erythroid progenitors 
(MEPs) and common lymphoid progenitors (CLPs) were all significantly up (Fig 2B-C). 
Of these, CMP/GMPs were the most dramatically increased, being up nine-fold in MG-
125b animals compared to MG controls (Fig 2B). Notably, pro-B and pre-B cell numbers 
were severely decreased (Fig 2B), providing a developmental basis for the decreased B 
cell numbers we observed in MG-125b animals. This also demonstrates that miR-125b 
overexpression causes a developmental block between the CLP and Pro-B cell stages. 
In summary, we show here that miR-125b, even prior to the onset of leukemic disease, 
strongly enhances myeloid development at the expense of B cell development by 
regulating their precursor cells. 
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Physiological regulation of hematopoiesis by miR-125b 
 While overexpression studies are relevant in the context of understanding the 
role of miR-125b as an onco-miR capable of promoting hematopoietic cancer, we 
needed to develop a robust loss-of-function system to assess its potential physiological 
function in hematopoiesis. Thus we generated a “sponge” decoy system to competitively 
inhibit miR-125b binding to its natural targets (Fig 3A). We designed our sponge by 
placing four adjacent miR-125b antisense sites directly downstream of GFP in the MG 
vector (Fig 3A). Each site contained a region corresponding to nucleotides 9-12 of the 
microRNA that were mismatched. Expression in the MG vector system allowed us to 
monitor sponge-expressing cells by tracking GFP. 
 To test whether the sponge decoy is capable of de-repressing a miR-125b target 
sequence, we tested whether a reporter adjacent to an artificial 3’ UTR composed of two 
perfect miR-125b complementary sequences could be de-repressed by the sponge. We 
observed that co-expression of this 2-mer reporter with miR-125b and the sponge led to 
significant de-repression of the reporter compared to MG control in 293T cells (Fig 3B). 
An empty control reporter was not de-repressed by the sponge, demonstrating target 
specificity of our sponge decoy (Fig 3C). 
 In order to determine the hematopoietic effect of the miR-125b sponge, we 
sorted GFP+ cells from MG and sponge transduced bone marrow and reconstituted 
recipient animals with equal numbers of cells (Fig 4A). At 1 month post-reconstitution we 
analyzed the blood of recipient mice by FACS and observed significant decreases in 
numbers of total white blood cells (CD45+), myeloid cells (CD45+ CD11b+), granulocytes 
(CD45+ Gr1+), B cells (CD45+ CD19+ CD3e-), T cells (CD45+ CD3e+ CD19-) and pre-
erythrocytes (CD45+ Ter119+) (Fig 4B). The blood was also noticeably thinner in the 
sponge mice compared to controls, indicating that mature erythrocytes were decreased 
as well. Of note, the sponge mouse with the thinnest-appearing blood and lowest CD45+ 
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count died at four weeks post-reconstitution, likely due to impaired hematopoiesis, while 
all the controls survived. Together our data shows a physiological role for miR-125b in 
the development of all blood lineages. 
 
Lin28 is a primary target of miR-125b in the hematopoietic system 
Next, we strove to identify miR-125b targets that also regulate hematopoietic 
development. We performed a nonbiased screen using Targetscan27-29 to isolate putative 
miR-125b targets with PConserved Targeting > 0.8 (P < 0.2 that the putative microRNA site is 
maintained due to selective microRNA targeting rather than by chance29). Application of 
this screen yielded 192 genes. We focused on those that were pro-apoptotic or involved 
in the stem cell state, as these processes have been correlated with leukemic 
development. This yielded four genes, Bak1, Trp53inp1, BMF and Lin28, which 
independently have been previously validated as miR-125b targets by other 
groups14,18,30,31. To test whether miR-125b represses these genes in hematopoietic cells, 
we transduced hematopoietic progenitor-enriched bone marrow with MG-125b or MG 
control vectors and assessed levels of each of these genes by qPCR. Indeed, we saw 
efficient repression of all four targets, with Lin28 being most repressed by miR-125b (Fig 
5A). Upon miR-125b overexpression, Lin28 expression was reduced to 20% of the 
control. Validation by luciferase reporter paralleled the qPCR results—the 3’ UTRs of all 
the target genes were significantly repressed by miR-125b with that from Lin28 being the 
most repressed (Fig 5B). As a positive control we used an antisense 2-mer sequence 
complementary to miR-125b. However, a luciferase empty vector reporter or one 
harboring a non-target 3’ UTR (Picalm) was not repressed by miR-125b expression, 
demonstrating that miR-125b specifically represses Bak1, Trp53inp1, BMF and Lin28 
expression via their 3’ UTRs. Of note, Lin28 was also more de-repressed in miR-125b 
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loss-of-function progenitor-enriched bone marrow than the other measured targets (Fig 
5C). 
 Lin28 is known to be involved in maintaining pluripotency of embryonic stem cells 
but its role in hematopoiesis remains largely uninvestigated. To investigate the potential 
role of Lin28 in miR-125b-mediated hematopoiesis, we first investigated whether miR-
125b can physiologically regulate gene expression via the Lin28 3’ UTR. Lin28 contains 
one putative miR-125b site with a 9 nucleotide seed region complementary to the 
microRNA 5’ end and a significant amount of complementarity to the 3’ end as well (Fig 
5D). Co-transfecting the miR-125b sponge decoy compared to MG control with a 
luciferase reporter containing the mouse Lin28 3’ UTR led to five-fold de-repression (Fig 
5E). Demonstrating that the miR-125b-Lin28 interaction exhibits species conservation 
between mouse and human hematopoietic cells, human myeloid K562 cells transduced 
with either MGP, MGP-125b-1, MGP-125b-2 or a seed mutant of miR-125b exhibited 
seed-dependent repression of Lin28 by both miR-125b species at both the RNA and 
protein level (Fig 5F,G). Thus miR-125b represses Lin28 in hematopoietic cells, an 
interaction conserved between mouse and human.  
 
Lin28 regulates aspects of hematopoiesis that mirror those controlled by miR-
125b 
To determine whether miR-125b-mediated repression of Lin28 has a role in the 
hematopoietic system, we bypassed the repressive effect exerted by endogenous miR-
125b by overexpressing Lin28 lacking its 3’UTR. We utilized the MSCV-IRES-GFP 
(MIG) vector system32, which allowed the co-expression of Lin28 and GFP from the 
same vector. Western blot was performed to confirm expression of Lin28 from the MIG-
Lin28 vector in transfected 293T cells (Fig 6A). Next we performed bone marrow 
transplant experiments with progenitor-enriched bone marrow cells transduced with 
 
174 
either MIG or MIG-Lin28. We achieved over 80% transduction efficiency as measured by 
GFP-positive cells (Fig 6B). Similar to mice reconstituted with the miR-125b sponge 
decoy (Fig 4), animals with Lin28 overexpression had significant decreases in total white 
blood cells (CD45+), total myeloid cells (CD45+ CD11b+), granulocytes (CD45+ Gr1+), T 
cells (CD45+ CD3e+ CD19-), NK cells (CD45+ NK1.1+) and erythrocytes (Ter119+ CD11b-
) (Fig 6C). Also similar to the sponge mice, the blood was noticeably thinner in MIG-
Lin28 animals compared to MIG controls, likely due to decreased erythrocyte numbers. 
Of importance, the Lin28 overexpressing mice with the thinnest blood (2 out of 15) died 
at five weeks post-reconstitution whereas none of the controls died, likely a 
consequence of impaired hematopoietic development. Thus, overexpressing Lin28 in the 
hematopoietic system mirrored the phenotypes observed upon miR-125b inhibition (Fig 
4).  
 Next, we applied Lin28 loss-of-function studies to examine whether Lin28 
physiologically regulates hematopoiesis. Also, loss-of-function assays allowed us to 
determine whether inhibiting Lin28 function would mimic specific aspects of 
hematopoietic development observed upon overexpressing miR-125b. Thus we 
transduced progenitor-enriched bone marrow with Lin28 shRNA and achieved ~ 70% 
transduction with two-fold knockdown of Lin28 (Fig 7A,B), less than the level of 
repression exerted by miR-125b overexpression. Strikingly, mice reconstituted with 
shLin28 exhibited similar but less dramatic features in hematopoietic development as 
those that overexpressed miR-125b in the pre-cancerous stage; knockdown of Lin28 led 
to an expansion of myeloid cells (CD45+CD11b+, CD45+Gr1+) and decrease of B cells 
(CD19+CD11b-) (Fig 7C). Thus Lin28 knockdown mimicked rearrangement of the 
hematopoietic system that we saw early post-reconsitution in miR-125b overexpressers 
(Fig 7D), namely an increase in myeloid cells at the expense of B cells, suggesting that 
Lin28 knockdown by miR-125b plays a role in setting the stage for myeloid leukemia. We 
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did not, however, observe obvious signs of leukemia in the shLin28 mice after ten weeks 
following bone marrow transplantation, suggesting that repression of other targets such 
as the pro-apoptotic genes Bak1, Trp53inp1 and BMF, likely collaborate with Lin28 
during miR-125b mediated tumorigenesis. 
 
Discussion 
 In this study, we show that: 1) MiR-125b overexpression causes a highly 
aggressive myeloid leukemia capable of infiltrating non-hematopoietic organs, including 
the brain. 2) Early in the disease course at the pre-cancerous stage, miR-125b ectopic 
expression induces a rearrangement of the hematopoietic system favoring myeloid 
development at the expense of B cell development. 3) Before terminal leukemic 
development, miR-125b does not affect HSC numbers but drastically increases 
CMP/GMP numbers while blocking pro-B cell development. 4) In addition to the role of 
miR-125b in pathological disease, miR-125b also physiologically regulates 
hematopoiesis. 5) Lin28 is a primary target of miR-125b in hematopoietic cells. 6) Lin28 
overexpression and knockdown mimic important aspects of miR-125b loss-of-function 
and gain-of-function, respectively. We conclude that miR-125b physiologically regulates 
hematopoiesis, and constitutive overexpression of miR-125b leads to uncontrolled 
generation of myeloid progenitors that subsequently causes a myeloid leukemia. We 
also conclude that the miR-125b’s direct target Lin28 is an important regulator of 
hematopoietic development that may be targeted by miR-125b in the pathogenesis of 
myeloid leukemia. 
In our previous study, we observed that miR-125b overexpression induces 
leukemia16. In this study, we begin by further characterizing this phenotype and 
determined that 86% of the mice analyzed develop a highly aggressive form of myeloid 
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leukemia. Two mice out of the fourteen analyzed (14%) developed mixed myeloid-
lymphoid leukemias, confirming the studies by Bousquet et al., Ooi et al. and Enomoto et 
al. that miR-125b is also capable of causing leukemias involving lymphoid cell types. 
Interestingly, restricted overexpression of miR-125b in B lineage cells was shown to be 
capable of inducing lymphoid leukemia18, similar to the effect previously observed with 
miR-155 B lineage-specific overexpression33. Here, we show that upon overexpressing 
miR-125b in a mixed population of bone marrow progenitor cells, 86% of the 
transplanted mice exhibited myeloid-only leukemia characterized by a profound increase 
in the number of myeloid cells, which were capable of infiltrating into peripheral organs. 
Thus, it appears that miR-125b overexpression favors myeloid over lymphoid 
development in an environment where these different cell types may need to compete 
for survival. Potentially, miR-125b-overexpressing myeloid progenitors and mature 
myeloid cells have a greater capacity to proliferate and survive than miR-125b 
overexpressing lymphoid cells, giving these myeloid cells the capacity to outcompete 
their lymphoid neighbors. Still, Enomoto et al. confirms miR-125b’s potency as an onco-
miR, showing that B-cell restricted ectopic expression of miR-125b leads to lymphoid 
leukemia18. Of importance, miR-125b has been found to be overexpressed in a variety of 
human leukemias, including AML17,18, CML18, AMkL19, and ALL18,20, indicating that 
deregulated miR-125b expression in different contexts can lead to distinct cancer types. 
 In this study, we reveal that miR-125b overexpression does not induce an 
increase in HSC numbers after 7 weeks post-reconstitution, which is at the pre-leukemic 
stage. Interestingly, Ooi et al. showed that recipient mice reconstituted with miR-125b 
overexpression in purified HSCs resulted in elevated HSC numbers at later time points15. 
Guo et al. also showed that overexpressing the miR-125b homologue miR-125a 
increased HSC numbers after 4-5 months of reconstitution34. These mice were likely 
undergoing leukemic transformation, as suggested by the surface marker profile of their 
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HSCs being altered34. Indeed, we have shown here that constitutive overexpression of 
miR-125a causes leukemia and premature death, with the gross appearance of the 
disease being similar to miR-125b overexpression. Collectively, it appears that the 
impact of miR-125b and its homologues might have different influences on HSC 
numbers at varying stages of cancer development. Here we show that prior to the onset 
of proliferative disease, miR-125b overexpression does not affect HSC numbers but 
leads instead to a significant increase in early progenitors (MPP, CMP/GMP, MEP, 
CLP), with CMP/GMPs exhibiting the most profound magnitude of elevation. These 
findings have several important implications. First, it suggests that miR-125b likely does 
not initiate leukemic development by driving uncontrollable HSC proliferation, which is 
supported by our data that HSC numbers were not affected at the pre-cancerous stage. 
It is possible that miR-125b overexpression promotes HSC differentiation into 
downstream progenitors and mature cells, and through repression of its apoptotic target 
genes, gives these cells a survival advantage that eventually leads to cancer; indeed, 
the numbers of progenitors downstream of HSC were elevated. If HSC differentiation 
capacity alone was sufficient to drive leukemia, one might expect that miR-125b 
overexpressing mice would have similar frequency of myeloid and lymphoid leukemia. 
However, we found that the majority of these mice exhibited only myeloid leukemia. One 
possibility is that myeloid development is the default pathway for hematopoiesis since it 
has fewer negative checkpoints than lymphoid development35. Alternatively miR-125b 
might act intrinsically in the CMP to drive expansion of these cells. In the future, it will be 
interesting and important to distinguish between these possibilities and determine if 
myeloid progenitors and/or the mature myeloid cells that overexpress miR-125b can 
initiate tumorigenesis.   
 In searching for a mechanism by which miR-125b exerts its effects on the 
hematopoietic system, we tested Lin28, a gene we saw was potently regulated by miR-
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125b in both mouse and human hematopoietic cells. In performing gain- and loss-of-
function of Lin28 in the hematopoietic system, we further identified Lin28 as a novel 
regulator of hematopoietic development. Lin28 is an RNA binding protein that is capable 
of de-differentiating mature mammalian cells back to pluripotent stem cells when co-
expressed with the genes Oct4, Sox2 and Nanog25. Expression of Lin28 has been 
shown to be stem cell specific36-38 and to enhance stem cell growth and survival39,40; its 
downregulation in embryonic stem cells corresponds temporally with differentiation of 
these cells37,38. Our data here suggests that miR-125b might similarly promote 
differentiation of HSCs into downstream progenitors. This process might rely on Lin28, 
and it is conceivable that repression of Lin28 by miR-125b may promote HSCs to 
differentiate into downstream progenitors. Coordinated repression of other miR-125b 
target genes, such as those involved in the anti-apoptotic process, may then endow 
these cells with an enhanced survival advantage, providing them with the opportunity to 
increase in number and eventually transform into leukemia. 
 We show here that miR-125b is an important regulator of hematopoiesis both 
physiologically and pathologically. MiR-125b overexpression promotes early 
hematopoieic progenitors, especially myeloid progenitors, and eventually leads to 
myeloid leukemia. Our results indicate that the effects miR-125b has on the 
hematopoietic system are in part due to its ability to efficiently repress Lin28 expression. 
Indeed, we show that manipulating Lin28 expression levels in mice mimicked the 
hematopoietic phenotypes of those with modulated miR-125b function. Collectively, this 
report further advances our understanding of the mechanism by which miR-125b 
regulates hematopiesis and leukemic development. Indeed the interplay between miR-
125b and Lin28 appears to be a powerful regulatory pathway in this process, and one 
that could be toggled therapeutically in order to ameliorate hematopoietic disorders such 
as leukemia and bone marrow failure. 
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Materials and Methods 
Cell culture. 293T cells were cultured in complete DMEM with 10% FBS, 100 units/ml 
penicillin and 100 units/ml streptomycin. K562 cells and splenocytes from mice were 
cultured in complete RPMI with 10% FBS, 100 units/ml penicillin, 100 units/ml 
streptomycin and 50 µM 2-Mercaptoethanol. 
DNA constructs. The retroviral vectors MG, MGP, MGP-125b-1 and MGP-125b-2 have 
been described previously. The miR-125b sponge decoy vector was constructed by 
cloning four miR-125b antisense sites downstream of GFP in MG, where each anti-
sense site was separated by a 4-6 nucleotide spacer sequence, and each anti-sense 
site contained a binding mismatch with miR-125b corresponding to nucleotides 9-12 of 
the microRNA. Both Lin28 shRNA and MGP-125b-Mutant were cloned using a miR-155 
arms-and-loop format, which was previously described. The Lin28 shRNA sequence was 
predicted using the Invitrogen BlockiT RNAi Designer. The 3’ UTRs for mouse Lin28, 
Trp53inp1, Bak1 and BMF as well as the antisense 2-mer were cloned downstream of 
luciferase in the pMIR-REPORT vector. For the Lin28 overexpression vector, the mouse 
Lin28 coding sequence (Open Biosystems) was cloned downstream of the LTR and prior 
to the IRES-GFP segment of the MSCV Ires GFP (MIG) vector. All primers are listed in 
Table S1. 
Retroviral transduction and bone marrow reconstitution experiments. C57Bl/6 mice 
were bred and housed in the Caltech Office of Laboratory Animal Resources (OLAR) 
facility. The Caltech Institutional Animal Care and Use Committee (IACUC) approved all 
experiments related to mice. Virus production and reconstitution experiments were 
performed as previously described (O’Connell et al., 2008). Experimental groups of four 
to ten mice received each of the vectors described. The health of recipient animals was 
closely monitored, and flow cytometry on the peripheral blood was performed 
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periodically. K562 cells were transduced with VSV-G pseudotyped MGP, MGP-125b-1, 
MGP-125b-2 and MGP-125b-Mut as described previously. 
Cell counting. Cells were counted using a Coulter Counter (Beckman Coulter) or a 
MACSQuant flow cytometer (Miltenyi Biosciences). Absolute cell counts in the blood 
were obtained by FACS-staining equivalent volumes of blood, resuspending the stained 
samples in equivalent volumes of FACS buffer, and running equal volumes of each 
sample using the MACSQuant.  
Flow cytometry. Cells were isolated from relevant tissues, homogenized, and red blood 
cells were lysed with RBC lysis buffer (Biolegend). Cells were stained with the following 
fluorophore-conjugated antibodies that were purchased from Biolegend, Ebioscience or 
BD Pharmingen in various colors and combinations: CD11b, CD45, CD3ε, Ter119, Gr1, 
CD19, CD11c, B220, CD138, cKit, Thy1.2, IL7Rα, Lin, CD34, Sca1, Flk2, CD43, CD48, 
CD150, CD45, F480 (Biolegend); IgM, CD34 (eBioscience); AnnexinV (BD Pharmingen). 
7AAD (BD Pharmingen) was used in some stains to distinguish live from dead cells. 
Cells were sorted with a MACSQuant (Miltenyi Biosciences) or a FACSCalibur (Becton 
Dickinson) and all data was analyzed with FlowJo software (Treestar). Specific gating 
strategies are available upon request. 
Cell sorting for sponge reconstitution. 5-FU enriched bone marrow was transduced 
with retroviral vectors as previously described. Prior to IV injection into mice, GFP-
positive MG and MG-Sponge transduced samples were sorted using an iCyt cell sorter. 
Equal numbers of cells were then injected into lethally irradiated recipient animals. 
Target analysis. Predicted miR-125b targets in H. Sapien were downloaded from 
Targetscan and rank-ordered by their Probability of Conserved Targeting (PCT) scores. 
Repeated target genes were removed from this list using a PERL script (available upon 
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request). Literature search was performed on the resulting list in order to identify 
candidate target genes. For one target, Lin28, the 3’ UTR for the mouse version of the 
gene was obtained and aligned with miR-125b using TargetScan. 
Luciferase reporter assays. Luciferase reporter assays to measure microRNA-based 
repression of target 3’ UTRs were performed as previously described. For de-repression 
assays with the sponge construct, we added MG (empty vector) or MG-Sponge to the 
transfection mix. After 24 hours, cells were lysed with Passive Lysis Buffer (Promega) 
and luciferase reporter assays were performed as previously described. 
RNA preparation and quantitation. RNA was isolated with TRIzol (Invitrogen) as per 
the manufacturer’s instructions. We performed SYBR Green (Quanta Biosciences) 
based quantitative real-time PCR (qPCR) with a 7300 Real-Time PCR machine (Applied 
Biosystems) to assay Lin28, BMF, Trp53inp1, Bak1, mutant miR-125b and L32 mRNA 
levels. A Taqman approach was used to quantitate levels of miR-125b and snoRNA-202 
(Applied Biosystems). All genes measured using SYBR Green were normalized to L32. 
MicroRNA-125b levels measured by Taqman were normalized to snoRNA-202. 
Sequence specific primers are listed in Table S1. 
Immunoblotting. Total cell extracts were fractionated by electrophoresis on a 12% SDS 
polyacrylamide gel and electroblotted onto a Trans-Blot nitrocellulose membrane with a 
semidry transfer apparatus. Protein detection was performed using the following 
antibodies: Lin28 (A177) (Cell Signaling); Beta-Actin (A1978) (Sigma); anti-rabbit HRP-
conjugated secondary antibody and anti-mouse HRP-conjugated secondary antibody 
(Santa Cruz Biotechnology). 
Statistical tests. Statistical tests were performed using Graphpad PRISM software or 
Microsoft Excel. The two-tailed student’s T test was used to determine P values. 
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Figure Legends 
Figure 1. MiR-125b overexpression causes an aggressive myeloid leukemia 4-5 
months post-reconstitution. A) CD45+CD11b+ cells were analyzed in the blood of MG 
and MG-125b expressing mice 4.5 months post-reconstitution. (Left) A representative 
plot is shown. (Right) CD45+ CD11b+ (cells / ml) are shown for 8 MG and 4 MG-125b 
mice. B) Tissue was taken from the kidney, lung and liver from MG and MG-125b 
expressing mice 5 months post-reconstitution, and stained with hematoxylin and eosin. 
The normal structures of the MG-125b mouse kidney, lung and liver are effaced by a 
dramatic infiltrate of leukemic cells. A representative image for each tissue is shown. 
Scale bar, 40 microns. C) CD45+ GFP+ and CD11b+ GFP+ cells were analyzed in the 
brain of MG and MG-125b expressing mice 5 months post-reconstitution. (Top) A 
representative plot is shown. (Bottom) % GFP+ CD45+ and % GFP+ CD11b+ are shown 
for 3 MG and 2 MG-125b mice. Data shown graphically represents Mean + SEM. All 
data is representative of two independent experiments. Abbreviations: Inf, Infiltrate; G, 
Glomerulus; A, alveolar space; CV, central vein.  
 
Figure 2. MiR-125b overexpression causes a rearrangement of the hematopoietic 
system at 7 weeks post-bone marrow reconstitution. A) Leukocyte and erythroid 
compartments in the spleens of MG and MG-125b overexpressing mice were measured 
by flow cytometry. B) GFP+ hematopoietic progenitor populations in the bone marrow of 
MG and MG-125b mice were measured by flow cytometry. C) The percent of GFP+ 
long-term HSCs (LT HSC) and multipotent progenitors (MPPs) were measured by flow 
cytometry in the bone marrow. Horizontal lines represent the mean and each dot 
represents an individual mouse. Data is representative of 2-3 independent experiments 
with 4-5 mice per group. Abbreviations: CMP/GMP, Common Myeloid 
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Progenitor/Granulocyte Macrophage Progenitor; MEP, Myeloid Erythroid Progenitor; 
CLP, Common Lymphoid Progenitor. 
 
Figure 3. Design of the miR-125b “sponge” decoy system. A) MiR-125b sponge 
decoy was constructed by placing four miR-125b complementary sites downstream of 
GFP in MG, with 4-6 nucleotide spacers in-between each site and a region of mismatch 
corresponding to nucleotides 9-12 of the microRNA. B) Sponge de-represses a miR-
125b reporter vector comprised of 2 perfect antisense sites placed downstream of 
luciferase. C) Sponge does not de-repress the pMiR-Report negative control vector. 
Luciferase values were measured and normalized to the loading control Beta-gal. 
Assays were performed with three samples per group. Results are representative of 
three independent experiments. 
 
Figure 4. MiR-125b loss-of-function decreases hematopoietic output. A) GFP+ cells 
were FACS-sorted from MG and MG-Sponge transduced progenitor-enriched bone 
marrow. Equal numbers were injected into two groups of 10 recipient animals. (Left) 
Oval indicates gating on the primary population of cells. (Right) GFP+ cells within the 
primary population were FACS-sorted as indicated by the blue arrow. B) Total numbers 
of white blood cells (CD45+), myeloid (CD45+ CD11b+), granulocytes (CD45+ Gr1+), B 
cells (CD45+ CD19+ CD3-), T cells (CD45+ CD3+ CD19-) and pre-erythrocytes (CD45+ 
Ter119+ CD19-) were measured by flow cytometry. Data shown represent Mean + SEM 
and indicate number of cells/ml of blood. P values were calculated using a student’s T 
test and are indicated for each graph. All results are representative of two independent 
experiments with 9-10 animals per group. 
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Figure 5. Lin28 is a primary target of miR-125b in the hematopoietic system. A) 
Relative expression of miR-125b candidate targets in miR-125b overexpressing 
progenitor-enriched bone marrow compared to MG control was measured by qPCR. B) 
Relative luminescence of miR-125b candidate targets in the presence of miR-125b and 
normalized to empty vector control. The Picalm 3’ UTR is shown as a negative control 
since it contains no miR-125b putative binding sites. 2-mer consists of two adjacent miR-
125b antisense sites and serves as a positive control. C) Relative expression of the 
genes Lin28, trp53inp1 and BMF were measured in sponge-transduced progenitor-
enriched bone marrow and normalized to MG transduced controls. The percent 
expression relative to MG is shown. Broken line demarcates 100%. Data is Mean + SEM 
of five samples per group. D) Schematic layout of the Lin28 mRNA coding sequence 
(blue) and 3’ UTR with relative location of the miR-125b binding site. Depiction is not to 
scale. Predicted interaction between the Lin28 3’ UTR and miR-125b microRNA is 
shown below. E) Relative luminescence of a reporter vector containing the Lin28 3’ UTR 
co-transfected into 293T cells with either MG or miR-125b sponge decoy vector. The 
relative luminescence is depicted graphically as the Mean + SEM of six samples per 
group. K562 cells were transduced with either MGP empty vector or MGP expressing 
miR-125b-1, miR-125b-2 or a miR-125b seed mutant. F) Relative RNA and G) protein 
expression of Lin28 are shown. β-actin is included as a loading control for Western 
blotting. L32 is used as a loading control for mRNA expression. All data shown represent 
Mean + SEM. * indicates p < 0.02; ** indicates p < 0.01. A, E, F and G are 
representative of 2-3 independent experiments. B depicts the Mean + SEM of three 
independent experiments with three technical replicates per sample. 
 
Figure 6. Lin28 overexpression inhibits all hematopoietic lineages in the blood. A) 
MIG and MIG-Lin28 were transfected into 293T cells. Lin28 expression was measured 
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by Western blot. β-actin serves as a loading control. B) Progenitor-enriched bone 
marrow was transduced with MIG or MIG-Lin28. The % GFP+ cells in each sample were 
measured by flow cytometry and the results are indicated on each FACS plot. C) Five 
weeks post-reconstitution, the number of cells/ml in the blood of the following cell types 
were measured by flow cytometry: white blood cells (CD45+), myeloid (CD45+ CD11b+), 
granulocytes (CD45+ Gr1+), B cells (CD45+ CD19+ CD3-), T cells (CD45+ CD3+ CD19-
), NK cells (CD45+ NK1.1+) and erythrocytes (Ter119+ CD11b-). Data shown graphically 
represents the Mean + SEM. P values are also shown. Data is pooled from two 
independent groups of MIG-Lin28 animals, each with 7-8 animals and compared to MIG 
(6 animals). 
 
Figure 7. ShRNA knockdown of Lin28 increases myeloid cells at the expense of B 
cells. A) Flow cytometry of progenitor-enriched bone marrow transduced with MG or 
MG-Lin28 shRNA was performed and the percent GFP+ cells is indicated. B) Lin28 
mRNA expression was performed on the samples shown in A, and results were 
normalized to L32. Representative of two independent experiments with 4 samples per 
group. C) (Left) Total myeloid (CD45+ CD11b+), granulocytes (CD45+ Gr1+) and B cells 
(CD19+ CD3-) were measured from MG and MG-Lin28 shRNA animals and (Right) total 
myeloid (CD45+ CD11b+ CD19-), granulocytes (CD45+ Gr1+) and B cells (CD45+ 
CD19+ CD3ε-) from MG and MG-125b animals. Data depicts the number of cells/ml of 
blood as Mean + SEM, and was collected 5 weeks post-bone marrow reconstitution with 
8-10 animals per group. P values are indicated. 
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Figures 
 
Figure 1.  MiR-125b overexpression causes an aggressive myeloid leukemia 4-5 
months post-reconstitution 
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Figure 2.  MiR-125b overexpression causes a rearrangement of the hematopoietic 
system at 7 weeks post-bone marrow reconstitution 
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Figure 3.  Design of the miR-125b “sponge” decoy system 
 
 
 
 
 
 
189 
 
 
Figure 4.  MiR-125b loss-of-function decreases hematopoietic output 
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Figure 5.  Lin28 is a primary target of miR-125b in the hematopoietic system 
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Figure 6.  Lin28 overexpression inhibits all hematopoietic lineages in the blood 
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Figure 7.  ShRNA knockdown of Lin28 increases myeloid cells at the expense of B 
cells 
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Supplemental Figure Legends 
Figure S1. MG-125b animals develop large spleens 5 months post-reconstitution. 
A) Design of MG-125b, an MSCV-based retrovirus that expresses GFP and pri-miR-
125b-1. B) Pre-transplant FACS showing transduction efficiency in progenitor-enriched 
bone marrow with MG and MG-125b. C) Quantitative PCR was performed to determine 
the relative expression of miR-125b in each sample. Fold-increase of miR-125b 
expression in the MG-125b transduced sample is indicated. D) By 5 months post-
reconstitution, animals developed cancer. A representative image indicating spleen sizes 
of MG and MG-125b overexpressing mice at this time point is shown. E) Spleen weight 
in milligrams (mg) is indicated graphically. Data is from 11 MG and 11 MG-125b animals 
from three independent experiments harvested ~ 5 months post-reconstitution. 
 
Figure S2. MiR-125b causes extramedullary myelopoiesis 5 months post-
reconstitution. A) Relative leukocyte counts, as measured by flow cytometry, of MG 
and MG-125b spleens 5 months post-reconstitution were measured by flow cytometry. 
B) Representative FACS data showing the percent of GFP+ CD11b+, GFP+ CD19+, 
CD11b+ Gr1+ and GFP+ CD3+ in MG-125b animals 5 months post-reconstitution 
compared to MG controls. Data is representative of 7 MG and 7 MG-125b animals. 
 
Figure S3. MG-125b overexpression leads to death by 5 months post-
reconstitution. A) Survival curve showing percent survival of 8 MG and 4 MG-125b 
animals over a 5 month period. B) B cell (CD45+ CD19+ CD11b-) and T cell (CD45+ 
CD3+) numbers (number of cells/ml) were measured by flow cytometry 4.5 months post-
reconstitution. Mean + SEM are indicated. Data are from 4 MG-125b and 8 MG animals. 
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Figure S4. Progression of MG-125b cohort #2 towards cancer. A) FACS to 
determine the percent GFP+ cells was performed on MG and MG-125b transduced 
donor bone marrow cells prior to bone marrow transplantation. B) Survival curve of miR-
125b overexpressing animals compared to MG controls. The arrow just prior to 21 
weeks indicates when these animals were bled for FACS. Data is from 4 MG and 10 
MG-125b animals. C) The number of total myeloid cells (CD45+ CD11b+ CD19-), D) B 
cells (CD45+ CD19+ CD11b-), and E) T cells (CD45+ CD3ε+) was measured at the 
indicated time point. Values shown represent the number of cells/ml. C represents Mean 
+ SEM. For D and E, each dot represents an individual mouse, and the horizontal bar 
represents the group average. 
 
Figure S5. MiR-125b overexpressing animals exhibit myeloid infiltration into 
peripheral organs 5 months post-reconstitution. Moribund MG-125b animals were 
sacrificed and their organs harvested. Flow cytometry on GFP+ CD45+ and GFP+ 
CD11b+ populations were performed for the A) kidney, C) lung and E) liver. Gross 
pathology comparing MG and MG-125b B) kidney and D) lung are shown. F) A 
representative MG-125b liver is also shown. All data is representative of 8 MG animals 
and 5 MG-125b animals. 
 
Figure S6. MiR-125b expression is increased in peripheral organs from MG-125b 
animals 5 months post-reconstitution compared to controls. RNA was harvested 
from moribund MG-125b animals after 5 months post-reconstitution. MiR-125b 
expression was measured by Taqman in A) kidney, B) lung and C) liver. Data shown is 
the Mean + SEM of 2-3 animals per group. 
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Figure S7. MiR-125a overexpression causes an aggressive leukemia 6 months 
post-reconstitution. Mice overexpressing miR-125a became moribund 6 months post-
reconstitution and were thus harvested. Gross pathology from A) liver, B) spleen and C) 
kidneys are shown. Representative of two animals. 
 
Figure S8. MG-125b splenocytes display less apoptosis than MG controls. A) 
Percent 7AAD+ splenocytes cultured in vitro for 204 hours is shown graphically on the 
left. A representative FACS plot is shown on right. B) % AnnexinV+ splenocytes cultured 
in vitro for 204 hours is shown on the left. A representative FACS plot is shown on right. 
Each dot represents a spleen culture taken from a separate mouse. Mean and SEM are 
shown for each set of samples, and P values are indicated. 
 
Figure S9. Representative blood smear at 4.5 months post-reconstitution. MG-
125b animals display a dramatic increase in myeloid white blood cells. Examples of this 
cell type are indicated by black arrows. 
 
Figure S10. Bone marrow from MG-125b animals isolated 7 weeks post-
reconstitution display hematopoietic rearrangement. A) Total white blood cell counts 
and B) total GFP+ white blood cells were measured in MG and MG-125b mouse bone 
marrows. C) Total number of GFP+ granulocytes (GFP+ Gr1+), D) dendritic cells (GFP+ 
CD11c+ CD19-), E) macrophages (GFP+ F480+) and F) B cells (GFP+ CD19+ CD11c-) 
were measured by flow cytometry. Each dot represents a separate mouse. Data is 
representative of two independent experiments. 
 
Figure S11. Hematopoietic stem cell gating strategy. 1) The primary population of 
cells, as determined by forward scatter (FSC) and side scatter (SSC) is gated. 2) From 
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these cells, GFP+ Lineage- cells are gated. 3) From this population, cKit+ Sca1+ cells 
are subgated. 4) Within this population of cells, gating on CD150+ CD48- cells results in 
the long-term HSC compartment. 
 
Figure S12. MiR-125b mutant vector expresses seed mutant version of miR-125b. 
A) MGP-125b-Mutant vector was designed to express a seed mutant version of miR-
125b by utilizing a miR-155 arms-and-loop format (top). Sequences expressed by wild-
type miR-125b and the mutant are shown below. B) Quantitative PCR shows relative 
expression of the mutant version of miR-125b (normalized to L32) in K562 cells 
transduced with MGP-125b-Mutant or MGP control. 
 
Figure S13. Lin28 is efficiently expressed by MIG-Lin28 in progenitor-enriched 
bone marrow. Relative expression of Lin28 was measured in 5-FU treated bone marrow 
transduced with either MIG or MIG-Lin28. Each dot represents an independent sample. 
Horizontal lines represents the mean for each group and error bars represent SEM. 
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Supplemental Figures 
 
 
Figure S1.  MG-125b animals develop large spleens 5 months post-reconstitution 
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Figure S2.  MiR-125b causes extramedullary myelopoiesis 5 months post-
reconstitution 
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Figure S3.  MG-125b overexpression leads to death by 5 months post-
reconstitution 
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Figure S4.  Progression of MG-125b cohort #2 towards cancer 
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Figure S5.  MiR-125b overexpressing animals exhibit myeloid infiltration into 
peripheral organs 5 months post-reconstitution 
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Figure S6.  MiR-125b expression is increased in peripheral organs from MG-125b 
animals 5 months post-reconstitution compared to controls 
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Figure S7.  MiR-125a overexpression causes an aggressive leukemia 6 months 
post-reconstitution 
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Figure S8.  MG-125b splenocytes display less apoptosis than MG controls 
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Figure S9.  Representative blood smear at 4.5 months post-reconstitution 
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Figure S10.  Bone marrow from MG-125b animals isolated 7 weeks post-
reconstitution display hematopoietic rearrangement 
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Figure S11.  Hematopoietic stem cell gating strategy 
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Figure S12.  MiR-125b mutant vector expresses seed mutant version of miR-125b 
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Figure S13.  Lin28 is efficiently expressed by MIG-Lin28 in progenitor-enriched 
bone marrow 
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Supplemental Table 
Table S1. Primer Sequences 
Primer       Sequence 
125b Sponge NotI 5’ 
oligo 
GGCCGCTCACAAGTTACCACTCAGGGACGATTCACAAGTT
ACCACTCAGGGAACCGGTTCACAAGTTACCACTCAGGGAT
CACTCACAAGTTACCACTCAGGGAC 
125b Sponge XhoI 3’ 
oligo 
TCGAGTCCCTGAGTGGTAACTTGTGAGTGATCCCTGAGTG
GTAACTTGTGAACCGGTTCCCTGAGTGGTAACTTGTGAATC
GTCCCTGAGTGGTAACTTGTGAGC 
Antisense 2-mer SpeI 
5’ oligo 
CTAGTTCACAAGTTAGGGTCTCAGGGATCACAAGTTAGGG
TCTCAGGGAA 
Antisense 2-mer 
HindIII 3’ oligo 
AGCTTTCCCTGAGACCCTAACTTGTGATCCCTGAGACCCTA
ACTTGTGAA 
mouse Lin28 3’ UTR 
SpeI Fw 
TTCACTAGTGGCCCAGGAGTCAGGGTTATTCTTT 
mouse Lin28 3’ UTR 
HindIII Rev 
TTCAAGCTTTGAGCCTAAGTTTTCTTACGAGGGAGAA 
mouse Trp53inp1 3’ 
UTR SpeI Fw 
TTCACTAGTAATGTTGAGTTATGTTGGTTTGTTTCCTTAGG 
mouse Trp53inp1 3’ 
UTR MluI Rev 
TTCACGCGTTTGCTGATTTACAGGAACAAAACACTAAGC 
mouse BAK1 3’ UTR 
SpeI Fw 
TTCACTAGTTCCCGGGGAGCCCCACTG 
mouse BAK1 3’ UTR 
HindIII Rev 
TTCAAGCTTCCCTCTGCCTCCCCCTCTTCC 
mouse Lin28 shRNA 
oligo 
GAAGGCTGTATGCTGTTCCTTGGCATGATGGTCTAGGTTTT
GGCCACTGACTGACCTAGACCAATGCCAAGGAACAGGACA
CAAGGCCTG 
miR-125b seed 
Mutant oligo 
GAAGGCTGTATGCTGTGGGACTGACCCTAACTTGTGAGTT
TTGGCCACTGACTGACTCACAAGTGGGTCAGTCCCACAGG
ACACAAGGCCTG 
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mouse Lin28 CDS 
BglII Fw 
TTCAGATCTATGGGCTCGGTGTCCAACCAG 
mouse Lin28 CDS 
XhoI Rev 
TTCCTCGAGTCAATTCTGGGCTTCTGGGAGCA 
Mutant miR-125b 
qPCR Fw 
TCACAAGTTAGGGTCAGTCCCA 
Lin28 qPCR Fw GTTCACCTTTAAGAAGTCTGCCA 
mouse Lin28 qPCR 
Rev 
TGTCTCCTTTGGATCTTCGCTT 
human Lin28 qPCR 
Rev 
CACCTGTCTCCTTTTGATCTGC 
mouse L32 qPCR Fw AAGCGAAACTGGCGGAAAC 
mouse L32 qPCR Rev TAACCGATGTTGGGCATCAG 
human Actin qPCR 
Fw 
CTGTGCTATCCCTGTACGCCTC 
human Actin qPCR 
Rev 
CATGATGGAGTTGAAGGTAGTTTCGT 
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MicroRNAs in leukemia: Markers of disease and potential targets of 
therapy 
 Many groups are exploring the role of specific microRNAs in hematopoietic cell 
lineages. Georgantas III et al. found 33 miRNAs expressed in CD34+ hematopoietic 
stem progenitor cells (HSPCs) from normal human bone marrow and human peripheral 
blood stem cell harvests1. Bartel and colleagues showed that overexpression of mir-181 
in the hematopoietic system leads to increased numbers of B cells at the expense of T 
cells2. Later, mir-150 was shown by the Rajewsky group to control B1 versus B2 B-cell 
differentiation via repression of c-Myb. Mir-150 was shown by luciferase assay to 
strongly repress via the c-Myb 3’ UTR. Mir-150-/- mice had an expansion of B1 B cells in 
the spleen and periotineal cavity, likely due to de-repression of c-Myb3. 
  Given the emerging role of miRNAs in controlling differentiation of hematopoietic 
progenitors into specific lineages, several groups performed screens on leukemic cells to 
reveal differences in miRNA expression compared to normal. Navarro et al. analyzed 
miRNA expression in the lymph nodes of patients with Hodgkin lymphoma. They 
revealed that 36 microRNAs were differentially expressed in nodular sclerosis versus 
mixed cellularity Hodgkin’s lymphoma. Chromogenic in situ hybridization was used to 
show that Reed-Sternberg cells, the pathognomonic cell type of Hodgkin’s lymphoma, 
preferentially express mir-21, mir-134 and mir-138 in their cytoplasm.4  
  Mi et al. showed that microRNA expression signatures can distinguish between 
two different forms of leukemia, acute lymphoblastic leukemia (ALL) and acute myeloid 
leukemia (AML). ALL is the most common childhood cancer, while AML is the most 
common acute leukemia in adults. Mir-128a and mir-128b were significantly 
overexpressed in ALL compared to AML, while let-7b and mir-223 were significantly 
overexpressed in AML compared to ALL.5  
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  The Croce and Falini groups looked at AML more extensively, specifically NPMc+ 
NK-AML. NPMc+ NK-AML is AML with a normal karyotype and a mutation in the 
nucleophosmin (NPM1) gene occurring on exon-12 and more rarely on exon-11. Several 
miRNAs were upregulated in NPMc+ NK-AML versus NPMc- NK-AML including miR-
155.6 Our own studies show here that AML patients have 4.5 times higher levels of miR-
155 in their bone marrow compared to normal. Also several groups have now shown that 
miR-125b is dysregulated in a plethora of human leukemias. By overexpressing miR-155 
and miR-125b specifically in the mouse hematopoietic disease, we have been able, in 
some ways, to model what happens in human disease.  
  It will be interesting to use our robust mouse models of miR-155 and miR-125b 
overexpression as testbeds for microRNA-based therapies that attempt to ameliorate the 
profound symptoms we observed by targeting microRNA levels and related pathways 
following disease onset. Is the miR-125b cancer phenotype driven entirely by miR-125b? 
Are there secondary mutations that are required to ultimately push the mouse towards 
disease? Indeed it will be interesting to sequence the mouse cancer genome 5 months 
post-reconstitution, when the mice become moribund from the cancer, and see what 
genes are mutated. It is possible that miR-125b overexpression merely provides cells 
with enough of a growth advantage to acquire other secondary mutations, which then 
ultimately become responsible for pushing the mouse towards cancer. We can test this 
idea by performing loss-of-function on the miR-125b overexpression mice at different 
time points and determine whether miR-125b loss-of-function can A) prevent disease 
when applied during the pre-leukemic stage (4-7 weeks), B) stop disease progression 
during leukemic progression but prior to blast crisis (2.5-3.5 months), or C) actually halt 
blast crisis and instigate recovery when the mice are on the verge of death (4-5 months). 
Performing these experiments will be a critical step towards developing a miR-125b 
based therapy to treat human leukemia. 
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MiR-155 target identification: Can one target be the silver bullet? 
  MiR-155 is normally expressed at very low levels in the bone marrow 
compartment of mice. Expression is strongly but transiently induced after intraperitoneal 
(IP) injection of bacterial LPS. This injection correlates with a granulocyte/monocyte 
(GM) expansion7. Enforced high expression of miR-155 in mouse bone marrow cells 
leads to a similar GM expansion, but the GM cells have dysplastic characteristics 
reminiscent of myeloproliferative disorder (MPD) and pre-AML7. I was fascinated by this 
profound phenotype and also by its relevance to human disease. Thus I devoted the first 
half of my PhD to determining the mechanism by which miR-155 causes a 
myeloproliferative disorder in mice. 
  Since miRNA seed regions are small in size, targeting algorithms predict that 
gene regulation by microRNAs is promiscuous, with several genes targeted by the same 
microRNA, and several microRNAs targeting the same gene8,9. Here we show that miR-
155 is capable of regulating several genes important for hematopoiesis by repressing 
expression by 22-73% via their 3’ UTR regions7. Thus we hypothesized that sustained 
miR-155 expression leads to myeloproliferative disorder via combinatorial repression of 
several target genes. In some physiological contexts, however, a single target may 
account for a majority of a miRNA’s physiological or pathological effects. For example, 
mir-150 targeting of c-Myb leads to a defect in B-cell maturation3. Indeed, of the 1080 
genes downregulated by miR-155 overexpression in RAW cells, 89 had putative miR-
155 target sites, 11 were implicated in hematopoietic development or disease, and 
knockdown of just one of these target genes, SHIP1, recapitulated the miR-155 
overexpression phenotype in vivo. The ability for one target out of such a plethora of 
possible candidates to be responsible for a microRNA’s phenotype is intriguing. 
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 Similarly, for miR-125b, of the 604 candidate targets in the human genome10, one, 
IRF4, appeared responsible for the macrophage activation phenotype and another, 
Lin28, appears to be more important than others in miR-125b’s role as a regulator of 
hematopoiesis. It will be interesting to explore further in the future whether selective use 
of just a handful of targets in specific settings, similar to siRNA targeting, is a general 
theme in microRNA targeting. If this were the case, then why didn’t microRNAs evolve to 
be like siRNAs? Indeed it seems on the surface that the reason microRNAs don’t bind 
their targets perfectly, like siRNAs do, is to preserve the option to target many genes. It’s 
the age-old quality over quantity debate; if microRNAs imperfectly bind several targets, 
rather than perfectly bind any one of them, then we would expect phenotypes arising 
from their dysregulation to be multi-target in nature, involving graded modulation of 
hundreds of target genes. While we did view reduction of 1,080 target genes by miR-155 
overexpression in macrophages, it is nonetheless intriguing that just one of these 
targets, SHIP1, was primarily important in the context of hematopoietic disease. 
 
MiR-125b as a macrophage activator 
 Here we show that miR-125b is enriched in macrophages and that elevating miR-
125b promotes macrophage activation, IFNγ response, and immune function of these 
cells. Interestingly, miR-125b in macrophages promoted the ability of these cells to 
present antigen and induce T cell activation, demonstrating that miR-125b can enhance 
the macrophage’s role in mediating adaptive immunity. In addition to its intrinsic function 
in macrophages, miR-125b likely further amplifies its role in these cells in vivo through a 
paracrine mechanism by enhancing their response to interferon γ.  
We found that macrophages overexpressing miR-125b had increased surface 
expression of co-stimulatory molecules, allowing them to be more effective at activating 
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T cells. The increase in activated T cells would in theory result in more secretion of IFNγ, 
which in turn further magnifies the activation status of miR-125b expressing 
macrophages, given that these cells exhibit a higher response to IFNγ signaling. In this 
model, by affecting macrophage function alone, miR-125b could amplify immune 
responses by orchestrating positive feedback loops between macrophages and T cells. 
Breaking this positive feedback loop by inhibiting miR-125b in macrophages in vivo may 
be an effective strategy to treat autoimmune diseases such as Multiple Sclerosis and 
Macrophage Activation Syndrome that involve both macrophages and T cells in their 
pathogenesis. 
 We demonstrated here that IRF4 is a target of miR-125b and that IRF4 
knockdown mimics the miR-125b overexpression phenotype in macrophages. MiR-
125b’s ability to potentiate macrophage activation is consistent with previously 
demonstrated ability of IRF4 to inhibit pro-inflammatory macrophage polarization. IRF4 is 
a competitive inhibitor of IRF5 11, a transcription factor that upregulates macrophage 
inflammatory genes 12. By inhibiting IRF4, miR-125b may de-repress IRF5, allowing 
IRF5 to more effectively undergo its function, thus heightening macrophage activation. 
Indeed, polymorphisms in the IRF5 gene associated with increased IRF5 mRNA levels 
have been reported in Macrophage Activation System 13, Multiple Sclerosis 14-16, 
Systemic Lupus Erythematosus 17-19, Rheumatoid Arthiritis 20,21 and Inflammatory Bowel 
Disease 22. It will be interesting to examine whether dysregulated miR-125b levels are 
also associated with these autoimmune disorders.  
 MiR-125b enhances macrophage activation and appears to do so by inhibiting 
IRF4 expression. IRF4 has been shown to polarize macrophages towards the anti-
inflammatory (M2) type 23, while the factor it inhibits, IRF5, polarizes macrophages 
towards the pro-inflammatory (M1) type 12. Thus it will be interesting to investigate 
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whether miR-125b acts as a toggle switch that regulates macrophage polarization in 
response to situations such as acute infection, sepsis or cancer. 
MiR-125b is upregulated in certain leukemias and downregulated in many solid 
non-hematopoietic solid tumors 24-35. While tumor associated macrophages (TAMs) are 
known to infiltrate solid tumor cancers and help promote tumor development 36, to our 
knowledge none of these studies separated macrophages from the cancerous tissue 
prior to analyzing microRNA levels. Thus it is tempting to speculate that the results of 
these studies may be due to the presence of tumor infiltrating macrophages in the 
cancerous tissue. We have shown here that increased miR-125b expression in tumor 
macrophages slows tumor growth. TAMs that promote tumor growth may thus 
downregulate miR-125b; it will be interesting to measure miR-125b levels in TAMs and 
determine if this is indeed the case. Our data suggests that supplementing tumor 
macrophages with miR-125b may be a useful therapeutic strategy for treating solid 
tumor cancers. 
 
MiR-125b as a positive regulator of myelopoiesis 
We show here that miR-125b very strongly promotes early myeloid progenitors, 
and promotes all downstream myeloid lineages in vivo even prior to the onset of 
hematopoietic disease. Thus we suggest that miR-125b causes an aggressive myeloid 
leukemia by strongly driving development of early myeloid progenitors. Consistent with 
this result, we saw that miR-125b overexpression dramatically increased numbers of 
myeloid progenitors even prior to the onset of overt disease. Indeed, it has been 
suggested that certain leukemias may arise from committed progenitor cells that have 
acquired stem cell capacity for self renewal37,38. While miR-125b has been shown to 
have anti-apoptotic effects in multiple cell types28,39,40, it is possible that miR-125b 
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endows myeloid progenitors with a particularly potent survival advantage, giving them 
the opportunity to transform into cancer stem cells. 
 While miR-125b loss-of-function leads to a decrease in all downstream 
hematopoietic lineages suggesting a physiological role in hematopoietic stem cells, our 
overexpression data suggests that miR-125b has different roles in different 
hematopoietic lineages. MiR-125b enhanced all lineages immediately downstream of 
HSCs including multipotent progenitors (MPPs), common lymphoid progenitors (CLPs) 
and myeloid progenitors (MPs). Enhancement of myeloid progenitors was much greater 
than that of other lineages. On the contrary, pro-B cells were significantly decreased in 
both the bone marrow and spleen in mice overexpressing miR-125b. Indeed, miR-125b 
overexpressing animals displayed decreased numbers of B cells in the blood, spleen 
and bone marrow. Interestingly, miR-125b sponge mice also displayed decreased B cell 
numbers. We believe this is because miR-125b loss-of-function decreases CLP 
numbers, which is upstream of the pro-B cell stage of hematopoiesis; thus all lymphoid 
cells, including B cells, become subsequently decreased. 
 The differential effects of miR-125b on different hematopoietic progenitors may 
be explained by regulation of different sets of targets. Our data here suggests that Lin28 
is a primary target of miR-125b in the context of hematopoietic stem cell output. Indeed, 
Lin28 overexpression in vivo led to a significant decrease in all downstream 
hematopoietic lineages examined, mimicking the miR-125b loss-of-function phenotype. 
Other groups have shown Lin28 is an embryonic stem cell specific gene41-43. Our data 
suggests that it also has important roles in hematopoietic stem and progenitor cells, and 
that its interaction with miR-125b controls hematopoietic output. 
 We observed a significant decrease in pro-B and pre-B cells in mice 
hematopoietically overexpressing miR-125b, suggesting that miR-125b represses genes 
necessary for early B cell development. We note that miR-125b has been shown in vitro 
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to repress the transcription factors IRF4 and BLIMP1 in B cell lines44,45, and it has been 
suggested that these interactions are responsible for miR-125b’s demonstrated in vitro 
ability to prevent the ability of these cell lines to acquire CD138, a marker for 
plasmablasts44. In our studies here, we observed decreased numbers of plasmablasts in 
vivo in MG-125b mice, as well as decreased antigen-specific antibody response in MG-
125b mice compared to controls. We note that IRF4 is also an important transcription 
factor for early B cell development46. Thus miR-125b impedes in vivo the development of 
B cells and plasmablasts, and may do so via repression of the transcription factors IRF4 
and BLIMP1. 
 MiR-125b may also interact with other targets to selectively enhance 
myelopoiesis. Indeed, we observed that miR-125b overexpression enhances myeloid 
lineages dramatically, and increases myeloid progenitor numbers more than any other 
progenitor type. We show here and others have shown previously, that miR-125b is 
capable of repressing a number of pro-apoptotic genes including BMF, BAK1 and 
Trp53inp139,47-49. Efficient repression of these genes in myeloid progenitors may enhance 
survival of these cells, providing them with the opportunity to eventually transform into a 
cancer stem cell pool. 
 
MiR-125b mediated cancer: Is this mouse CML? 
 The cancer disease process in MG-125b mice is interesting in the sense that the 
mice appear healthy and disease-free for 7 weeks post-reconstitution. White blood cell 
counts in the bone marrow and spleen are even during this time period. The mice 
continue to appear healthy and active until 3.5-4 months post-reconstitution, at which 
point they suddenly fall ill, rapidly deteriorate, and become moribund with the symptoms 
of an aggressive myeloid leukemia. Indeed, it appears that the disease goes through an 
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indolent phase, followed by a rapidly progressing phase and then death. In many ways 
the disease course resembles that of Chronic Myeloid Leukemia (CML)38, a disease 
characterized by the BCR-Abl translocation50. Interestingly, IRF4/IRF8 double knockout 
mice develop a disease that also resembles CML51. IRF8-/- mice also develop cancer, 
but addition of IRF4-/- to the IRF8-/- background cause the mice to deteriorate much 
more rapidly after the onset of disease51. IRF4 is a published target of miR-125b44,45, and 
its repression by miR-125b may play an important role in the overexpression leukemia 
phenotype. 
 In CML, the cancer stem cell during the indolent chronic phase strongly 
resembles a hematopoietic stem cell38. As the cancer progresses into the accelerated 
phase, the cancer stem cell pool appears to shift, resembling an early myeloid 
progenitor38. BCR-Abl inhibitors such as Imatinib effectively halt the disease, but do not 
cure it, since stopping therapy leads to a return of the disease50. It is thought that the 
reason for this is that the cancer stem cell pool does not require BCR-Abl for its survival 
even though downstream cells do38. Thus Imatinib appears to kill cancer cells, but not 
the cancer stem cell pool. It is possible that the cancer stem cells are instead addicted to 
miR-125b, a microRNA that we show here is enriched in HSCs52 and which upregulates 
myeloid progenitors, thus leading to a disease in mice that appears on the surface to 
resemble CML. Treatment of CML using miR-125b antagonists, perhaps in addition to 
BCR-ABL inhibitors, may therefore prove therapeutically useful. 
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Appendix: Review of physiological and 
pathological roles for microRNAs in the 
immune system 
The recent discovery of microRNAs (miRNAs) has 
revealed a new layer of gene expression regulation that 
affects many biological systems, including the mamma-
lian immune system1,2. miRNAs are small, single-stranded 
non-coding RNAs, many of which have been highly con-
served throughout evolution. They function by directly 
binding to the 3ʹ untranslated regions (UTRs) of specific 
target mRNAs, leading to the repression of protein expres-
sion and the promotion of target mRNA degradation. So 
far, ~700 different miRNAs have been identified in the 
human genome. Each miRNA could have the potential to 
repress the expression of many, perhaps hundreds of, target 
genes, highlighting the extent of this form of regulation in 
mammals. More than 100 different miRNAs are expressed 
by cells of the immune system; they have the potential to 
broadly influence the molecular pathways that control the 
development and function of innate and adaptive immune 
responses (TABLE 1). The expression of miRNAs is also 
markedly dysregulated in cancers of immunological ori-
gin, in which they are thought to have tumour suppressive 
or tumour promoting activities depending on the nature 
of their specific target mRNAs3.
In this Review, we describe newly discovered mecha-
nisms that regulate miRNA biogenesis and so determine 
the spatial and temporal patterns of miRNA expression 
in the immune system. We then review relevant exam-
ples of how miRNAs influence both innate and adaptive 
immune cell development and function and highlight 
emerging paradigms. In the final sections, we discuss 
the connection between miRNAs and human diseases of 
immunological origin. We focus on examples in which 
the expression of specific miRNAs becomes dysregu-
lated, leading to inappropriate target mRNA repression 
or derepression and the exacerbation of disease.
Regulating miRNA biogenesis
Our knowledge of miRNA biogenesis and mechanisms of 
target mRNA regulation by miRNAs is expanding in par-
allel with our understanding of their physiological roles in 
the immune system. Characterization of these processes is 
crucial for determining how, when and where miRNAs are 
produced and for clarifying the mechanistic activities that 
underlie their physiological functions in immune cells.
The processes of miRNA biogenesis and target mRNA 
repression have been intensively studied in recent years4. 
miRNAs are encoded by genomic DNA and are most 
commonly transcribed by RNA polymerase II. Some 
miRNA-containing primary transcripts produce a single 
miRNA, whereas other transcripts encode proteins in their 
exons and miRNAs in their introns. Alternatively, certain 
miRNAs, such as the miR-17–92 family, are grouped 
in clusters on a single unprocessed transcript and are 
expressed together. miRNAs are processed from their pri-
mary transcripts (known as pri-miRNAs) by the enzymes 
Drosha (also known as ribonuclease 3) and DiGeorge 
syndrome critical region gene 8 (DGCR8), and recent 
data suggest that this occurs co-transcriptionally5. Pre-
miRNAs are then exported from the nucleus by exportin 5. 
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Physiological and pathological roles 
for microRNAs in the immune system
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Abstract | Mammalian microRNAs (miRNAs) have recently been identified as important 
regulators of gene expression, and they function by repressing specific target genes at the 
post-transcriptional level. Now, studies of miRNAs are resolving some unsolved issues in 
immunology. Recent studies have shown that miRNAs have unique expression profiles in 
cells of the innate and adaptive immune systems and have pivotal roles in the regulation of 
both cell development and function. Furthermore, when miRNAs are aberrantly expressed 
they can contribute to pathological conditions involving the immune system, such as cancer 
and autoimmunity; they have also been shown to be useful as diagnostic and prognostic 
indicators of disease type and severity. This Review discusses recent advances in our 
understanding of both the intended functions of miRNAs in managing immune cell biology 
and their pathological roles when their expression is dysregulated. 
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RNA-induced silencing 
complex
A multicomponent 
ribonucleoprotein complex, 
comprising miRNAs or siRNAs 
and Argonaute proteins, that 
silences the expression of 
proteins from target mRNAs by 
cleavage or other unknown 
mechanisms depending on the 
complementarity of mRNA 
sequences to the packaged 
small RNAs.
Processing bodies 
Cytoplasmic foci that are 
thought to store and degrade 
translationally repressed RNA.
On reaching the cytoplasm, further processing of the pre-
miRNA is carried out by Dicer, resulting in the formation 
of a miRNA duplex. The duplex is unwound, and one 
strand, the guide strand, is packaged into the RNA-induced 
silencing complex (RISC), which comprises Argonaute 
and other proteins. The miRNA then guides the RISC 
to its target 3ʹ UTRs, leading to inhibition of trans-
lation and/or a decrease in mRNA stability as a result 
of accelerated uncapping and deadenylation6,7. There is 
evidence that the miRNA-silenced mRNA is directed to 
processing bodies, in which the targeted transcript is 
released from its inhibition or actively degraded8. Recent 
work in plants and worms has also identified proteins that 
regulate miRNA turnover9,10; however, a role for turnover 
control of miRNAs in mammals has yet to be shown.
Several recent studies indicate that the regulation of 
miRNA expression and function occurs at three levels: 
transcription, processing and subcellular localization 
(FIG. 1). There is emerging evidence that some of these 
processes are influenced by immune challenge, inflam-
mation or other forms of cellular stress. The expression 
of miRNAs is initially controlled at the transcriptional 
level by transcription factors that regulate the production 
of miRNA-containing primary transcripts in specific cell 
types during development or in response to different 
environmental cues. for example, the transcription of 
certain miRNAs found in immune cells, such as miR-155 
and miR-146a, is upregulated in response to inflamma-
tory stimuli such as Toll-like receptor (TlR) ligands or 
pro-inflammatory cytokines11,12. 
In addition, several post-transcriptional regulatory 
mechanisms that affect miRNA processing have recently 
been identified, functioning at various stages from the 
initial primary transcript to the delivery of mature, single- 
stranded miRNAs to their target mRNAs. Among the 
factors involved are the SMAD proteins, which have 
been shown to regulate miR-21 processing in a ligand-
dependent manner13. Arsenate-resistance protein 2 
(ARS2; also known as SRRT) is expressed by prolifer-
ating haematopoietic cells and is a component of the 
RNA cap-binding complex that promotes processing of 
pri-miRNA transcripts14. Adenosine deaminase acting 
on RNA (ADAR; also known as DRADA) expression 
is upregulated during inflammation and can regulate 
pri-miRNA processing through mutation of the double- 
stranded miRNA stem sequence15. In addition, the 
tumour suppressor protein p53 has an important role 
in miRNA processing following the onset of DNA dam-
age16. p53 forms a complex with Drosha and induces 
increased processing of pri-miRNAs to pre-miRNAs. 
The miRNA loop also mediates regulatory control over 
miRNA processing, and KH-type splicing regulatory 
protein (KSRP; also known as fUbP2) has been implicated 
in this process17,18. In an apparently specific form of regu-
lation, lIN28 binds to the loop of the let-7 pre-miRNA 
in human stem cells and inhibits its processing19.
After transport into the cytoplasm, post-transcriptional 
modifications of some pre-miRNAs are catalysed by 
terminal uridylyltransferase 4 (TUT4), which has been 
shown to be recruited by lIN28 to mediate uridylation 
of pre-let-7 miRNA20,21. This modification prevents 
further processing of pre-let-7 miRNA, thus inhibiting 
its function. The abundance of pri-miRNA processing 
factors themselves can be influenced during immune 
responses. for example, cytokines such as interferons 
have been shown to inhibit Dicer expression, decreasing 
the processing of pre-miRNAs22. On reaching matura-
tion, delivery of the RISC containing a fully processed 
miRNA guide strand to a cognate target mRNA has been 
shown to involve importin 8 (REF. 23). miRNAs can also 
be regulated by subcellular localization mechanisms. 
for example, miRNAs have been shown to associate 
with stress granules following the onset of cell stress; 
however, the roles of these organelles in miRNA biology 
remain unknown24. 
Together, these recent findings show that there is great 
complexity underlying both the production and subcellu-
lar localization of mature miRNAs. future studies will be 
required to determine if differential miRNA processing 
occurs in particular immune cell types or under specific 
inflammatory conditions as a means of controlling the 
spatial and temporal patterns of miRNA expression that 
have been observed in the immune system. 
Table 1 | Selected microRNAs with roles in the immune system
microRnA Cell type expressing 
microRnA
Target genes
miR-221 and miR-222 HSCs Kit
miR-10 HSCs Hox family 
miR-196b HSCs Hox family
miR-126 HSCs HoxA9 and PLK2
miR-155 B cells, T cells, 
macrophages and DCs
SHiP1, PU.1, AiD, SocS1, BAcH1, 
ceBPB, cSfr, tAB2, MAf and JAriD2
miR-150 B cells and T cells MyB
miR-17–92 B cells and T cells BiM and Pten
miR-181a T cells DUSP5, DUSP6, SHP2 and PtPn22
miR-326 T cells etS1
miR-142-3p T
Reg
 cells Ac9
miR-424 Myeloid cells nfiA and SPi1
miR-21 Myeloid cells Pten, PDcD4 and iL12A
miR-17-5p-20a-106a Myeloid cells rUnx1
miR-223 Myeloid cells Mef2c
miR-146 Monocytes irAK1, irAK2 and trAf6
let-7e Macrophages tLr4
miR-9 Myeloid cells nfKB1
miR-34 DCs and B cells JAg1, Wnt1 and foxP1
Ac9, adenylate cyclase 9; AiD, activation-induced cytidine deaminase; BAcH1, BTB-, CNC- 
and bZIP-domain-containing transciption factor; BiM , BCL-2-interacting mediator of cell 
death; ceBPB, CCAAT/enhancer binding protein-β; cSfr, colony-stimulating factor receptor; 
DC, dendritic cell; DUSP, dual-specificity protein phosphatase; foxP1, forkhead box P1;  
Hox, homeobox; HSC, haematopoietic stem cell; iL12A, interleukin-12A; irAK, IL-1R-associated 
kinase; JAg1, Jagged1; JAriD2, jumonji, AT rich interactive domain 2; Mef2c, myeloid ELF1-like 
factor 2C; miR, microRNA; NFIA; nuclear factor I/A; nfKB1, nuclear factor-κB subunit 1; 
PDcD4, programmed cell death 4; PLK2, polo-like kinase 2; Pten, phosphatase and tensin 
homologue; PtPn22, protein tyrosine phosphatase, non-receptor type 22; rUnx1, runt-related 
transcription factor 1; SHiP1, SH2-domain-containing inositol-5-phosphatase 1; SHP2, 
SH2-domain-containing protein tyrosine phosphatase 2; SocS1, suppressor of cytokine 
signalling 1; tAB2, TAK1-binding protein 2; tLr4, Toll-like receptor 4; trAf6, TNFR-associated 
factor 6; T
Reg
 cell, regulatory T cell.
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miRNA regulation of haematopoietic stem cells
Haematopoietic stem cells (HSCs) reside mainly in the 
bone marrow and give rise to all blood cell lineages, 
including cells that constitute the immune system25. 
HSCs must maintain a precise balance between self-
renewal and differentiation into multipotent progenitors, 
which subsequently give rise to both the lymphoid and 
myeloid branches of the haematopoietic system (FIG. 2). 
Although miRNAs have been studied in other stem cell 
types, such as embryonic stem cells, there are currently 
limited data on the role of miRNAs in HSCs26. Several 
groups have carried out global miRNA expression profil-
ing of human CD34+ stem and progenitor cells and have 
identified certain miRNAs expressed by this cell popula-
tion27,28. Mice deficient in ARS2, which contributes to pri-
miRNA processing, have bone marrow failure possibly 
owing to defective HSC function14. These studies provide 
initial evidence that the miRNA pathway is important in 
HSC function.
Individual miRNAs have also been implicated in HSC 
biology. Homeobox (HOX) genes have important roles 
in regulating HSC homeostasis, and miRNAs from the 
miR-196 and miR-10 families were found to be located 
in the HOX loci; both could directly repress HOX family 
expression29–32. miR-196b is expressed specifically in mouse 
short-term HSCs, regulated by the HSC transcription 
factor family mixed lineage leukaemia (Mll), and has 
a functional role in modulating HSC homeostasis and 
lineage commitment, possibly through the regulation of 
expression of certain HOX genes33. miR-126 has also been 
shown to regulate expression of HOXA9 (REF. 34) and the 
tumour suppressor polo-like kinase 2 (PlK2)35, through 
which miR-126 is thought to mediate its biological effects. 
functional studies of bone marrow progenitors showed 
that miR-126 increased colony formation in vitro, suggest-
ing that it may promote the production of downstream 
progenitors by HSCs35. miR-221 and miR-222 were also 
shown to inhibit KIT expression by stem and progenitor 
cells, leading to impaired cell proliferation and engraftment 
potential36. Although these studies suggest a role for spe-
cific miRNAs in HSC biology, additional work is needed to 
directly assess the influence of these and other miRNAs on 
the function of carefully sorted HSC populations regarding 
long-term, multilineage engraftment in vivo. 
Regulation of innate immunity by miRNAs
Cells of the innate immune system, such as granulocytes, 
monocytes (which differentiate into myeloid-derived den-
dritic cells (DCs) or macrophages) and natural killer (NK) 
cells, provide an important first line of defence against 
infection. Emerging data have identified an important 
contribution of miRNAs to the development and function 
of innate immune cells (FIG. 3). furthermore, studies inves-
tigating myeloid cell development and function have iden-
tified a common theme of a dynamic interplay between 
lineage-specific transcription factors and miRNAs. 
Granulocytes. Granulocytes arise from granulocyte–
monocyte progenitors under the influence of the tran-
scription factor growth factor independent 1 (GfI1). GfI1 
was recently shown to bind to the promoter regions of 
pri-miR-21 and pri-miR-196b and repress their expres-
sion37. furthermore, overexpression of miR-21 and 
miR-196 in lineage-depleted bone marrow cells blocked 
granulopoiesis in vitro, a phenotype also observed in 
Figure 1 | microRnA expression and function are 
regulated at three levels and influenced by 
inflammation and stress. MicroRNA (miRNA) expression 
is first regulated by transcription factors (TFs) that can 
themselves be activated or repressed during immune 
responses by Toll-like receptor (TLR) ligands, antigens or 
cytokines. Following the production of a miRNA primary 
transcript (pri-miRNA) in the nucleus, its processing into  
a pre-miRNA is regulated by various factors, including 
Drosha, DiGeorge syndrome critical region gene 8 
(DGCR8), LIN28, KH-type splicing regulatory protein 
(KSRP), arsenate resistance protein 2 (ARS2), SMADs, p53 
and adenosine deaminase acting on RNA (ADAR), some 
of which are themselves influenced by inflammation.  
The pre-miRNA is then exported to the cytoplasm by 
exportin 5. on reaching the cytoplasm, the pre-miRNA is 
processed by Dicer (or modified by terminal uridylyltrans-
ferase 4 (TUT4) in the case of let-7). The miRNA duplex is 
unwound and the guide strand is loaded onto the 
RNA-induced silencing complex (RISC). This complex is 
then transported by importin 8 to its cognate mRNA, 
leading to repression of the target. Finally, miRNAs can be 
localized to specific organelles, such as stress granules or 
processing (P-) bodies, some of which are thought to be 
used during stress. Pol II, RNA polymerase II. 
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Gfi1–/– mice38. Our group has found that sustained expres-
sion of miR-155 can increase immature granulocyte 
numbers in vivo, and that several of its targets, includ-
ing SH2-domain-containing inositol-5-phosphatase 1 
(SHIP1; also known as INPP5D) are probably involved 
in this process39,40. 
In addition to regulating granulocyte development, 
miRNAs also regulate granulocyte function. miR-223 is 
induced by the myeloid transcription factors PU.1 and 
CCAAT/enhancer-binding protein-β (C/EbPβ)41, and 
it negatively regulates both the proliferation and acti-
vation of neutrophils42. miR-223-deficient neutrophils 
had increased capacity to undergo oxidative burst and 
more effectively killed Candida albicans than did wild-
type cells42. Myeloid Elf1-like factor 2C (MEF2C) was 
shown to be a direct target of miR-223, although this 
was only responsible for the increased neutrophil pro-
liferation observed in miR-223-deficient mice and not 
the higher neutrophil activation status. This indicates 
that different miR-223 targets regulate distinct aspects 
of neutrophil biology.
Monocytes, macrophages and DCs. both macrophages 
and myeloid-derived DCs have key roles in the innate 
immune response to infection. Similar to granulopoie-
sis, several studies have shown that transcription factors 
involved in monocytopoiesis43 are regulated by, and/or 
regulate, specific miRNAs, which indicates a connection 
between these molecular species during development.
The expression levels of miR-17-5p, miR-20a and miR-
106a, members of the miR-17–92 and related miR-106a–92 
families, have been shown to decrease during the dif-
ferentiation of human haematopoietic progenitor cells 
into monocytes. This led to derepression of their target 
runt-related transcription factor 1 (RUNX1; also known 
as AML1)44. The resulting increase in RUNX1 expres-
sion promoted monocyte differentiation, presumably 
by increasing colony-stimulating factor receptor (CSfR) 
expression. RUNX1 was also found to bind the miR-17–92 
and miR-106a–92 promoter regions and repress their 
expression, suggesting that miR-17–92 and RUNX1 are 
involved in a mutual negative feedback loop. PU.1 is 
another transcription factor that is crucial for monocyte 
and macrophage differentiation and has been shown to 
upregulate miR-424 levels during 12-O-tetradecanoyl 
phorbol 13-acetate (TPA)-mediated monocyte differen-
tiation of Nb4 cells45. Enforced expression of miR-424 in 
Nb4 cells promoted monocytic differentiation, increasing 
the numbers of CD11b+CD14+ cells and inducing mor-
phological changes consistent with monocytic matura-
tion. miR-424 promoted monocytic differentiation by 
inhibiting the expression of nuclear factor I/A (NFIA), 
which is important for myeloid cell differentiation and 
had also been shown previously to be targeted by miR-223 
during granulocyte differentiation in vitro46. 
The macrophage inflammatory response to infec-
tion involves the upregulation of several miRNAs, such 
as miR-155, miR-146, miR-147, miR-21 and miR-9 
(REFs 11,12,47–49). Indeed, miR-155 expression is 
induced in mouse bone marrow-derived macrophages 
in response to various TlR ligands and by the pro-
inflammatory cytokines tumour necrosis factor (TNf) 
and interferon-β11. Interferons do not directly induce 
miR-155 expression by macrophages but instead do so 
indirectly through TNf autocrine or paracrine signal-
ling11. The primary transcript encoding miR-155, known 
as the b cell integration cluster (BIC)50, was shown to 
be transcriptionally activated by the transcription fac-
tors activator protein 1 (AP1) and nuclear factor-κb 
(Nf-κb)11,51–53. Certain cognate ligands for TlRs and the 
cytoplasmic sensor retinoic acid-inducible gene I (RIG-I; 
also known as DDX58) also induce miR-146 expres-
sion in a Nf-κb-dependent manner12,54. In peripheral 
human monocytes and neutrophils, miR-9 is similarly 
upregulated by pro-inflammatory signals in a myeloid 
differentiation primary-response protein 88 (MyD88)- 
and Nf-κb-dependent manner49. Therefore, certain 
inflammatory miRNAs are regulated transcriptionally 
in a similar manner to other inflammatory genes. 
The inflammatory response to infection must be 
robust enough to eradicate microbial pathogens but 
resolved in a timely manner to avoid excessive damage 
to the host. miRNAs have been shown to influence both 
of these aspects of inflammation. There is evidence that 
many of the miRNAs induced by TlRs, such as miR-146, 
miR-9, miR-147, miR-21 and miR-155, can negatively 
regulate the activation of inflammatory pathways in 
myeloid cells12,17,47,48,54. for example, miR-146 directly 
represses several signalling molecules that are down-
stream of TlRs, including Il-1R-associated kinase 1 
(IRAK1), IRAK2 and TNfR-associated factor 6 (TRAF6), 
all of which promote inflammation12,54. miR-9 represses 
Nf-κb subunit 1 (NFKB1) and helps to maintain a con-
stant level of Nf-κb1 protein expression during TlR4-
mediated activation of monocytes and neutrophils. 
Figure 2 | microRnA-mediated regulation of early haematopoietic cell 
development. The microRNA (miRNA) pathway, which involves arsenate resistance 
protein 2 (ARS2), has a general role in haematopoietic stem cell (HSC) engraftment, 
which probably influences the reconstitution potential of long-term HSCs (LT-HSCs). 
Individual miRNAs have been shown to repress the expression of HSC-relevant genes 
and affect the production of haematopoietic progenitor and lineage-positive cells. 
Potential points of miRNA function during early haematopoiesis are indicated. miR-221 
or miR-222 regulate KIT expression, which is thought to affect stem cell homeostasis. 
miR-196b is specifically expressed by short-term HSCs (ST-HSCs) and regulates mRNAs 
encoding the homeobox (Hox) family, in cooperation with miR-10 family members.  
The expression of miR-10 family members by HSCs is not as clearly defined. miR-126 
represses the mRNAs encoding polo-like kinase 2 (PLK2) and HoxA9, and has been 
shown to promote expansion of progenitor cells. CLP, common lymphoid progenitor; 
CMP, common myeloid progenitor; MPP, multipotent progenitor.
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In human myeloid-derived DCs, knockdown of miR-155 
expression significantly increased protein expression of 
the pro-inflammatory cytokine interleukin-1β (Il-1β)55. 
furthermore, addition of a miR-155 mimic decreased the 
expression of a Nf-κb reporter plasmid in cell lines55,56. 
miR-155 has also been shown to repress the expression of 
the pro-inflammatory signalling protein TAK1-binding 
protein 2 (TAb2; also known as MAP3K7IP2), suggesting 
a mechanistic basis for its anti-inflammatory effect in cer-
tain settings55. by contrast, it has been shown that in some 
situations miR-155 can positively regulate inflammatory 
pathways, enhancing instead of diminishing them. Indeed, 
enforced expression of miR-155 in the bone marrow 
compartment of adult mice leads to a myeloproliferative 
phenotype that is similar to that which occurs transiently 
after lipopolysaccharide (lPS) injection40. miR-155 was 
shown to negatively regulate SHIP1, an important nega-
tive regulator of phosphoinositide 3-kinase (PI3K) and 
the downstream AKT pathway39,57. SHIP1 is a negative 
regulator of TlR4 signalling58, and therefore repres-
sion of SHIP1 by miR-155 may counter this negative 
regulation and increase downstream AKT signalling.
Figure 3 | microRnA-mediated regulation of myeloid cell development and function. The generation of different 
myeloid cell types is regulated by the interactions between microRNAs (miRNAs) and relevant transcription factors. 
Common myeloid progenitors (CMPs) give rise to granulocyte–monocyte progenitors (GMPs). GMPs produce both 
monocytes and neutrophils, and monocytes can further differentiate into macrophages and dendritic cells (DCs). The 
miR-17–92 cluster represses runt-related transcription factor 1 (RUNx1) production, which regulates colony-stimulating 
factor receptor (CSFR) expression during monocytopoiesis. Growth factor independent 1 (GFI1) represses miR-196b and 
miR-21 during granulocyte development. The myeloid transcription factors PU.1 and CCAAT/enhancer-binding protein-β  
(C/EBPβ) help to promote miR-223 expression. miR-223 and miR-424 promote monocyte and neutrophil differentiation, 
respectively, by repressing nuclear factor I/A (NFI-A) production. miR-223 also represses C/EBPβ and myeloid ELF1-like factor 
2C (MEF2C) expression to modulate neutrophil differentiation and proliferation. miR-155 has roles in myeloid cell 
differentiation and activation. miR-155 represses SH2-domain-containing inositol-5-phosphatase 1 (SHIP1), PU.1, C/EBPβ 
and CSFR production; these interactions may influence myeloid differentiation. miR-155 also represses expression of 
dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN) through the suppression of PU.1 expression to affect  
antigen presentation by DCs. miR-34 and miR-21 repress the mRNAs encoding WNT1 and Jagged 1 (JAG1) to promote DC 
differentiation. During Toll-like receptor (TLR) activation, activator protein 1 (AP1; not shown) and nuclear factor-κB (NF-κB) 
enter the nucleus and induce the expression of several miRNAs, including miR-9, miR-155, miR-146, miR-21 and miR-147. 
miR-155 represses the mRNA encoding TAK1-associated binding protein 2 (TAB2), miR-9 targets a mRNA encoding NF-κB 
and miR-146 represses the mRNAs encoding IL-1R-associated kinase 1 (IRAK1), IRAK2 and TNF-receptor-associated factor 6 
(TRAF6), which are TLR signalling molecules. miR-21 negatively regulates macrophage activation by repressing expression 
of programmed cell death 4 (PDCD4) and interleukin-12 p35 subunit (IL-12p35). miR-155 also represses expression of 
suppressor of cytokine signalling 1 (SoCS1) and SHIP1, which are negative regulators of the TLR pathway.
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Interestingly, AKT signalling has recently been shown 
to repress miR-155 expression in macrophages59, sug-
gesting the existence of a negative feedback loop. lPS-
stimulated Akt–/– macrophages expressed higher levels of 
miR-155 and miR-125b and also lower levels of let-7e and 
miR-181c than wild-type controls. Akt–/– macrophages 
were more responsive to lPS, an effect mediated in part 
by the increased miR-155 and decreased let-7e levels. 
Notably, miR-155 directly repressed levels of suppressor 
of cytokine signalling 1 (SOCS1), which, similar to SHIP1, 
is a negative regulator of the TlR pathway. let-7e directly 
downregulated expression of the lPS receptor TlR4. 
The in vivo relevance of this pathway is supported by the 
finding that Akt–/– mice have a lower tolerance to systemi-
cally delivered lPS than wild-type mice. Taken together, 
it is clear that specific miRNAs are involved in regulat-
ing inflammation, presumably to help create a properly 
balanced response to pathogens and noxious stimuli. 
However, the role of miR-155 seems to be complex, pos-
sibly owing to its wide range of relevant target mRNAs 
and the cellular contexts in which it is expressed.
There are also reports indicating that miRNAs regu-
late distinct aspects of DC biology, and so are involved 
in the crucial connection between innate and adaptive 
immune responses. miR-34 and miR-21 were shown to be 
important for human myeloid-derived DC differentiation 
by targeting the mRNAs encoding Jagged1 and WNT1 
(REF. 60). Myeloid-derived DCs from Bic–/– (miR-155- 
deficient) mice show defects in antigen presentation to 
T cells, despite expressing normal levels of MHC class II 
and co-stimulatory molecules; so, the mechanism 
behind the defect remains elusive61. In addition, another 
study found that miR-155 downregulates expression of 
DC-specific ICAM3-grabbing non-integrin (DC-SIGN; 
also known as CD209) by human monocyte-derived DCs 
through suppression of PU.1 expression62. DC-SIGN is a 
cell surface C-type lectin that binds pathogens, implicating 
miRNAs in the regulation of pathogen uptake by DCs.
NK and NKT cells. NK cells are important components of 
immune surveillance against cancer and viral infection, 
and miRNAs have been implicated in their development 
and function. NK cells express the receptor natural killer 
group 2, member D (NKG2D), which recognizes ligands 
— MHC class I polypeptide-related sequence A (MICA) 
and MICb — that are expressed by cells undergoing stress 
triggered by events such as viral infection or cell trans-
formation. Engagement of NKG2D on NK cells leads to 
direct killing of the target cell. A recent study showed that 
a set of miRNAs, many of which are overexpressed by var-
ious cancer cells, could downregulate MICA and MICb 
expression in human cell lines63. Treatment of cells with 
antagomirs (antisense oligodeoxynucleotides) that inhibit 
the specific miRNAs being tested led to increased cell 
surface expression of MICA and MICb and increased NK 
cell-dependent killing; overexpression of these miRNAs 
had the opposite effect. Although heat shock-induced 
cell stress increased MICA and MICb expression in the 
HCT-116 cell line, expression of the relevant miRNAs did 
not concomitantly decrease. Instead, these miRNAs seem 
to set a threshold for MICA and MICb expression that 
prevents their expression during non-stress conditions. 
It is interesting to note that certain herpesvirus family 
members, namely cytomegalovirus, Epstein–barr virus 
and Kaposi’s sarcoma-associated herpesvirus (KSHv), 
produce miRNAs that target MICB mRNA, and this has 
been proposed as a mechanism of immune evasion by 
these viruses64,65. 
Invariant NKT (iNKT) cells are a class of innate-like 
T cells that express an invariant T cell receptor (TCR) 
that recognizes lipids presented by the MHC class I-like 
CD1d molecule. Two recent studies identified a require-
ment for Dicer in the development of iNKT cells66,67. 
both studies observed a near complete loss of iNKT cells 
in the thymus and periphery in the absence of Dicer. 
Developing iNKT cells from conditional Dicer-knockout 
animals exhibited increased apoptosis and decreased 
differentiation, whereas mature iNKT cells had severe 
activation defects.
The studies described above clearly implicate miRNAs 
in the regulation of various aspects of innate immunity. 
This includes regulation of direct microbial killing, the pro-
duction of cytokines and the antigen presentation by MHC 
molecules. All of these mechanisms are important for host 
defence and are instrumental in initiating antigen-specific 
responses by cells of the adaptive immune system. 
Regulation of adaptive immunity by miRNAs
T cells. Similar to the development of innate immune 
cells, the development of T cells in the thymus and their 
activation in the periphery are also controlled by com-
plex protein signalling networks that are subject to regu-
lation by miRNAs (FIG. 4). Expression profiling of T cells 
has identified a broad range of expressed miRNA spe-
cies and found that the expression patterns vary between 
T cell subsets and stages of development68–70. Adding to 
this complexity, several variants of a given miRNA spe-
cies can be found in T cells, with the mature miRNAs 
varying in length at either the 3ʹ or 5ʹ end or containing 
mutated sequences70. furthermore, proliferating T cells 
express genes with shorter 3ʹ UTRs than those in rest-
ing T cells71, rendering these mRNAs less susceptible to 
regulation by miRNAs owing to the loss of miRNA bind-
ing sites. These findings suggest that miRNA-mediated 
regulation of mRNA targets in T cells, and probably other 
immune cells, is a dynamic process that is influenced 
by a broad range of factors. 
T cell-specific deletion of Dicer has revealed a 
requirement for the miRNA pathway in the development 
of mature T cells, the total numbers of which are lower 
in the mutant mice than wild-type mice72,73. Two specific 
miRNAs have been implicated in T cell development, 
and probably account for some of the phenotype of Dicer 
deficiency in T cells. The miR-17–92 cluster impairs 
the expression of mRNAs encoding pro-apoptotic 
proteins, including bCl-2-interacting mediator of cell 
death (bIM; also known as bCl2l11) and phosphatase 
and tensin homologue (PTEN). This miRNA cluster is 
thought to increase T cell survival during development 
and is expressed during the double negative 2 stage of 
thymopoiesis74. furthermore, the strength of TCR sig-
nalling influences whether thymocytes are positively 
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process by which the class of 
immunoglobulin is switched 
from IgM to IgG, IgA or IgE.
or negatively selected during thymic development, and 
specific miRNAs have been implicated in this process. 
miR-181a, which is increased during early T cell devel-
opment, enhances TCR signalling strength by directly 
targeting a group of protein phosphatases, including 
dual-specificity protein phosphatase 5 (DUSP5), DUSP6, 
SH2-domain-containing protein tyrosine phosphatase 
2 (SHP2; also known as PTPN11) and protein tyrosine 
phosphatase, non-receptor type 22 (PTPN22)75.
Recent data have also indicated a role for miRNAs in 
the differentiation of T cells into distinct effector T helper 
cell subsets. This is best exemplified by mice deficient in 
miR-155, in which T cells are biased towards T helper 2 
(TH2)-cell differentiation, indicating that miR-155 pro-
motes differentiation into TH1 cells51,61. Certain miRNAs, 
such as the miR-17–92 cluster, might also be involved 
in the development and function of T follicular helper 
(TfH) cells, which are specialized T cells that are dedi-
cated to supporting b cells in germinal centres and facili-
tating antibody affinity maturation and class switching76,77. 
TH17 cells have been identified as important mediators 
of inflammatory disease. A recent study found that 
miR-326 promotes TH17 cell development both in vitro 
and in vivo by targeting ETS1 (REF. 78).
The generation of mice with a conditional deletion 
of Dicer or Drosha in regulatory T (TReg) cells has shown 
a requirement for the miRNA pathway in forkhead 
box P3 (fOXP3)+ TReg cells79–81. These mice develop 
a lethal autoimmune inflammatory disease, consist-
ent with impaired development or function of TReg 
cells. Specifically, it was shown that miR-155 is impor-
tant for TReg cell homeostasis and overall survival, and 
this is thought to involve the direct targeting of Socs1 
(REFs 82,83). However, because the absence of miR-155 did 
not reproduce the severe disease that occurs in mice 
with a conditional deletion of Dicer, additional miRNAs 
are probably involved in TReg cell biology. Of note, the 
expression of miR-142-3p was recently shown to be 
repressed by fOXP3, leading to increased production 
of cyclic AMP and suppressor function of TReg cells84. 
Several other miRNAs are expressed by TReg cells and 
await functional assessment85.
B cells. The generation of b cells that express high-
affinity antigen receptors involves two main stages: 
antigen-independent development in the bone marrow 
and antigen-dependent selection in the secondary lym-
phoid organs; both of which are associated with dynamic 
regulation by miRNAs (FIG. 5). miRNA profiling studies 
during early b cell development have not been carried 
out but several groups have analysed the expression of 
miRNAs in naive, germinal centre and post-germinal 
centre b cells86–88. Temporal regulation of several dif-
ferent miRNAs was observed and putative new cell 
type-specific miRNAs were identified, suggesting the 
involvement of many, but undefined, regulatory path-
ways in b cell development and maturation. 
The control of b cell development in the bone mar-
row depends on the commitment of progenitor cells to 
the b cell lineage by the activation of transcription fac-
tor networks, V(D)J recombination events and selection for 
effective antigen receptors. The roles of miRNAs in con-
trolling the early development of b cells are now thought 
to involve the modulation of key protein factors that con-
trol these aspects of b cell development89. An initial study 
found that overexpression of miR-181 causes a skewing of 
haematopoiesis towards the development of b cells, lead-
ing to a two to threefold increase in the number of b cells 
and no increase in T cells or myeloid cells90. by contrast, 
mice with a conditional deletion of Dicer in b cells had 
a complete block in b cell development91. This block is 
thought to relate to dysregulated expression of the pro-
apoptotic protein bIM, probably during the selection 
of effective antigen receptors. The block in b cell devel-
opment in these mice could be overcome by transgenic 
expression of b cell lymphoma 2 (bCl-2), but the mature 
b cells had an abnormal distribution of v(D)J rearrange-
ments, indicating that there is a defect in the regulation 
of b cell selection. Notably, the changes observed by gene 
expression profiling of Dicer-deficient b cell precursors 
were generally similar to those observed in b cells lacking 
the miR-17–92 family92, which has been associated with 
Figure 4 | microRnA-mediated regulation of T cell development and function. 
a | The production of microRNAs (miRNAs) by Dicer is required for efficient T cell 
development in vivo. T cells go through a stepwise developmental programme in the 
thymus. During this process, T cell survival and selection is influenced by the miR-17–92 
cluster (which targets the mRNAs encoding BCL-2-interacting mediator of cell death 
(BIM), and phosphatase and tensin homologue (PTEN)) and miR-181a (which targets 
mRNAs encoding several phosphatases, including dual-specificity protein phosphatase 5 
(DUSP5), DUSP6, SH2-domain-containing protein tyrosine phosphatase 2 (SHP2) and 
protein tyrosine phosphatase, non-receptor type 22 (PTPN22)). b | In the periphery, mature 
T cell differentiation is modulated by miRNAs, including miR-155, which promotes 
skewing towards T helper 1 (T
H
1) cells through macrophage-activating factor (MAF) 
repression, and miR-326, which promotes skewing towards T
H
17 cells by targeting the 
mRNA encoding ETS1. Regulatory T (T
Reg
) cells also depend on miRNAs to maintain 
immune tolerance to self tissues, thereby preventing autoimmunity. miR-155 repression of 
suppressor of cytokine signalling 1 (SoCS1) expression has been implicated in T
Reg
 cell 
survival. CLP, common lymphoid progenitor; DN, double negative; DP, double positive; 
FoxP3, forkhead box P3; SP, single positive.
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Regulatory T (TReg) cells 
A small population of CD4+ 
T cells that naturally express 
high levels of CD25 (the 
interleukin-2 receptor α-chain) 
and FOXP3. They have 
suppressive regulatory activity 
towards other T cells that are 
stimulated through their  
T cell receptor. An absence  
of TReg cells or their dysfunction 
is associated with severe 
autoimmunity.
V(D)J recombination 
somatic rearrangement of 
variable (V), diversity (D) and 
joining (J) regions of the genes 
that encode antigen receptors, 
leading to repertoire diversity 
of both T cell and B cell 
receptors.
B-1 B cells
A subset of self-renewing 
B cells found mainly in the 
peritoneal cavity and the 
pleural cavity. They recognize 
self components, as well as 
common bacterial antigens, 
and they secrete antibodies 
that generally have low affinity 
and broad specificity.
B-2 B cells
Conventional B cells. These 
cells reside in secondary 
lymphoid organs and secrete 
antibodies with high affinity 
and narrow specificity.
RAG proteins
RAG1 and RAG2 are proteins 
that mediate V(D)J 
recombination in pre-B cells 
and thymocytes, which allows 
the production of antibodies 
and T cell receptors, 
respectively.
Activation-induced cytidine 
deaminase
(AID). An RNA-editing enzyme 
that is necessary for antibody 
affinity maturation and class 
switching. 
Fragile site 
A site in a chromosome that is 
susceptible to chromosome 
breakage and fusion with other 
chromosomes.
pathological lymphoproliferative conditions in humans 
and mice74. So, the key effects of conditional deletion of 
Dicer in b cells could be mainly due to the absence of these 
crucial, clustered miRNAs in early b cells. 
In addition to effects on antigen receptor selection, 
miRNAs also regulate the transcription factors involved 
in early b cell development. Constitutive expression of 
miR-150, which has a dynamic expression profile in the 
early b cell lineage, causes a block at a proximal stage of 
b cell development, the pro-b to pre-b cell transition93, 
and this inhibition depends on dysregulation of Myb 
expression. by contrast, mice deficient in miR-150 
have an accumulation of B-1 B cells in the spleen and 
the peritoneal cavity, with a relative decrease in the 
number of B-2 B cells94. We have found that constitutive 
expression of miR-34a perturbs b cell development by 
causing an increase in cells at the pro-b to pre-b cell 
transition. This is mainly the result of miR-34a tar-
geting of the transcription factor Foxp1, which regu-
lates expression of the recombination-activating genes 
(Rag1 and Rag2) (D.S.R. and D.b., unpublished obser-
vations). because miR-34a is a p53-induced miRNA95, 
this effect may link the regulation of DNA damage 
responses with regulation of RAG proteins.
An involvement for miRNAs in the antigen-driven 
stages of the humoral response in secondary lymphoid 
organs has also been described. Despite a decrease 
in total numbers of b-2 b cells (mentioned above), 
miR-150-deficient mice have increased levels of anti-
body secretion both at baseline and following T cell-
dependent antigenic stimulation; the mechanism of the 
antigen-dependent defect is not understood94. Perhaps 
the best characterized miRNA during this stage of the 
b cell response is miR-155, which is upregulated follow-
ing b cell activation in the germinal centre. miR-155-
deficient b cells have defective antibody class switching 
and differentiation into plasma cells, resulting in an 
impaired humoral response to T cell-dependent anti-
genic stimulation51,61,96. These effects are likely to be 
the consequence of miR-155-mediated regulation of 
many targets: indeed, two proteins that are important 
for T cell-dependent antibody responses — PU.1 and 
activation-induced cytidine deaminase (AID) — are directly 
repressed by miR-155 (REFs 96–98). The repression of 
AID has been investigated by germline mutation of the 
miR-155 target sequence in the 3ʹ UTR of mouse Aicda 
(which encodes AID)98. from these studies, it is clear 
that miRNAs are important for normal b cell develop-
ment, implying that defects in miRNA regulation could 
be associated with b cell-mediated diseases. 
miRNAs in diseases of immunological origin
As discussed, miRNAs directly modulate the concen-
tration of many regulatory proteins that are required 
for normal development and function of the immune 
system. These proteins have been linked to immuno-
logical diseases, in which the miRNAs are found to be 
mutated or their expression levels dysregulated, conse-
quently triggering altered or impaired function. miRNA 
levels are also dysregulated in diseases of immunologi-
cal origins and many are known to be encoded near 
fragile sites in the genome99. Emerging data indicate that 
this can have a causative effect during disease initiation 
and progression owing to inappropriate repression or 
derepression of crucial protein targets (FIG. 6).
Cancers with immune cell origins. Profiling studies of 
immune cell-associated cancers have revealed changes 
in expression patterns of many miRNA species in dif-
ferent types of malignancy compared with normal 
cells3,100,101. In many cases, miRNA expression patterns 
have been correlated with clinical and/or pathological 
parameters of the cancer, revealing useful and some-
times clinically relevant markers for disease. for exam-
ple, miRNA ‘signatures’ can be used to distinguish some 
subclasses of acute myeloid leukaemia (AMl) and to 
distinguish b cell lymphoma from follicular hyperpla-
sia102–104. functional characterization of these miRNAs 
has been carried out in cell culture model systems, as 
well as gain-of-function and loss-of-function analyses 
in model organisms. We discuss the best characterized 
miRNAs that have tumour suppressive or oncogenic 
properties in immune cell-based cancers and describe 
how this knowledge has provided insight into the causes 
and progression of cancer (FIG. 6).
Figure 5 | microRnA-mediated regulation of B cell 
development and function. a | The survival and 
maturation of developing B cells requires microRNAs 
(miRNAs). Dicer-deficient animals have defective B cell 
development owing to a survival defect at the progenitor 
(pro) to precursor (pre) B cell transition. miR-150 and the 
miR-17–92 cluster influence early development through 
repression of MYB and BCL-2-interacting mediator of cell 
death (BIM) expression, respectively. b | In the periphery, 
further development of mature B cells is regulated by 
miR-155. This miRNA targets mRNAs encoding 
activation-induced cytidine deaminase (AID) and PU.1, 
which promotes antibody class switching and antibody 
production. CLP, common lymphoid progenitor; 
GC, germinal centre
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The alteration of gene 
expression through 
transcriptional mechanisms 
(owing to promoter 
methylation) or post- 
transcriptional mechanisms 
instead of ‘genetic’ alteration 
of sequences of bases in  
genomic DNA.
AML1–ETO
The fusion protein that is 
generated by the t(8;21) 
translocation found in some 
acute myeloid leukaemias.
The first miRNAs identified as tumour suppressors, 
miR-15a and miR-16, were discovered by Croce and col-
leagues105 in a region of chromosome 13 that was deleted 
in chronic lymphocytic leukaemia (Cll). These investi-
gations subsequently showed that miR-15a and miR-16 
negatively regulated the survival of cells in vitro, probably 
by targeting the pro-survival protein bCl-2 (REF. 106). 
More recently, the miR-34 family of miRNAs, consist-
ing of miR-34a, miR-34b and miR-34c, were identified as 
transcriptional targets of p53 and shown to target mRNAs 
important in cell cycle progression and cell survival95. 
Profiling studies have revealed that miR-34a expression 
is downregulated in Cll107. In addition, the expression of 
the miR-34b and miR-34c primary transcript seems to be 
downregulated owing to promoter methylation in AMl 
cell lines108. Other putative tumour suppressor miRNAs 
include miR-29ab and miR-181b, which are downregu-
lated in Cll, and target BCL2, T cell lymphoma 1 (TCL1) 
and myeloid cell leukaemia sequence 1 (MCL1), which 
are all oncogenes109. In the context of miRNA-induced 
tumour suppression, it is important to note that the dem-
onstration of tumorigenesis by genetic loss-of-function 
analysis has not yet been reported. However, our unpub-
lished observations indicate that miR-146a-deficient 
mice develop a spontaneous malignancy (M. boldin, 
K. Taganov and D.b., unpublished observations).
Epigenetic regulation of miRNAs and their targets also 
seems to be associated with cancer development and 
progression. for example, the expression of miR-223 is 
silenced following promoter methylation by the onco-
genic fusion protein AML1–ETO110. In addition, miR-29b 
has been shown to repress specific DNA methyltrans-
ferases leading to global DNA hypomethylation and re-
expression of tumour suppressor genes, thus implicating 
this miRNA as a tumour suppressor111.
miR-17–92 and miR-155 have been found to cause 
oncogenesis. miR-17–92 is overexpressed by many 
human haematopoietic cell neoplasms, including 
acute lymphoblastic leukaemia (All), diffuse large 
b cell lymphoma (DlbCl) and chronic myeloid leu-
kaemia (CMl)112. In mouse b and T cells, miR-17–92 
overexpression leads to a marked lymphoproliferative 
disease, characterized by lymphoid hyperplasia in the 
spleen, activated lymphocytes and lymphoid infiltration 
of peripheral tissues with autoimmune sequelae74. The 
mRNA targets in this context are thought to encode 
PTEN and bIM, both of which have tumour suppres-
sive activities. A mechanism involving bIM is consistent 
with the findings that Bim+/– mice develop a phenotype 
similar to that of mice overexpressing miR-17–92 and 
that heterozygous deficiency of bIM, similar to over-
expression of miR-17–92, cooperates with Eμ–Myc to 
induce oncogenesis113.
miR-155 is also overexpressed in a diverse array 
of immune cell cancers, including Cll, DlbCl and 
AMl30,40,50,114–116. forced overexpression of miR-155 
causes features of both lymphoid and myeloid onco-
genesis, as shown by a low-grade b cell lymphoma 
that develops in mice that overexpress miR-155 in all 
b cells (Eμ–miR-155 transgenic mice) and by marked 
myeloproliferative disease in mice following adoptive 
transfer of bone marrow cells overexpressing miR-155 
(REFs 40,117). In both of these cases, SHIP1 mRNA is an 
important target of miR-155 (REFs 39,57). In the bone 
marrow adoptive transfer model, the myeloprolifera-
tive phenotype can be almost completely reproduced by 
knockdown of SHIP1 expression, providing in vivo evi-
dence of target specificity39,57. In a similar manner, a viral 
orthologue of miR-155 encoded by KSHv (miR-K12-11) 
can have growth-promoting effects on cells and lead to 
KSHv-induced tumours, especially in patients with 
immunodeficiency118. 
Emerging roles for miRNAs in autoimmunity. The roles 
of miRNAs are only beginning to be explored in the con-
text of autoimmunity, in which they may be involved 
in regulating immune responses against self tissues119. 
Interestingly, synovial tissue samples from patients with 
rheumatoid arthritis show some changes in the expres-
sion of miR-155 and miR-146a compared with control 
samples120. T cells isolated from such patients also show 
increases in the expression of miR-146a, miR-155 and 
miR-16. Several miRNAs were either upregulated or 
downregulated in rheumatoid fibroblast-like synovio-
cytes treated with lPS, and, among these, miR-346 was 
shown to modulate Il-18 production, albeit through an 
indirect mechanism121. 
Figure 6 | mechanisms of microRnA contribution to cancer. MicroRNAs (miRNAs) 
can influence immune cell-based malignant phenotypes through different mechanisms, 
including functioning as oncogenes (miR-155 and miR-17–92) or tumour suppressors 
(miR-15a and miR-16). miRNAs can also affect cancer by their involvement in epigenetic 
regulatory pathways. For example, miR-29b represses DNA methyltransferases (DNMTs), 
and AML1–ETo recruits chromatin remodelling factors to the miR-223 locus, leading  
to repressed miRNA expression. miRNAs, in the form of viral orthologues, might also 
modulate cancer-associated gene expression during viral infection. Kaposi’s 
sarcoma-associated herpesvirus (KSHV) produces an orthologue of miR-155 known  
as miR-K12-11. BIM, BCL-2-interacting mediator of cell death; PTEN, phosphatase  
and tensin homologue; SHIP1, SH2-domain-containing inositol-5-phosphatase.
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Another study identified three miRNAs, miR-18b, 
miR-599 and miR-96, that are differentially expressed 
by peripheral blood mononuclear cells from patients 
with multiple sclerosis compared with control cells122. 
A recent investigation identified miR-326 as being over-
expressed in a cohort of patients with multiple sclerosis. 
Studies in mice showed that miR-326 could potentiate 
disease severity in the context of experimental auto-
immune encephalomyelitis by promoting the develop-
ment of TH17 cells, which are important mediators of 
tissue damage during antigen-specific inflammation78. 
further support for a causal relationship between 
specific miRNAs and the onset of autoimmunity has 
come from studies involving miR-17–92 overexpression 
in mice. miR-17–92 overexpression promoted marked 
lymphoproliferation, the presence of serum autoanti-
bodies and tissue changes such as lymphoid infiltrates 
and antibody deposition74. T cells seem to develop nor-
mally in these mice, but the number of mature CD4+ 
T cells was markedly increased and they had a highly 
activated profile, suggesting a failure of peripheral tol-
erance. There are also recent data showing that inhibi-
tion of miR-181a in T cells during thymic development 
converts endogenous positively selecting peptides into 
autoantigens123. Other evidence for a role of miRNAs 
in autoimmunity is provided by studies in TReg cells79–81 
(described above), by a report that the 3ʹ UTR of induc-
ible T cell co-stimulator (ICOS) contains a binding site 
for miR-101 (REF. 124), and by the findings that expres-
sion of the anti-inflammatory protein Il-10 is regulated 
by miR-106a and the mRNA encoding the Il-12 p35 
subunit (Il-12p35) is targeted by miR-21 (REFs 125,126). 
The relevance of these findings to human auto immune 
diseases remains to be established, but should be 
addressed in future studies. 
Concluding remarks and future perspectives
As described in this Review, miRNAs are being identi-
fied as key regulators of immune cell development and 
function, as well as disease pathogenesis. The observa-
tions that a single miRNA can have several effects on 
different cellular lineages indicate that miRNA targets in 
individual cell types may vary, allowing one miRNA to 
have many roles just as single transcription factors have 
unique functions in distinct immune cell lineages. There 
is also an emerging theme that miRNAs and transcrip-
tion factors modulate one another in regulatory loops 
during development, and that this helps to establish a 
stable cellular identity. 
It is now evident that aberrant miRNA expression in 
the immune system is sufficient to cause disease, and so 
proper regulation of miRNA expression seems to be cru-
cial for disease prevention. furthermore, it is instructive 
to note that knowledge of miRNA targets could provide 
a missing link between pathways that previously seemed 
separate. for example, miR-155 may connect Nf-κb 
activation to repression of SHIP1 expression11,39,56, and 
MyC-mediated miR-17–92 expression may be linked to 
suppression of PTEN74,127. As such, miRNAs may have 
an important role in the organization of gene regulation 
networks, and so it is possible that these systems are far 
larger than previously thought. Recognizing the interac-
tions between these pathways may prove to be important 
for determining how cellular proliferation, differentia-
tion and apoptosis are modulated, all of which are central 
to the development and function of the immune system 
and the initiation of cancer and autoimmunity. 
Several areas of miRNA biology warrant future inves-
tigation both for our basic understanding and to enable 
translational utility. first, the ability of miRNAs to com-
binatorially regulate key mRNAs containing several 
3ʹ UTR miRNA-binding sites should be assessed. This 
may lead to an even greater level of target mRNA repres-
sion than that mediated by a single miRNA, and could 
have important physiological and disease relevance. It may 
also identify miRNAs that commonly function together. 
Second, the importance of a single miRNA repressing 
many target mRNAs simultaneously needs to be further 
elucidated, and this may reveal new gene networks. Third, 
the mechanisms controlling miRNA levels and stability as 
cells differentiate or divide must be determined, including 
the processes by which mature miRNAs are degraded or 
cleared from the cell. Defining these cellular and molecu-
lar mechanisms will help us to further understand miRNA 
homeostasis in the context of dynamic cellular systems. 
finally, the development of improved technologies for 
delivering miRNA antagonists or agonists to specific cell 
types in vivo would facilitate target mRNA identifica-
tion and allow the exploitation of miRNAs as therapeutic 
entities for the treatment of disease. 
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